0001362703 2022-10-01 2022-12-31 0001362703 2023-02-21 0001362703 2022-12-31 0001362703 2022-09-30 0001362703 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001362703 us-gaap:SeriesEPreferredStockMember 2022-09-30 0001362703 us-gaap:SeriesFPreferredStockMember 2022-12-31 0001362703 us-gaap:SeriesFPreferredStockMember 2022-09-30 0001362703 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001362703 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001362703 THER:SeriesCOnePreferredStockMember 2022-12-31 0001362703 THER:SeriesCOnePreferredStockMember 2022-09-30 0001362703 THER:SeriesCTwoPreferredStockMember 2022-12-31 0001362703 THER:SeriesCTwoPreferredStockMember 2022-09-30 0001362703 THER:SeriesDOnePreferredStockMember 2022-12-31 0001362703 THER:SeriesDOnePreferredStockMember 2022-09-30 0001362703 THER:SeriesDTwoPreferredStockMember 2022-12-31 0001362703 THER:SeriesDTwoPreferredStockMember 2022-09-30 0001362703 2021-10-01 2021-12-31 0001362703 us-gaap:SeriesEPreferredStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:SeriesEPreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:SeriesFPreferredStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:SeriesFPreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:PreferredStockMember 2022-09-30 0001362703 us-gaap:CommonStockMember 2022-09-30 0001362703 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001362703 us-gaap:RetainedEarningsMember 2022-09-30 0001362703 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001362703 THER:SeriesCTwoPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001362703 us-gaap:PreferredStockMember 2021-09-30 0001362703 us-gaap:CommonStockMember 2021-09-30 0001362703 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001362703 us-gaap:RetainedEarningsMember 2021-09-30 0001362703 2021-09-30 0001362703 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001362703 THER:SeriesCTwoPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001362703 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001362703 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001362703 THER:SeriesCTwoPreferredStockMember us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001362703 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001362703 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:PreferredStockMember 2022-12-31 0001362703 us-gaap:CommonStockMember 2022-12-31 0001362703 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001362703 us-gaap:RetainedEarningsMember 2022-12-31 0001362703 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001362703 THER:SeriesCTwoPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001362703 us-gaap:PreferredStockMember 2021-12-31 0001362703 us-gaap:CommonStockMember 2021-12-31 0001362703 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001362703 us-gaap:RetainedEarningsMember 2021-12-31 0001362703 2021-12-31 0001362703 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001362703 THER:SeriesCTwoPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001362703 THER:SeriesDOnePreferredStockMember THER:AssetPurchaseAgreementMember 2020-06-02 2020-06-05 0001362703 THER:AvantMember THER:SeriesDOnePreferredStockMember THER:AssetPurchaseAgreementMember 2020-06-05 0001362703 THER:SeriesDOnePreferredStockMember THER:AssetPurchaseAgreementMember 2020-06-05 0001362703 THER:SeriesDOnePreferredStockMember THER:AssetPurchaseAgreementMember 2022-12-31 0001362703 THER:AvantMember THER:AssetPurchaseAgreementMember 2022-10-01 2022-12-31 0001362703 us-gaap:InvestorMember THER:OncBioMuneSubIncMember 2021-07-25 2021-07-26 0001362703 srt:MinimumMember 2022-10-01 2022-12-31 0001362703 srt:MaximumMember 2022-10-01 2022-12-31 0001362703 us-gaap:GeneralAndAdministrativeExpenseMember 2022-10-01 2022-12-31 0001362703 us-gaap:GeneralAndAdministrativeExpenseMember 2021-10-01 2021-12-31 0001362703 srt:MaximumMember 2022-12-31 0001362703 THER:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2022-12-31 0001362703 THER:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2021-12-31 0001362703 THER:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2021-12-31 0001362703 THER:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2022-12-31 0001362703 THER:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001362703 THER:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001362703 THER:CustomerOneMember THER:DeferredRevenueMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2022-12-31 0001362703 THER:CustomerTwoMember THER:DeferredRevenueMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2022-12-31 0001362703 THER:CustomerOneMember THER:DeferredRevenueMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001362703 THER:CustomerTwoMember THER:DeferredRevenueMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001362703 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001362703 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001362703 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001362703 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001362703 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001362703 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001362703 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001362703 us-gaap:FairValueInputsLevel3Member 2022-10-01 2022-12-31 0001362703 us-gaap:FairValueInputsLevel3Member 2021-10-01 2021-12-31 0001362703 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001362703 us-gaap:WarrantMember 2022-10-01 2022-12-31 0001362703 us-gaap:WarrantMember 2021-10-01 2021-12-31 0001362703 us-gaap:EmployeeStockOptionMember 2022-10-01 2022-12-31 0001362703 us-gaap:EmployeeStockOptionMember 2021-10-01 2021-12-31 0001362703 THER:SeriesCOnePreferredStockMember 2022-10-01 2022-12-31 0001362703 THER:SeriesCOnePreferredStockMember 2021-10-01 2021-12-31 0001362703 THER:SeriesCTwoPreferredStockMember 2022-10-01 2022-12-31 0001362703 THER:SeriesCTwoPreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:SeriesEPreferredStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:SeriesEPreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:SeriesFPreferredStockMember 2022-10-01 2022-12-31 0001362703 us-gaap:SeriesFPreferredStockMember 2021-10-01 2021-12-31 0001362703 us-gaap:ConvertibleDebtSecuritiesMember 2022-10-01 2022-12-31 0001362703 us-gaap:ConvertibleDebtSecuritiesMember 2021-10-01 2021-12-31 0001362703 THER:AmarantusBioScienceHoldingsIncMember 2017-01-01 2017-12-31 0001362703 THER:LaboratoryEquipmentMember 2022-10-01 2022-12-31 0001362703 us-gaap:FurnitureAndFixturesMember 2022-10-01 2022-12-31 0001362703 us-gaap:LeaseholdImprovementsMember 2022-10-01 2022-12-31 0001362703 us-gaap:ComputerEquipmentMember 2022-10-01 2022-12-31 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-05-12 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-05-12 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-05-12 2021-05-12 0001362703 THER:FirstTrancheMember THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-05-01 2021-05-31 0001362703 THER:SecondTrancheMember THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-06-01 2021-06-30 0001362703 THER:ThirdTrancheMember THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-07-01 2021-07-31 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:InvestorsMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-05-12 0001362703 THER:InvestorsMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-05-12 2021-05-12 0001362703 us-gaap:InvestorMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 2021-11-01 0001362703 THER:InvestorsMember THER:NoteOneMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:InvestorsMember THER:NoteTwoMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 us-gaap:InvestorMember THER:WarrantTwoMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:InvestorsMember THER:NoteThreeMember THER:SecuritiesPurchaseAgreementMember 2022-01-01 0001362703 us-gaap:InvestorMember THER:WarrantThreeMember THER:SecuritiesPurchaseAgreementMember 2022-01-01 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 2021-11-01 0001362703 THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:FirstInvestorMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 2021-11-01 0001362703 THER:FirstInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:FirstInvestorMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:FirstInvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:NoteMember 2022-04-05 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2022-04-05 0001362703 THER:NoteMember 2022-03-24 2022-03-24 0001362703 THER:NoteMember 2022-04-05 2022-04-05 0001362703 THER:NoteMember 2022-09-30 0001362703 THER:MatthewSchwartzMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:NoteMember 2022-05-09 2022-05-09 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-05-09 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2022-05-09 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-05-24 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2022-05-24 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-06-10 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2022-06-10 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-07-01 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2022-07-01 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-05-09 2022-05-09 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember 2022-05-09 2022-05-09 0001362703 THER:NoteMember 2022-05-09 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember 2022-06-15 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember 2022-06-15 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember 2022-06-15 2022-06-15 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember 2022-09-30 0001362703 THER:JeffreyBuschMember THER:DemandPromissoryNoteAgreementMember 2022-07-29 0001362703 THER:JeffreyBuschMember THER:DemandPromissoryNoteAgreementMember 2022-08-02 0001362703 THER:JeffreyBuschMember THER:DemandPromissoryNoteAgreementMember 2022-09-30 0001362703 THER:DemandPromissoryNoteAgreementMember 2022-08-11 0001362703 THER:DemandPromissoryNoteAgreementMember 2022-09-30 0001362703 us-gaap:ConvertibleDebtMember THER:DemandPromissoryNoteAgreementMember 2022-09-02 0001362703 us-gaap:ConvertibleDebtMember THER:DemandPromissoryNoteAgreementMember 2022-09-30 0001362703 us-gaap:ConvertibleDebtMember 2022-09-30 0001362703 THER:DemandPromissoryNoteAgreementMember 2022-11-01 0001362703 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-11-29 0001362703 us-gaap:ConvertibleDebtMember us-gaap:SeriesFPreferredStockMember us-gaap:WarrantMember 2022-11-29 0001362703 srt:MinimumMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-11-29 0001362703 srt:MaximumMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-11-29 0001362703 us-gaap:PrivatePlacementMember 2022-11-29 0001362703 THER:NewRelatedPartyDebenturesMember 2022-11-29 0001362703 THER:NewRelatedPartyDebenturesMember 2022-11-29 2022-11-29 0001362703 THER:DemandPromissoryNotesMember THER:SecuritiesPurchaseAgreementMember 2022-09-02 0001362703 THER:NewRelatedPartyDebenturesMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 2022-11-29 0001362703 THER:DemandPromissoryNotesMember THER:SecuritiesPurchaseAgreementMember 2022-08-11 0001362703 THER:NewRelatedPartyDebenturesMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 0001362703 us-gaap:SeriesEPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 2022-11-29 0001362703 us-gaap:SeriesEPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 0001362703 us-gaap:SeriesFPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 2022-11-29 0001362703 us-gaap:SeriesFPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 0001362703 THER:SecuritiesPurchaseAgreementMember 2022-11-29 2022-11-29 0001362703 THER:SecuritiesPurchaseAgreementMember 2022-11-29 0001362703 us-gaap:ConvertibleDebtSecuritiesMember THER:NewRelatedPartyDebenturesMember 2022-11-29 0001362703 2022-11-29 0001362703 THER:SecuritiesExchangeAgreementsMember 2022-11-29 0001362703 THER:SecuritiesExchangeAgreementsMember 2022-11-29 2022-11-29 0001362703 THER:SecuritiesPurchaseAgreementMember 2022-08-11 0001362703 THER:SecuritiesPurchaseAgreementMember 2022-09-02 0001362703 THER:DemandPromissoryNotesMember 2022-09-02 0001362703 THER:SecuritiesPurchaseAgreementMember 2022-10-01 2022-12-31 0001362703 THER:SecondInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementSecondNovemberTwoThousandTwentyOneMember 2021-10-27 2021-11-01 0001362703 THER:SecondInvestorMember THER:NoteOneMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:SecondInvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:SecondInvestorMember THER:NoteTwoMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:SecondInvestorMember THER:WarrantTwoMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:SecondInvestorMember THER:SecuritiesPurchaseAgreementMember 2021-11-25 2021-12-01 0001362703 THER:SecondInvestorMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:SecondInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:SecondInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-11-25 2021-12-01 0001362703 THER:SecondInvestorMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-01-24 2022-01-26 0001362703 THER:SecondInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-01-26 0001362703 THER:SecondNovemberTwoThousnadAndTwentyOneNotesMember THER:SecuritiesPurchaseAgreementMember 2021-10-01 2022-09-30 0001362703 THER:SecondNovemberTwoThousnadAndTwentyOneNotesMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:ThirdInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-10-27 2021-11-01 0001362703 THER:ThirdInvestorMember THER:NoteOneMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:ThirdInvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:ThirdInvestorMember THER:NoteTwoMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:ThirdInvestorMember THER:WarrantTwoMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:ThirdInvestorMember THER:SecuritiesPurchaseAgreementMember 2021-11-25 2021-12-01 0001362703 THER:ThirdInvestorMember THER:SecuritiesPurchaseAgreementMember 2021-12-01 0001362703 THER:ThirdInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:ThirdInvestorMember THER:SecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:ThirdInvestorMember THER:ConvertibleNoteMember THER:SecuritiesPurchaseAgreementMember 2022-01-24 2022-01-26 0001362703 THER:ThirdInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-01-26 0001362703 THER:ThirdInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:FirstInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-01-27 0001362703 THER:FirstInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-01-27 2022-01-27 0001362703 THER:FirstInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-01-27 0001362703 THER:FirstInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-01-27 2022-01-27 0001362703 THER:FirstInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:SecondInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-01-31 0001362703 THER:SecondInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-01-30 2022-01-31 0001362703 THER:SecondInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-01-31 0001362703 THER:SecondInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-01-30 2022-01-31 0001362703 THER:SecondInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 us-gaap:InvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-04-30 0001362703 us-gaap:InvestorMember THER:NoteMember THER:SecuritiesPurchaseAgreementMember 2022-04-01 2022-04-30 0001362703 us-gaap:InvestorMember THER:WarrantOneMember THER:SecuritiesPurchaseAgreementMember 2022-04-30 0001362703 us-gaap:InvestorMember THER:NoteTwoMember THER:SecuritiesPurchaseAgreementMember 2022-04-01 2022-04-30 0001362703 us-gaap:InvestorMember THER:SecuritiesPurchaseAgreementMember 2022-04-30 0001362703 us-gaap:InvestorMember THER:SecuritiesPurchaseAgreementMember 2022-04-01 2022-04-30 0001362703 us-gaap:InvestorMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:JulyInvestorMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2022-07-02 0001362703 THER:JulyInvestorMember THER:NoteMember THER:SecuritiesPurchaseAgreementMember 2022-06-27 2022-07-02 0001362703 THER:JulyInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-07-02 0001362703 THER:JulyInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-06-27 2022-07-02 0001362703 THER:JulyInvestorMember THER:NoteTwoMember THER:SecuritiesPurchaseAgreementMember 2022-06-27 2022-07-02 0001362703 THER:JulyInvestorMember THER:SecuritiesPurchaseAgreementMember 2021-10-01 2022-09-30 0001362703 THER:JulyInvestorMember THER:SecuritiesPurchaseAgreementMember 2022-09-30 0001362703 2022-10-22 0001362703 2022-10-22 2022-10-22 0001362703 us-gaap:ConvertibleDebtMember us-gaap:WarrantMember THER:ShareExchangeAgreementMember 2022-11-29 0001362703 THER:PlacementAgentMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-01-31 0001362703 THER:PlacementAgentMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-11-29 0001362703 THER:NewDebenturesMember THER:SecuritiesExchangeAgreementMember 2022-11-29 0001362703 THER:AccreditedInvestorsMember THER:NewDebenturesMember THER:SecuritiesExchangeAgreementMember 2022-11-29 0001362703 THER:NewDebenturesMember THER:SecuritiesExchangeAgreementMember 2022-11-29 2022-11-29 0001362703 THER:ExchangedConvertibleNotesMember THER:SecuritiesExchangeAgreementMember 2022-11-29 0001362703 THER:SecuritiesExchangeAgreementMember 2022-11-29 2022-11-29 0001362703 THER:NewDebenturesMember THER:DemandPromissoryNotesMember 2022-11-29 0001362703 THER:SecuritiesExchangeAgreementMember 2022-11-29 0001362703 THER:NewDebenturesMember THER:SeriesCOnePreferredStockMember THER:SecuritiesExchangeAgreementMember 2022-11-29 2022-11-29 0001362703 THER:NewDebenturesMember THER:SeriesCTwoPreferredStockMember THER:SecuritiesExchangeAgreementMember 2022-11-29 2022-11-29 0001362703 THER:NewDebenturesMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 0001362703 THER:NewDebenturesMember 2022-11-29 2022-11-29 0001362703 THER:NewDebenturesMember 2022-11-29 0001362703 srt:MaximumMember THER:SecuritiesExchangeAgreementMember 2022-11-29 0001362703 THER:NewDebenturesMember THER:SecuritiesExchangeAgreementsMember 2022-11-29 0001362703 THER:DemandPromissoryNotesMember 2022-11-29 0001362703 THER:NewDebenturesMember THER:SecuritiesExchangeAgreementMember 2022-10-01 2022-12-31 0001362703 THER:PlacementAgencyAgreementMember 2022-11-29 2022-11-29 0001362703 THER:GunnarMember THER:PlacementAgencyAgreementMember 2022-11-29 2022-11-29 0001362703 THER:GunnarMember THER:PlacementAgencyAgreementMember 2022-11-29 0001362703 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-10-01 2022-12-31 0001362703 THER:RelatedPartyDebentureAndNewDebenturesMember THER:ExchangeAgreementsMember 2022-11-29 2022-11-29 0001362703 THER:RelatedPartyDebentureAndNewDebenturesMember THER:ExchangeAgreementsMember 2022-12-31 0001362703 THER:RelatedPartyDebentureAndNewDebenturesMember 2022-11-29 0001362703 THER:NewRelatedPartyDebenturesMember us-gaap:WarrantMember 2022-11-29 0001362703 THER:NewDebenturesMember us-gaap:WarrantMember 2022-11-29 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-10-21 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-10-21 2022-10-21 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-10-21 2021-10-21 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-04-26 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-04-25 2022-04-26 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-04-26 2022-04-26 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-04-26 2021-04-26 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2022-05-05 2022-05-05 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-05-05 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-05-05 2022-05-05 0001362703 srt:MaximumMember THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2021-05-05 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2022-12-31 0001362703 THER:JeffreyBuschMember THER:NotesPayableRelatedPartyMember THER:PromissoryNoteAgreementMember 2022-09-30 0001362703 THER:NotesPayableMember THER:NoteAgreementMember 2017-09-30 0001362703 THER:NotesPayableMember THER:NoteAgreementMember 2022-12-31 0001362703 THER:NotesPayableMember THER:NoteAgreementMember 2022-09-30 0001362703 us-gaap:MeasurementInputExpectedDividendRateMember 2022-11-29 0001362703 srt:MinimumMember 2022-11-29 0001362703 srt:MaximumMember 2022-11-29 0001362703 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember 2022-11-29 0001362703 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember 2022-11-29 0001362703 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-11-29 0001362703 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-11-29 0001362703 THER:FirstLessorMember THER:FinancingAgreementMember 2018-11-01 2018-11-30 0001362703 THER:FirstLessorMember THER:FinancingAgreementMember 2018-11-30 0001362703 THER:SecondLessorMember THER:FinancingAgreementMember 2018-11-01 2018-11-30 0001362703 THER:SecondLessorMember THER:FinancingAgreementMember 2018-11-30 0001362703 THER:ThirdLessorMember THER:FinancingAgreementMember 2019-03-01 2019-03-31 0001362703 THER:ThirdLessorMember THER:FinancingAgreementMember 2019-03-31 0001362703 THER:FourthLessorMember THER:FinancingAgreementMember 2019-08-01 2019-08-31 0001362703 THER:FourthLessorMember THER:FinancingAgreementMember 2019-08-31 0001362703 THER:FifthLessorMember THER:FinancingAgreementMember 2020-01-01 2020-01-31 0001362703 THER:FifthLessorMember THER:FinancingAgreementMember 2020-01-31 0001362703 srt:MinimumMember 2022-12-31 0001362703 THER:LeaseAgreementMember 2019-12-01 2019-12-31 0001362703 THER:FirstYearMember THER:LeaseAgreementMember 2019-12-01 2019-12-31 0001362703 THER:SecondYearMember THER:LeaseAgreementMember 2019-12-01 2019-12-31 0001362703 THER:ThirdYearMember THER:LeaseAgreementMember 2019-12-01 2019-12-31 0001362703 THER:FourthYearMember THER:LeaseAgreementMember 2019-12-01 2019-12-31 0001362703 THER:FifthYearMember THER:LeaseAgreementMember 2019-12-01 2019-12-31 0001362703 us-gaap:AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember 2020-02-29 0001362703 THER:LeaseAmendmentMember 2021-06-10 0001362703 THER:LeaseAmendmentMember 2021-06-09 2021-06-10 0001362703 us-gaap:AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember 2021-10-31 0001362703 us-gaap:AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember 2021-10-01 2021-10-31 0001362703 THER:MrKucharchukMember 2021-01-01 2021-01-01 0001362703 THER:MrKucharchukMember 2022-12-31 0001362703 THER:MrKucharchukMember 2022-09-30 0001362703 THER:JeffreyBuschMember THER:PromissoryNoteAgreementMember 2021-04-26 0001362703 srt:BoardOfDirectorsChairmanMember 2022-05-04 2022-05-05 0001362703 srt:BoardOfDirectorsChairmanMember 2022-05-05 0001362703 srt:BoardOfDirectorsChairmanMember 2022-12-31 0001362703 srt:BoardOfDirectorsChairmanMember 2022-09-30 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:MayTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2021-05-12 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:MayTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:JeffreyBuschMember THER:PromissoryNoteAgreementMember 2021-10-21 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2021-11-01 0001362703 THER:InvestorsMember THER:ConvertibleNoteMember THER:FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:InvestorsMember THER:FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2022-01-26 2022-01-26 0001362703 THER:InvestorsMember us-gaap:WarrantMember THER:FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2022-01-26 0001362703 THER:InvestorsMember us-gaap:WarrantMember THER:FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember 2022-01-26 2022-01-26 0001362703 THER:MatthewSchwartzMember THER:FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-04-05 0001362703 THER:MatthewSchwartzMember THER:FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-03-23 2022-03-24 0001362703 THER:MatthewSchwartzMember THER:FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:InvestorsMember THER:FourConvertibleNotesMember THER:MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-05-09 0001362703 THER:InvestorsMember THER:FourConvertibleNotesMember THER:MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-05-09 2022-05-09 0001362703 THER:InvestorsMember THER:FourConvertibleNotesMember THER:MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:DanicaHolleyMember THER:JuneTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-06-15 0001362703 THER:DanicaHolleyMember THER:JuneTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember 2022-09-30 0001362703 THER:JeffreyBuschMember THER:SecondDemandPromissoryNoteAgreementMember 2022-09-02 0001362703 THER:DemandPromissoryNoteAgreementOneMember 2022-09-02 0001362703 THER:DemandPromissoryNoteAgreementOneMember 2022-09-30 0001362703 us-gaap:MajorityShareholderMember 2022-09-30 0001362703 us-gaap:MajorityShareholderMember 2021-10-01 2022-09-30 0001362703 us-gaap:IPOMember 2022-11-29 0001362703 us-gaap:IPOMember 2022-11-29 2022-11-29 0001362703 THER:DemandPromissoryNotesMember 2022-08-11 0001362703 us-gaap:SeriesFPreferredStockMember 2022-11-29 0001362703 THER:ConvertibleNoteMember us-gaap:SeriesFPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 0001362703 2020-09-22 0001362703 2020-09-24 0001362703 2022-06-30 0001362703 2022-07-01 0001362703 us-gaap:SeriesAPreferredStockMember 2015-08-20 0001362703 us-gaap:SeriesAPreferredStockMember 2015-08-19 2015-08-20 0001362703 THER:BoardOfDirectorsMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001362703 THER:BoardOfDirectorsMember us-gaap:SeriesAPreferredStockMember 2022-09-30 0001362703 THER:SeriesCOnePreferredStockMember 2020-05-18 0001362703 THER:BoardOfDirectorsMember THER:SeriesCOnePreferredStockMember 2020-05-18 0001362703 THER:SeriesCTwoPreferredStockMember 2020-05-18 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:CommonStockMember 2020-05-18 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:CommonStockMember 2020-05-14 2020-05-18 0001362703 srt:MinimumMember THER:SeriesCOnePreferredStockMember 2020-05-18 0001362703 THER:SeriesCOnePreferredStockMember 2021-10-01 2022-09-30 0001362703 THER:SeriesCOnePreferredStockMember us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001362703 THER:SeriesCOnePreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 2022-11-29 0001362703 THER:BoardOfDirectorsMember THER:SeriesCTwoPreferredStockMember 2020-05-18 0001362703 THER:SeriesCTwoPreferredStockMember 2020-05-14 2020-05-18 0001362703 THER:SeriesCTwoPreferredStockMember 2021-10-01 2022-09-30 0001362703 THER:SeriesCTwoPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2022-11-29 2022-11-29 0001362703 us-gaap:SeriesEPreferredStockMember 2020-09-15 0001362703 us-gaap:SeriesEPreferredStockMember 2020-09-12 2020-09-15 0001362703 us-gaap:SeriesEPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2020-09-16 0001362703 us-gaap:SeriesEPreferredStockMember 2019-10-01 2020-09-30 0001362703 srt:MinimumMember us-gaap:SeriesEPreferredStockMember 2021-09-30 0001362703 srt:MaximumMember us-gaap:SeriesEPreferredStockMember 2021-09-30 0001362703 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001362703 us-gaap:SeriesFPreferredStockMember 2021-07-30 0001362703 us-gaap:SeriesFPreferredStockMember 2021-07-30 2021-07-30 0001362703 THER:InvestorsMember us-gaap:SeriesFPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2021-07-30 2021-07-30 0001362703 THER:InvestorsMember us-gaap:WarrantMember THER:SecuritiesPurchaseAgreementMember 2021-07-30 2021-07-30 0001362703 THER:InvestorsMember THER:SecuritiesPurchaseAgreementMember 2021-07-30 2021-07-30 0001362703 THER:InvestorsMember us-gaap:SeriesFPreferredStockMember THER:SecuritiesPurchaseAgreementMember 2021-07-30 0001362703 us-gaap:SeriesFPreferredStockMember 2020-10-01 2021-09-30 0001362703 2022-11-29 2022-11-29 0001362703 us-gaap:SeriesFPreferredStockMember 2022-07-01 2022-09-30 0001362703 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001362703 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001362703 us-gaap:StockOptionMember 2022-04-18 0001362703 us-gaap:StockOptionMember 2022-04-17 2022-04-18 0001362703 THER:TwoThousandTwentyTwentyTwoPlanMember 2022-08-16 0001362703 2022-08-16 0001362703 2022-08-16 2022-08-16 0001362703 us-gaap:StockOptionMember 2022-12-31 0001362703 THER:ConvertibleNoteMember 2021-05-12 0001362703 THER:ConvertibleNoteMember 2021-05-12 2021-05-12 0001362703 THER:FirstNovemberTwoThousandTwentyOneMember 2021-11-01 0001362703 THER:FirstNovemberTwoThousandTwentyOneMember 2021-11-01 2021-11-01 0001362703 THER:SecondNovemberTwoThousandTwentyOneMember 2021-11-01 0001362703 THER:SecondNovemberTwoThousandTwentyOneMember 2021-11-01 2021-11-01 0001362703 THER:ThirdNovemberTwoThousandTwentyOneMember 2021-11-01 0001362703 THER:ThirdNovemberTwoThousandTwentyOneMember 2021-11-01 2021-11-01 0001362703 THER:FirstNovemberTwoThousandTwentyOneMember 2022-01-26 0001362703 THER:FirstNovemberTwoThousandTwentyOneMember 2022-01-26 2022-01-26 0001362703 THER:SecondNovemberTwoThousandTwentyOneMember 2022-01-26 0001362703 THER:SecondNovemberTwoThousandTwentyOneMember 2022-01-26 2022-01-26 0001362703 THER:ThirdNovemberTwoThousandTwentyOneMember 2022-01-26 0001362703 THER:ThirdNovemberTwoThousandTwentyOneMember 2022-01-26 2022-01-26 0001362703 THER:FirstJanuaryTwoThousandTwentyTwoMember 2022-01-27 0001362703 THER:FirstJanuaryTwoThousandTwentyTwoMember 2022-01-27 2022-01-27 0001362703 THER:SecondJanuaryTwoThousandTwentyTwoMember 2022-01-31 0001362703 THER:SecondJanuaryTwoThousandTwentyTwoMember 2022-01-31 2022-01-31 0001362703 THER:TwoConsultantsMember us-gaap:WarrantMember 2022-01-31 0001362703 THER:TwoConsultantsMember us-gaap:WarrantMember 2022-01-31 2022-01-31 0001362703 THER:FirstAprilTwoThousandTwentyTwoMember 2022-04-05 0001362703 THER:FirstAprilTwoThousandTwentyTwoMember 2022-04-05 2022-04-05 0001362703 THER:SecondAprilTwoThousandTwentyTwoMember 2022-04-30 0001362703 THER:SecondAprilTwoThousandTwentyTwoMember 2022-04-30 2022-04-30 0001362703 THER:MayTwoThousandTwentyTwoMember 2022-05-09 0001362703 THER:MayTwoThousandTwentyTwoMember 2022-05-09 2022-05-09 0001362703 THER:JuneTwoThousandTwentyTwoMember 2022-06-15 0001362703 THER:JuneTwoThousandTwentyTwoMember 2022-06-15 2022-06-15 0001362703 THER:JulyTwoThousandTwentyTwoMember 2022-07-01 0001362703 THER:JulyTwoThousandTwentyTwoMember 2022-07-01 2022-07-01 0001362703 THER:FirstNovemberTwoThousandAndTwentyOneMember 2022-11-29 0001362703 THER:CurrentExercisePriceMember 2022-11-29 2022-11-29 0001362703 THER:NewExercisePriceMember 2022-11-29 2022-11-29 0001362703 THER:SecondNovemberTwoThousandAndTwentyOneMember 2022-11-29 0001362703 THER:SecondNovemberTwoThousandAndTwentyOneMember 2022-11-29 2022-11-29 0001362703 THER:SecondNovemberTwoThousandAndTwentyOneMember THER:NewExercisePriceMember 2022-11-29 2022-11-29 0001362703 us-gaap:WarrantMember THER:SecuritiesExchangeAgreementsMember 2022-10-01 2022-12-31 0001362703 THER:InvestorsMember us-gaap:WarrantMember THER:SecuritiesExchangeAgreementsMember 2022-10-01 2022-12-31 0001362703 THER:PlacementAgencyAgreementMember 2022-12-31 0001362703 THER:ConsultantMember THER:PlacementAgencyAgreementMember 2022-12-31 0001362703 2021-10-01 2022-09-30 0001362703 us-gaap:WarrantMember 2022-09-30 0001362703 us-gaap:WarrantMember 2021-10-01 2022-09-30 0001362703 us-gaap:WarrantMember 2022-10-01 2022-12-31 0001362703 us-gaap:WarrantMember 2022-12-31 0001362703 THER:DrMichaelRuxinMember THER:RuxinEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 THER:DrMichaelRuxinMember THER:RuxinEmploymentAgreementMember 2020-06-05 0001362703 THER:DrMichaelRuxinMember THER:TwoThousandTwentyTwentyTwoEquityIncentivePlanMember THER:RuxinEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 THER:DrMichaelRuxinMember us-gaap:EmployeeStockOptionMember THER:TwoThousandTwentyTwentyTwoEquityIncentivePlanMember THER:RuxinEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 THER:DrMichaelRuxinMember THER:TwoThousandTwentyTwentyTwoEquityIncentivePlanMember THER:RuxinEmploymentAgreementMember 2022-08-16 2022-08-16 0001362703 THER:DrMichaelRuxinMember THER:TwoThousandTwentyTwentyTwoEquityIncentivePlanMember THER:RuxinEmploymentAgreementMember 2022-08-16 0001362703 THER:DrMichaelRuxinMember 2022-10-01 2022-12-31 0001362703 THER:DrMichaelRuxinMember 2021-10-01 2022-09-30 0001362703 THER:JeffreyBuschMember THER:BuschEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 THER:JeffreyBuschMember us-gaap:RestrictedStockUnitsRSUMember THER:TwoThousandTwentyEquityIncentivePlanMember THER:BuschEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 THER:JeffreyBuschMember us-gaap:EmployeeStockOptionMember THER:TwoThousandTwentyEquityIncentivePlanMember THER:BuschEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 THER:JeffreyBuschMember us-gaap:RestrictedStockUnitsRSUMember THER:TwoThousandTwentyEquityIncentivePlanMember THER:BuschEmploymentAgreementMember 2022-08-16 2022-08-16 0001362703 THER:JeffreyBuschMember us-gaap:EmployeeStockOptionMember THER:TwoThousandTwentyEquityIncentivePlanMember THER:BuschEmploymentAgreementMember 2022-08-16 2022-08-16 0001362703 THER:JeffreyBuschMember us-gaap:RestrictedStockUnitsRSUMember THER:TwoThousandTwentyEquityIncentivePlanMember THER:BuschEmploymentAgreementMember 2020-06-05 0001362703 THER:JeffreyBuschMember THER:TwoThousandTwentyEquityIncentivePlanMember THER:BuschEmploymentAgreementMember 2020-06-03 2020-06-05 0001362703 us-gaap:RestrictedStockUnitsRSUMember THER:BuschEmploymentAgreementMember 2022-12-31 0001362703 us-gaap:RestrictedStockUnitsRSUMember THER:BuschEmploymentAgreementMember 2022-09-30 0001362703 THER:ThomasEChilcottThreeMember THER:OfferLetterMember 2020-09-23 2020-09-24 0001362703 srt:MinimumMember THER:ThomasEChilcottThreeMember 2021-12-30 2021-12-31 0001362703 srt:MaximumMember THER:ThomasEChilcottThreeMember 2021-12-30 2021-12-31 0001362703 THER:ThomasEChilcottThreeMember 2021-12-30 2021-12-31 0001362703 srt:MinimumMember THER:ThomasEChilcottThreeMember 2022-10-01 2022-12-31 0001362703 THER:ZaslavskyMember 2022-12-05 2022-12-05 0001362703 THER:ZaslavskyMember 2022-12-05 0001362703 THER:ZaslavskyMember us-gaap:EmployeeStockOptionMember 2022-12-05 0001362703 THER:ZaslavskyMember us-gaap:EmployeeStockOptionMember 2022-12-05 2022-12-05 0001362703 THER:ConsultantMember THER:ScientificAdvisoryBoardServiceAgreementMember 2020-07-03 2020-07-05 0001362703 THER:ConsultantMember THER:TwoThousandTwentyTwentyTwoPlanMember THER:ScientificAdvisoryBoardServiceAgreementMember 2020-07-03 2020-07-05 0001362703 THER:ConsultantMember THER:PathologyAdvisoryBoardServiceAgreementMember 2020-07-03 2020-07-05 0001362703 THER:ConsultantMember THER:TwoThousandTwentyTwentyTwoPlanMember THER:PathologyAdvisoryBoardServiceAgreementMember 2020-07-03 2020-07-05 0001362703 THER:ConsultingAgreementMember 2021-01-01 2021-01-01 0001362703 THER:ExclusiveLicenseAgreementMember THER:GeorgeMasonUniversityMember 2006-09-01 2006-09-30 0001362703 THER:SublicenseRoyaltyMember THER:ExclusiveLicenseAgreementMember THER:GeorgeMasonUniversityMember 2006-09-01 2006-09-30 0001362703 THER:ExclusiveLicenseAgreementMember THER:GeorgeMasonUniversityMember 2022-12-31 0001362703 THER:ExclusiveLicenseAgreementMember THER:GeorgeMasonUniversityMember 2022-09-30 0001362703 THER:LicenseAgreementMember THER:NationalInstitutesOfHealthMember 2018-03-01 2018-03-31 0001362703 THER:SublicenseRoyaltyMember THER:LicenseAgreementMember THER:NationalInstitutesOfHealthMember 2018-03-01 2018-03-31 0001362703 THER:LicenseAgreementMember THER:NationalInstitutesOfHealthMember 2022-12-31 0001362703 us-gaap:LeaseAgreementsMember 2019-12-01 2019-12-31 0001362703 us-gaap:LeaseAgreementsMember 2019-12-31 0001362703 srt:MinimumMember 2021-12-08 2021-12-10 0001362703 2017-09-30 0001362703 us-gaap:SubsequentEventMember 2023-01-27 0001362703 us-gaap:SubsequentEventMember 2023-01-27 2023-01-27 0001362703 THER:GunnarMember us-gaap:SubsequentEventMember 2023-01-27 2023-01-27 0001362703 THER:NewDebenturesMember us-gaap:SubsequentEventMember 2023-01-27 2023-01-27 0001362703 THER:NewDebenturesMember us-gaap:SubsequentEventMember 2023-01-27 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001362703 false --09-30 2022 Q1

P3Y

10-Q true 2022-12-31 false 000-52218 Theralink Technologies, Inc. NV 20-2590810 15000 W. 6th Avenue Suite 400 Golden CO 80401 (720) 420-0074 Yes Yes Non-accelerated Filer true false false false 6151499919

1130902

393460

48295

32125

197723

217699

1700

3700

1378620

646984

655220

686127

53362

64954

1142419

1154861

27270

18715

3248336

2598911

675358

730923

6000

16223

156925

268021

82043 76927

561472

383295

207500

192500

177050

156550

676584

771444 1000000

350000

1000

52037

53995

26960

25551

86497

122295

42466252

80240

78440

46377362

3455720

23469

34390

1150424

1157761

1305814

446281

47551255

6399966

0.0001

2000

1000

2040329

2000000

0.0001

2000

500

1020164

1000000

0.0001

26667

0.0001

1333

667

0.0001

3000

141

1043

0.0001

6000

3037

0.0001

1000

0.0001

4360

0.0001

100000000000

6151499919

615150

54385547

55391612

-99303616

-62807817

-44302919

-6801055

3248336

2598911

55295

78975

10818

43565

44477

35410

387438

217823

1752699

625855

31637 36092

448493

537656

2620267

1417426

-2575790

-1382016

1847035

135651

-5434447

-2000

5400

200000

26397075

-33880557

-130251

-36456347

-1512267

26301

40329

13151

20164

13151

20164

-36495799

-1572760

-0.01

-0.00

6151499846

5555474165

667

1043

3037

6151499919

615150

55391612

-62807817

-6801055

612173

-902

-3037

-1618238

26301

13151

-36456347

667

141

6151499919

615150

54385547

-99303616

-44302919

667

2966

4917

5124164690

512416

44368077

-49825855

-4945362

667

2966

4917

5124164690

512416

44368077

-49825855

-4945362

661088

991120 991120

40329

20164

-1436

-1512267

667

2966

4917

5124163254

512416

46020285

-51398615

-4865914

667

2966

4917

5124163254

512416

46020285

-51398615

-4865914

-36456347

-1512267

50479

47557

6514 7379

612173

1602646

92019

-5434447

-2000

5400

200000

26397075

8229

16170

49725

-19976

25318

-49356

-65788

-139398

416146

28484

20500

20750

-1776349

-1494792

7980

-7980

536562

667000

2118088

1000000

150000

120000

12879

11389

59988

2521771

1595623

737442

100831

393460

314151

1130902

414982

3574

21228

26301 40329 13151 20164 1212708 661088 991120 8837284 7231893 231841 3099945

1618238

129079 173375

<p id="xdx_802_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zEiYRzNOfk15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Theralink Technologies, Inc., formerly OncBioMune Pharmaceuticals, Inc. (the “Company”), was a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology. On June 5, 2020, the Company acquired the assets (the “Asset Sale Transaction”) of Avant Diagnostics, Inc., a Nevada corporation established in 2009 (“Avant”) pursuant to the Asset Purchase Agreement dated May 12, 2020, between the Company and Avant (the “Asset Purchase Agreement”). Avant is a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of a series of patented, proprietary data-generating assays that may provide important actionable information for physicians and patients, as well as biopharmaceutical companies, in the area of oncology. Pursuant to the Asset Purchase Agreement, the Company acquired substantially all of the assets of Avant and assumed certain of its liabilities. Upon the terms and subject to the conditions of the Asset Purchase Agreement, Avant sold to the Company, all of Avant’s title and interest in all the assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether existing or hereafter acquired, except for the specific excluded assets, which relate to, or are used or held for use in connection with, Avant’s business. The Company also hired Avant’s employees upon consummation of the Asset Sale Transaction. As consideration for the Asset Sale Transaction, the Company issued to Avant <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200602__20200605__us-gaap--StatementClassOfStockAxis__custom--SeriesDOnePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zZkDHdwtX3zd" title="Number of shares issued">1,000 shares of a newly created Series D-1 Preferred Stock which held <span id="xdx_90C_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20200605__us-gaap--StatementClassOfStockAxis__custom--SeriesDOnePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AvantMember_zddX1nDdz7cb" title="Percentage of voting Interests acquired">54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Company’s authorized shares of common stock from <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20200605__us-gaap--StatementClassOfStockAxis__custom--SeriesDOnePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zCFLLnbm7urd" title="Common stock shares authorized">6,666,667 shares to <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDOnePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zkkmgelwLtJc" title="Common stock shares authorized">12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20200602__20200605__us-gaap--StatementClassOfStockAxis__custom--SeriesDOnePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zp9u5AWSBcM2" title="Conversion of stock shares converted">5,081,549,184 shares of the Company’s common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction and controlled the Company’s Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Accordingly, the Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net asset by Avant and a recapitalization of Avant. Avant is considered the historical registrant and the historical operations presented are those of Avant since Avant obtained <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_dp_uPure_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--AvantMember_zZy0qQI4S2Q3" title="Sale of stock percentage of ownership after transaction">54.55% majority voting control of the Company. All share and per share data in the accompanying financial statements and footnotes has been retrospectively adjusted for the recapitalization. On July 11, 2021, the Company’s wholly-owned subsidiary, OncBioMune, LLC, was administratively dissolved by the Louisiana Secretary of State for failing to meet its filing requirements and pay the associated fees. In connection with the Asset Sale Transaction, the Company entered into an Exchange Agreement, effective June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the investors named therein, whereby the Company agreed to exchange certain convertible promissory notes and warrants outstanding for shares of Series C-1 Convertible Preferred Stock of the Company and options to purchase shares of the Company’s wholly-owned subsidiary, OncBioMune Sub Inc. OncBioMune Sub Inc. holds the patents used in the prior business of OncBioMune Pharmaceuticals, Inc. In July 2021, certain of those investors exercised their options to purchase the shares of OncBioMune Sub Inc. On July 26, 2021, the Company transferred all <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210725__20210726__dei--LegalEntityAxis__custom--OncBioMuneSubIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztOpcOGGJik4" title="Number of shares issued">10,000 shares of OncBioMune Sub Inc. held by the Company to the various investors for gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210725__20210726__dei--LegalEntityAxis__custom--OncBioMuneSubIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zVjFMcv4Jilc" title="Gross proceeds from issuance of stock">1,000 (see Note 3). On February 25, 2022, FINRA recognized the Company’s name change to Theralink Technologies, Inc. and the related ticker symbol change from “OBMP” to “THER” went into effect.

1000

0.5455

6666667

12000000000

5081549184

0.5455

10000

1000

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information, which present the unaudited financial statements of the Company as of December 31, 2022. The interim unaudited financial statements do not include all the information and notes necessary for a comprehensive presentation of financial position and results of operations and should be read in conjunction with the September 30, 2022 audited financial statements on Form 10-K filed on December 29, 2022. It is management’s opinion that all material adjustments (consisting of normal recurring adjustments and non-recurring adjustments) have been made for the fair presentation of the unaudited financial statements. The results for the interim period are not necessarily indicative of the results to be expected for the year ending September 30, 2023. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Going Concern These unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited financial statements, the Company had net loss and net cash used in operations of $36,456,347 and $1,776,349, respectively, for the three months ended December 31, 2022. Additionally, the Company had an accumulated deficit, stockholders’ deficit and working capital deficit of $99,303,616, $44,302,919 and $44,998,742 on December 31, 2022. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. The Company cannot provide assurance that it will ultimately achieve profitable operations or become cash flow positive or raise additional debt or equity capital. Additionally, the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and the issuance of promissory notes, convertible notes and convertible debentures, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the periods ended December 31, 2022 and 2021 include, but are not necessarily limited to, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use ROU assets and lease liabilities, assumptions used in assessing impairment of long-lived assets, allowances for accounts receivable, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of derivative liabilities, and the fair value of non-cash equity transactions. Fair Value of Financial Instruments and Fair Value Measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on December 31, 2022. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on the disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</td></tr> </table> The carrying amounts reported in the balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, contract liabilities, and accrued compensation approximate their fair market value based on the short-term maturity of these instruments. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Assets or liabilities measured at fair value or a recurring basis included embedded conversion options in convertible debt (see Note 6) and were as follows on December 31, 2022 and September 30, 2022: SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold">Description</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 1</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 1</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left">Derivative liabilities</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zL72Q6F8Lff9" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zuJuaoJhXOIh" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2748KBe4r9l" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">42,466,252</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9NeJ113Jhei" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfaMJjYAZvMa" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrLyrsb4cRZ6" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> A roll forward of the level 3 valuation financial instruments is as follows: SCHEDULE OF VALUATION ON DERIVATIVE INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_498_20221001__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze1BMEWXRMD2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_49C_20211001__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuWVVLj86rs9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">For the Three Months Ended December 31,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iS_zldhdlqwMYZ8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance at beginning of period</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DerivativeLiabilitiesIncludedInDebtDiscount_zzvRQdnQRj79" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify">Initial valuation of derivative liabilities included in debt discount</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">16,069,178</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DerivativeLiabilitiesIncludedInDerivativeExpenses_znCEF7t0mGMe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Initial valuation of derivative liabilities included in derivative expense</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">25,891,917</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeGainLossOnDerivativeNet_zL8uFiFBnT3g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Change in fair value included in derivative expense</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">505,158</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPpqPVJGHse6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance at end of period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">42,466,252</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of, the financial institutions with which it invests. Prepaid Assets Prepaid assets are carried at amortized cost. Significant prepaid assets as of December 31, 2022 and September 30, 2022 include, but are not necessarily limited to, prepaid insurance, prepaid consulting fees, prepaid equipment maintenance fees and retainers for professional services. Laboratory Supplies Laboratory supplies are normally consumed within a year from purchase and any unused laboratory supplies are classified as current assets and reflected in the accompanying balance sheets as laboratory supplies. Property and Equipment Fixed assets are stated at cost and depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of their useful life or the lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. <p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zc2jNnBvwE7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment of Long-Lived Assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation”, which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award be based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under the FASB’s Accounting Standards Update (“ASU”) 2016-09 Improvements to Employee Share-Based Payment. Revenue Recognition and Contract Assets and Liabilities In accordance with ASU Topic 606 - Revenue from Contracts with Customers, the Company recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company provides research and development support to biopharmaceutical companies to assist their drug development programs. In January 2021, the Company began performing tumor profiling to support clinical patient therapeutic intervention. The services provided by the Company are performance obligations under services contracts. These contracts are completed over time and may lead to deferred revenue for services not completed at the end of a period which is reflected as contract liabilities on the accompanying balance sheet. The Company may include, in accounts receivable, amounts billed to customers in advance of services being initiated or completed. If the Company has a right to such consideration that is unconditional such as for contractually allowed billings under non-cancellable contracts, such amounts billed in advance would be offset by a contract liability. Management reviews the completion status of all jobs monthly to determine the appropriate amount of revenue to recognize. The Company offers these services to biopharmaceutical companies and to private individuals. The Company uses various output methods to recognize revenues. The revenue recognized from services provided to private individuals during the three months ended December 31, 2022 and 2021 were minimal and therefore were not disaggregated for disclosure purposes. Contract Liabilities Contract liabilities are cash deposits received from customers and advance billing included in accounts receivable on uncompleted contracts for which revenues have not been recognized as of the balance sheet date. For the three months ended December 31, 2022 and 2021, contract liabilities activity is as follows: SCHEDULE OF CONTRACT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221001__20221231_zrGrunda7NS8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211001__20211231_zhQEs50zGw9a" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--ContractWithCustomerLiability_iS_zqOlUqT7e2Tl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Contract liabilities beginning balance</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">156,550</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">135,150</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BillingsAndCashReceiptsOnUncompletedContract_zUvAj49vOaE7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Billings and cash receipts on uncompleted contracts</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">43,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_zlOBVBg1Irm2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: revenues recognized during the period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,500</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(22,250</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_z5Clv1HFZEPg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total contract liabilities</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">177,050</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">155,900</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended December 31, 2022, the Company recognized $3,500 of the contract liabilities into revenue, of which $3,500 was related to the uncompleted contracts from the prior period. Cost of Revenue The cost of revenue consists of the cost of labor, supplies and materials. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Accounts Receivable and Allowance for Doubtful Accounts Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis and does not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. Research and Development In fiscal 2022, the Company joined and made an investment in an investigator-initiated study. As part of that investment, the Company obtained rights/access to various retrospective biobank clinical samples for research and product development purposes. In addition, the Company received active patient clinical samples for the following disease sites: ovarian, endometrial, and head & neck cancers. These samples were tested to provide RUO (Research Use Only) results reports for research and product validation efforts. The transaction term is for 5-years, starting in September 2021. During the three months ended December 31, 2022 and 2021, the Company had spent $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zmkXOpWppYRc" title="Research and development expense">50,000 and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zkFhT9Xt6yRg" title="Research and development expense">25,000 on this research and development project, which is included in general and administrative expenses on the accompanying unaudited statements of operations. Derivative Liabilities The Company has certain financial instruments that are embedded derivatives associated with capital raises. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10 - Derivative and Hedging - Contract in Entity’s Own Equity. This accounting treatment requires that the carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment. Concentrations Concentration of Credit Risk The Company maintains its cash in banks and financial institutions that at times may exceed the federally insured limit of $250,000. As of December 31, 2022 and September 30, 2022, the cash balances were in excess of the FDIC insured limit by $898,012 and $186,466, respectively. The Company has not experienced any losses in such accounts through December 31, 2022. Concentration of Revenues For the three months ended December 31, 2022, the Company generated total revenue of $55,295 of which <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zp19hbmrrSI8" title="Concentration risk, percentage">72% was from one of the Company’s customers. During the three months ended December 31, 2021, the Company generated total revenue of $78,975 of which <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zqBdUrUjePGc" title="Concentration risk, percentage">56% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXThANpY5IDk" title="Concentration risk, percentage">35% were from two of the Company’s customers. Concentration of Accounts Receivable As of December 31, 2022, the Company had net accounts receivable of $48,295 of which <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zD6QGWRb6Ic1" title="Concentration risk, percentage">82% was from one of the Company’s customers. As of September 30, 2022, the Company had net accounts receivable of $32,125 of which <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z65VYsq3LbI9" title="Concentration risk, percentage">59% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zKkwqVYM6f2e" title="Concentration risk, percentage">41% were from two of the Company’s customers, respectively. Concentration of Contract Liabilities As of December 31, 2022, the Company had deferred revenue reflected as contract liabilities of $177,050 of which <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z7ZBOQabNsI2" title="Concentration risk, percentage">73% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zpkj5J0qt7ni" title="Concentration risk, percentage">21% were from two of the Company’s customers. As of September 30, 2022, the Company had deferred revenue reflected as contract liabilities of $156,550 of which <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z6wDYFRCeZmk" title="Concentration risk, percentage">65% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zpDxGB2BASle" title="Concentration risk, percentage">24% were from two of the Company’s customers. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Concentration of Vendors Historically, the Company relied on one vendor to perform the Company’s patient reporting and contract research (formerly called sample analysis) which is an integral part of the Company’s operation and revenue stream. Any disruption in this service could have a material adverse effect on the Company’s business, financial condition and results of operations. The Company discontinued using this vendor in June 2022 as the patient reporting function has been moved in-house. During the three months ended December 31, 2022 and 2021, the Company incurred $0 and $113,295, respectively, or 100%, of its patient reporting and contract research (formerly called sample analysis) expense from one vendor. Basic and Diluted Loss Per Share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes, conversion of preferred stock, and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of December 31, 2022 and 2021 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zX7LMCQKxivc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20221001__20221231_zwXqHjN1hcwa" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_494_20211001__20211231_zXjYyFp6bAw7" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December 31,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z1JzOamc13Nc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Stock warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">6,862,673,594</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">1,075,563,017</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z1c5nmiNves" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Stock options</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCOnePreferredStockMember_zk6rF9jBPkPc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series C-1 preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">212,431</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">445,301,289</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCTwoPreferredStockMember_zaiyLQF0Ha57" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series C-2 preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">733,542,619</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zqxtgOQhTKn5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series E preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">638,977,636</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesFPreferredStockMember_zScbuGmzf1Ej" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series F preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">319,488,818</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zDNWyyJ6fMR5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,765,180,181</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">780,807,641</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zfU3twzUEZnh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Total antidilutive securities excluded from computation of earnings</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">17,529,476,725</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,993,681,020</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Income Taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes”. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. As of December 31, 2022 and 2021, the Company had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. The Company recognizes interest and penalties related to uncertain income tax positions in other expense. However, no such interest and penalties were recorded as of December 31, 2022 and 2021. Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Leases The Company accounts for its leases using the method prescribed by ASC 842 – Lease Accounting. The Company assess whether a contract is, or contains, a lease at the inception of the contract which is based on (i) whether the contract involves the use of a distinct identified asset, (ii) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating and financing lease ROU assets represent the right to use the leased asset for the lease term. Operating and financing lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the unaudited statements of operations. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s financial statements.

Basis of Presentation The accompanying interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information, which present the unaudited financial statements of the Company as of December 31, 2022. The interim unaudited financial statements do not include all the information and notes necessary for a comprehensive presentation of financial position and results of operations and should be read in conjunction with the September 30, 2022 audited financial statements on Form 10-K filed on December 29, 2022. It is management’s opinion that all material adjustments (consisting of normal recurring adjustments and non-recurring adjustments) have been made for the fair presentation of the unaudited financial statements. The results for the interim period are not necessarily indicative of the results to be expected for the year ending September 30, 2023. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED)

Going Concern These unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited financial statements, the Company had net loss and net cash used in operations of $36,456,347 and $1,776,349, respectively, for the three months ended December 31, 2022. Additionally, the Company had an accumulated deficit, stockholders’ deficit and working capital deficit of $99,303,616, $44,302,919 and $44,998,742 on December 31, 2022. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. The Company cannot provide assurance that it will ultimately achieve profitable operations or become cash flow positive or raise additional debt or equity capital. Additionally, the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and the issuance of promissory notes, convertible notes and convertible debentures, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

-36456347

-1776349

-99303616

-44302919

44998742

Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the periods ended December 31, 2022 and 2021 include, but are not necessarily limited to, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use ROU assets and lease liabilities, assumptions used in assessing impairment of long-lived assets, allowances for accounts receivable, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of derivative liabilities, and the fair value of non-cash equity transactions.

Fair Value of Financial Instruments and Fair Value Measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on December 31, 2022. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on the disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</td></tr> </table> The carrying amounts reported in the balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, contract liabilities, and accrued compensation approximate their fair market value based on the short-term maturity of these instruments. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Assets or liabilities measured at fair value or a recurring basis included embedded conversion options in convertible debt (see Note 6) and were as follows on December 31, 2022 and September 30, 2022: SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold">Description</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 1</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 1</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left">Derivative liabilities</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zL72Q6F8Lff9" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zuJuaoJhXOIh" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2748KBe4r9l" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">42,466,252</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9NeJ113Jhei" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfaMJjYAZvMa" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrLyrsb4cRZ6" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> A roll forward of the level 3 valuation financial instruments is as follows: SCHEDULE OF VALUATION ON DERIVATIVE INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_498_20221001__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze1BMEWXRMD2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_49C_20211001__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuWVVLj86rs9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">For the Three Months Ended December 31,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iS_zldhdlqwMYZ8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance at beginning of period</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DerivativeLiabilitiesIncludedInDebtDiscount_zzvRQdnQRj79" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify">Initial valuation of derivative liabilities included in debt discount</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">16,069,178</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DerivativeLiabilitiesIncludedInDerivativeExpenses_znCEF7t0mGMe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Initial valuation of derivative liabilities included in derivative expense</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">25,891,917</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeGainLossOnDerivativeNet_zL8uFiFBnT3g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Change in fair value included in derivative expense</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">505,158</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPpqPVJGHse6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance at end of period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">42,466,252</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.

Assets or liabilities measured at fair value or a recurring basis included embedded conversion options in convertible debt (see Note 6) and were as follows on December 31, 2022 and September 30, 2022: SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold">Description</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 1</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 1</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 2</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Level 3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left">Derivative liabilities</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zL72Q6F8Lff9" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zuJuaoJhXOIh" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2748KBe4r9l" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">42,466,252</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9NeJ113Jhei" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zfaMJjYAZvMa" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrLyrsb4cRZ6" style="font-family: Times New Roman, Times, Serif; width: 6%; text-align: right" title="Derivative liabilities">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table>

42466252

A roll forward of the level 3 valuation financial instruments is as follows: SCHEDULE OF VALUATION ON DERIVATIVE INSTRUMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_498_20221001__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ze1BMEWXRMD2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_49C_20211001__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuWVVLj86rs9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">For the Three Months Ended December 31,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iS_zldhdlqwMYZ8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance at beginning of period</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DerivativeLiabilitiesIncludedInDebtDiscount_zzvRQdnQRj79" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify">Initial valuation of derivative liabilities included in debt discount</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">16,069,178</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DerivativeLiabilitiesIncludedInDerivativeExpenses_znCEF7t0mGMe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Initial valuation of derivative liabilities included in derivative expense</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">25,891,917</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeGainLossOnDerivativeNet_zL8uFiFBnT3g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Change in fair value included in derivative expense</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">505,158</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DerivativeLiabilitiesCurrent_iE_zPpqPVJGHse6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance at end of period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">42,466,252</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

16069178 25891917

505158

42466252

Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The Company’s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of, the financial institutions with which it invests.

Prepaid Assets Prepaid assets are carried at amortized cost. Significant prepaid assets as of December 31, 2022 and September 30, 2022 include, but are not necessarily limited to, prepaid insurance, prepaid consulting fees, prepaid equipment maintenance fees and retainers for professional services. Laboratory Supplies Laboratory supplies are normally consumed within a year from purchase and any unused laboratory supplies are classified as current assets and reflected in the accompanying balance sheets as laboratory supplies.

Property and Equipment Fixed assets are stated at cost and depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of their useful life or the lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

P5Y

<p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zc2jNnBvwE7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment of Long-Lived Assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED)

Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation”, which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award be based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under the FASB’s Accounting Standards Update (“ASU”) 2016-09 Improvements to Employee Share-Based Payment.

Revenue Recognition and Contract Assets and Liabilities In accordance with ASU Topic 606 - Revenue from Contracts with Customers, the Company recognizes revenue in accordance with that core principle by applying the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company provides research and development support to biopharmaceutical companies to assist their drug development programs. In January 2021, the Company began performing tumor profiling to support clinical patient therapeutic intervention. The services provided by the Company are performance obligations under services contracts. These contracts are completed over time and may lead to deferred revenue for services not completed at the end of a period which is reflected as contract liabilities on the accompanying balance sheet. The Company may include, in accounts receivable, amounts billed to customers in advance of services being initiated or completed. If the Company has a right to such consideration that is unconditional such as for contractually allowed billings under non-cancellable contracts, such amounts billed in advance would be offset by a contract liability. Management reviews the completion status of all jobs monthly to determine the appropriate amount of revenue to recognize. The Company offers these services to biopharmaceutical companies and to private individuals. The Company uses various output methods to recognize revenues. The revenue recognized from services provided to private individuals during the three months ended December 31, 2022 and 2021 were minimal and therefore were not disaggregated for disclosure purposes.

Contract Liabilities Contract liabilities are cash deposits received from customers and advance billing included in accounts receivable on uncompleted contracts for which revenues have not been recognized as of the balance sheet date. For the three months ended December 31, 2022 and 2021, contract liabilities activity is as follows: SCHEDULE OF CONTRACT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221001__20221231_zrGrunda7NS8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211001__20211231_zhQEs50zGw9a" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--ContractWithCustomerLiability_iS_zqOlUqT7e2Tl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Contract liabilities beginning balance</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">156,550</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">135,150</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BillingsAndCashReceiptsOnUncompletedContract_zUvAj49vOaE7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Billings and cash receipts on uncompleted contracts</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">43,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_zlOBVBg1Irm2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: revenues recognized during the period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,500</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(22,250</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_z5Clv1HFZEPg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total contract liabilities</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">177,050</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">155,900</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended December 31, 2022, the Company recognized $3,500 of the contract liabilities into revenue, of which $3,500 was related to the uncompleted contracts from the prior period.

For the three months ended December 31, 2022 and 2021, contract liabilities activity is as follows: SCHEDULE OF CONTRACT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221001__20221231_zrGrunda7NS8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211001__20211231_zhQEs50zGw9a" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--ContractWithCustomerLiability_iS_zqOlUqT7e2Tl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Contract liabilities beginning balance</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">156,550</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">135,150</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BillingsAndCashReceiptsOnUncompletedContract_zUvAj49vOaE7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Billings and cash receipts on uncompleted contracts</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">43,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_zlOBVBg1Irm2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: revenues recognized during the period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,500</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(22,250</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_z5Clv1HFZEPg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total contract liabilities</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">177,050</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">155,900</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

156550

135150

24000 43000

3500

22250

177050

155900

3500

Cost of Revenue The cost of revenue consists of the cost of labor, supplies and materials. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED)

Accounts Receivable and Allowance for Doubtful Accounts Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis and does not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.

Research and Development In fiscal 2022, the Company joined and made an investment in an investigator-initiated study. As part of that investment, the Company obtained rights/access to various retrospective biobank clinical samples for research and product development purposes. In addition, the Company received active patient clinical samples for the following disease sites: ovarian, endometrial, and head & neck cancers. These samples were tested to provide RUO (Research Use Only) results reports for research and product validation efforts. The transaction term is for 5-years, starting in September 2021. During the three months ended December 31, 2022 and 2021, the Company had spent $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20221001__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zmkXOpWppYRc" title="Research and development expense">50,000 and $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20211001__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zkFhT9Xt6yRg" title="Research and development expense">25,000 on this research and development project, which is included in general and administrative expenses on the accompanying unaudited statements of operations.

The transaction term is for 5-years, starting in September 2021

50000

25000

Derivative Liabilities The Company has certain financial instruments that are embedded derivatives associated with capital raises. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10 - Derivative and Hedging - Contract in Entity’s Own Equity. This accounting treatment requires that the carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.

Concentrations Concentration of Credit Risk The Company maintains its cash in banks and financial institutions that at times may exceed the federally insured limit of $250,000. As of December 31, 2022 and September 30, 2022, the cash balances were in excess of the FDIC insured limit by $898,012 and $186,466, respectively. The Company has not experienced any losses in such accounts through December 31, 2022. Concentration of Revenues For the three months ended December 31, 2022, the Company generated total revenue of $55,295 of which <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zp19hbmrrSI8" title="Concentration risk, percentage">72% was from one of the Company’s customers. During the three months ended December 31, 2021, the Company generated total revenue of $78,975 of which <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zqBdUrUjePGc" title="Concentration risk, percentage">56% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zXThANpY5IDk" title="Concentration risk, percentage">35% were from two of the Company’s customers. Concentration of Accounts Receivable As of December 31, 2022, the Company had net accounts receivable of $48,295 of which <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zD6QGWRb6Ic1" title="Concentration risk, percentage">82% was from one of the Company’s customers. As of September 30, 2022, the Company had net accounts receivable of $32,125 of which <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z65VYsq3LbI9" title="Concentration risk, percentage">59% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zKkwqVYM6f2e" title="Concentration risk, percentage">41% were from two of the Company’s customers, respectively. Concentration of Contract Liabilities As of December 31, 2022, the Company had deferred revenue reflected as contract liabilities of $177,050 of which <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z7ZBOQabNsI2" title="Concentration risk, percentage">73% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zpkj5J0qt7ni" title="Concentration risk, percentage">21% were from two of the Company’s customers. As of September 30, 2022, the Company had deferred revenue reflected as contract liabilities of $156,550 of which <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z6wDYFRCeZmk" title="Concentration risk, percentage">65% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211001__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zpDxGB2BASle" title="Concentration risk, percentage">24% were from two of the Company’s customers. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Concentration of Vendors Historically, the Company relied on one vendor to perform the Company’s patient reporting and contract research (formerly called sample analysis) which is an integral part of the Company’s operation and revenue stream. Any disruption in this service could have a material adverse effect on the Company’s business, financial condition and results of operations. The Company discontinued using this vendor in June 2022 as the patient reporting function has been moved in-house. During the three months ended December 31, 2022 and 2021, the Company incurred $0 and $113,295, respectively, or 100%, of its patient reporting and contract research (formerly called sample analysis) expense from one vendor.

250000

898012

186466

55295

0.72

78975

0.56

0.35

48295

0.82

32125

0.59

0.41

177050

0.73

0.21

156550

0.65

0.24

113295

Basic and Diluted Loss Per Share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes, conversion of preferred stock, and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of December 31, 2022 and 2021 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zX7LMCQKxivc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20221001__20221231_zwXqHjN1hcwa" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_494_20211001__20211231_zXjYyFp6bAw7" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December 31,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z1JzOamc13Nc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Stock warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">6,862,673,594</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">1,075,563,017</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z1c5nmiNves" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Stock options</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCOnePreferredStockMember_zk6rF9jBPkPc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series C-1 preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">212,431</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">445,301,289</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCTwoPreferredStockMember_zaiyLQF0Ha57" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series C-2 preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">733,542,619</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zqxtgOQhTKn5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series E preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">638,977,636</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesFPreferredStockMember_zScbuGmzf1Ej" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series F preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">319,488,818</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zDNWyyJ6fMR5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,765,180,181</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">780,807,641</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zfU3twzUEZnh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Total antidilutive securities excluded from computation of earnings</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">17,529,476,725</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,993,681,020</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zX7LMCQKxivc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20221001__20221231_zwXqHjN1hcwa" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_494_20211001__20211231_zXjYyFp6bAw7" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">December 31,</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z1JzOamc13Nc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Stock warrants</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">6,862,673,594</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">1,075,563,017</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z1c5nmiNves" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Stock options</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCOnePreferredStockMember_zk6rF9jBPkPc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series C-1 preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">212,431</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">445,301,289</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCTwoPreferredStockMember_zaiyLQF0Ha57" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series C-2 preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">733,542,619</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zqxtgOQhTKn5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series E preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">638,977,636</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesFPreferredStockMember_zScbuGmzf1Ej" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Series F preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">319,488,818</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zDNWyyJ6fMR5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">8,765,180,181</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">780,807,641</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zfU3twzUEZnh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Total antidilutive securities excluded from computation of earnings</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">17,529,476,725</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">3,993,681,020</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6862673594

1075563017

1901410519

212431

445301289

733542619

638977636

319488818

8765180181

780807641

17529476725

3993681020

Income Taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes”. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. As of December 31, 2022 and 2021, the Company had no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. The Company recognizes interest and penalties related to uncertain income tax positions in other expense. However, no such interest and penalties were recorded as of December 31, 2022 and 2021.

Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED)

Leases The Company accounts for its leases using the method prescribed by ASC 842 – Lease Accounting. The Company assess whether a contract is, or contains, a lease at the inception of the contract which is based on (i) whether the contract involves the use of a distinct identified asset, (ii) whether the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the period, and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating and financing lease ROU assets represent the right to use the leased asset for the lease term. Operating and financing lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the unaudited statements of operations.

Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s financial statements.

<p id="xdx_808_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zGWpRUfDcH4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE 3 – MARKETABLE SECURITIES During the fiscal year ended 2017, the Company acquired <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20170101__20171231__us-gaap--BusinessAcquisitionAxis__custom--AmarantusBioScienceHoldingsIncMember_zMxc86Ixv1x2" title="Stock issued during period, shares, acquisitions">1,000,000 shares of common stock of Amarantus BioScience Holdings, Inc. (“AMBS”) with a fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20170101__20171231__us-gaap--BusinessAcquisitionAxis__custom--AmarantusBioScienceHoldingsIncMember_zJMBToblqSnk" title="Stock issued during period, value, acquisitions">40,980. The AMBS common stock is recorded as marketable securities in the accompanying balance sheets. Its fair value is adjusted every reporting period and the change in fair value is recorded in the statements of operations as unrealized gain or (loss) on marketable securities. During the three months ended December 31, 2022 and 2021, the Company recorded $(2,000) and $5,400 of unrealized (loss) gain on marketable securities, respectively. As of December 31, 2022 and September 30, 2022, the fair value of these shares was $1,700 and $3,700, respectively.

1000000

40980

-2000

5400

1700

3700

NOTE 4 – ACCOUNTS RECEIVABLE On December 31, 2022 and September 30, 2022, accounts receivable consisted of the following: SCHEDULE OF ACCOUNTS RECEIVABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_499_20221231_zw8X3imAmXPj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_495_20220930_ztmnryUHGga6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCzY5T_znvYWw7Dlscd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Accounts receivable</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">52,127</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">35,957</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCzY5T_zCF2tSDh1xP8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: allowance for doubtful accounts</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,832</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,832</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iI_mtARNCzY5T_zYGj1g8gKPHh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accounts receivable, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">48,295</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">32,125</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the three months ended December 31, 2022 and 2021, bad debt expense amounted to $0.

On December 31, 2022 and September 30, 2022, accounts receivable consisted of the following: SCHEDULE OF ACCOUNTS RECEIVABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_499_20221231_zw8X3imAmXPj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_495_20220930_ztmnryUHGga6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCzY5T_znvYWw7Dlscd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Accounts receivable</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">52,127</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">35,957</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCzY5T_zCF2tSDh1xP8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: allowance for doubtful accounts</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,832</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(3,832</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_iI_mtARNCzY5T_zYGj1g8gKPHh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accounts receivable, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">48,295</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">32,125</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

52127

35957

3832

48295

32125

NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Once placed in service, they are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Property and equipment consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49C_20221231_z6kVJdHFci2g" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49F_20220930_z2A9E5IHjKvc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Estimated Useful Life in Years</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_ecustom--LaboratoryEquipment_iI_pp0p0_maPPAEGzSm3_z3H7jk5hSVi1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left">Laboratory equipment</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zTwPuePUJsR1" title="Estimated useful life in years">5</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">597,059</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">597,059</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzSm3_z9ZRMqfwlUU5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Furniture</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRu2q1b5gWhk" title="Estimated useful life in years">5</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,567</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,567</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzSm3_zjEU1Gc1l9o9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBtTLbZwdEtl" title="Estimated useful life in years">5</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">353,826</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">353,826</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzSm3_zvSxs0RUlTH7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Computer equipment</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zMOtoGDv7gDk" title="Estimated useful life in years">3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">76,470</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">68,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_maPPAENz7Nk_mtPPAEGzSm3_zDknzCnSl3ge" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Property and equipment gross</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,051,922</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,043,942</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENz7Nk_z9A3gVLvK2E5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(396,702</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(357,815</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENz7Nk_zkmJ3W8h8ak4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">655,220</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">686,127</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) For the three months ended December 31, 2022 and 2021, depreciation expense related to property and equipment amounted to $38,887 and $35,965, respectively. Leased equipment was not included in the table above as it was accounted for in accordance with ASU 842 – Leases. These leases are discussed in Note 7 under financing lease right-of-use (“ROU”) assets and financing lease liabilities.

SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49C_20221231_z6kVJdHFci2g" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49F_20220930_z2A9E5IHjKvc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Estimated Useful Life in Years</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_ecustom--LaboratoryEquipment_iI_pp0p0_maPPAEGzSm3_z3H7jk5hSVi1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left">Laboratory equipment</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zTwPuePUJsR1" title="Estimated useful life in years">5</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">597,059</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">597,059</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzSm3_z9ZRMqfwlUU5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Furniture</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRu2q1b5gWhk" title="Estimated useful life in years">5</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,567</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">24,567</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzSm3_zjEU1Gc1l9o9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zBtTLbZwdEtl" title="Estimated useful life in years">5</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">353,826</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">353,826</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzSm3_zvSxs0RUlTH7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Computer equipment</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20221001__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zMOtoGDv7gDk" title="Estimated useful life in years">3</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">76,470</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">68,490</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_maPPAENz7Nk_mtPPAEGzSm3_zDknzCnSl3ge" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Property and equipment gross</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,051,922</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,043,942</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENz7Nk_z9A3gVLvK2E5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(396,702</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(357,815</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENz7Nk_zkmJ3W8h8ak4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">655,220</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">686,127</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P5Y

597059 597059

P5Y

24567

P5Y

353826

P3Y

76470

68490

1051922

1043942

396702

357815

655220

686127

38887

35965

NOTE 6 – DEBT On December 31, 2022 and September 30, 2022, convertible notes payable (third parties and related parties) consisted of the following: SCHEDULE OF CONVERTIBLE NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_499_20221231_zXmF692npZB1" style="font-family: Times New Roman, Times, Serif; text-align: center">1 </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_492_20220930_zIBBHE3UYJG8" style="font-family: Times New Roman, Times, Serif; text-align: center"> 2</td><td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_maCDNz70j_zJiYdl2Nxaoh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Principal amount</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">7,941,605</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">2,475,000</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msCDNz70j_zAoH14vrOxf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: debt discount</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(7,265,021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(2,028,719</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iTI_pp0p0_mtCDNz70j_maCDz2Xu_zdjPSWXFZ056" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes payable, net</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">676,584</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">446,281</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayableCurrent_iNI_pp0p0_di_zAIVNoAgbzLg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: current portion of convertible notes payable - related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(676,584</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_zTeuszMrsxJ5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Convertible notes payable, net – long-term</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">446,281</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DebtInstrumentFaceAmountRelatedParty_iI_pp0p0_maCDRPz1E9_zjPQz0ANKQdl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Principal amount – related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">8,975,192</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4,150,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DebtInstrumentUnamortizedDiscountRelatedParty_iNI_pp0p0_di_msCDRPz1E9_zLvrLOFkiWYb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: debt discount – related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(8,203,748</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,844,186</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ConvertibleDebtRelatedParty_iI_pp0p0_mtCDRPz1E9_maCDz2Xu_z9O5gQd1O086" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes payable - related parties, net</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">771,444</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,305,814</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ConvertibleDebtRelatedPartyCurrent_iNI_pp0p0_di_zdpTNeeO7aTi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: current portion of convertible notes payable - related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(771,444</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,000,000</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ConvertibleDebtRelatedPartyNonCurrent_iI_pp0p0_zVCBrORAYEWa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Convertible notes payable - related parties, net – long-term</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,305,814</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebt_iTI_pp0p0_mtCDz2Xu_z4cgb0JAf9m6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total convertible notes payable, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,448,028</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,752,095</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convertible Debt – Related Parties On May 12, 2021, the Company entered into a Securities Purchase Agreement (“May 2021 SPA”) with a related party, who is an affiliate stockholder (“May 2021 Investor”) to purchase a convertible note (“May 2021 Note”) and accompanying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pip0_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNvBXFRBvgVd" title="Warrants to purchase">63,897,764 warrants (“May 2021 Warrants”) for an aggregate investment amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbjjjASK8gf5" title="Debt Instrument, Face Amount">1,000,000 (see Note 8). The May 2021 Note had a principal value of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrH1bcihBFpf" title="Debt Instrument, Face Amount">1,000,000 and bore an interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zyzhzlLvlhX7" title="Debt Instrument, Interest Rate, Stated Percentage">8% per annum and was to mature on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20210512__20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgDYus3OiOo4" title="Debt Instrument, Maturity Date">May 12, 2026. The Company received the proceeds in three tranches with the first tranche of $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210501__20210531__srt--StatementScenarioAxis__custom--FirstTrancheMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zoU8nZu5vCDc" title="Proceeds from related party debt">333,334 received in May 2021, the second tranche of $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210601__20210630__srt--StatementScenarioAxis__custom--SecondTrancheMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDj0QlLzWANh" title="Proceeds from related party debt">333,333 received in June 2021 and the third tranche of $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_pp0p0_c20210701__20210731__srt--StatementScenarioAxis__custom--ThirdTrancheMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUEX2VwcjSoh" title="Proceeds from related party debt">333,333 received in July 2021. The May 2021 Note was convertible at any time into shares of the Company’s common stock at a conversion price equal to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4LwKYSeGDxd" title="Debt instrument, convertible, conversion price">0.00313 per share for any amount of principal and accrued interest remaining outstanding (subject to adjustment). The May 2021 Note and May 2021 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the May 2021 Note and May 2021 Warrants. As of September 30, 2022, the May 2021 Note had an outstanding principal balance of $<span id="xdx_908_eus-gaap--NotesPayable_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrhNuXBoKYSj" title="Notes Payable">1,000,000 and accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2zDPX9HvA9c" title="Interest Payable">20,164 and is included in the accompanying balance sheet at $<span id="xdx_901_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrgdTbnTByJ1" title="Convertible Notes Payable, Noncurrent">267,521 as a long-term convertible note payable – related party, net of discount in the amount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGyQLKl2Mpha" title="Debt discount">732,479 (see Note 8). The May 2021 Warrants had an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zapgVxWOV5H9" title="Class of warrant or right, exercise price of warrants or rights">0.00313 per share (subject to adjustment) until <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20210512__20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zpBivPPXfujd" title="Debt instrument, maturity date">May 12, 2026 and was exercisable for cash at any time. The May 2021 Warrants were valued at $<span id="xdx_903_eus-gaap--DebtInstrumentFairValue_iI_pp0p0_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zeEvCuZNMEJ1" title="Debt instrument, fair value disclosure">984,200 using the relative fair value method which was recorded as a debt discount which was being amortized over the life of the May 2021 Note. In addition, the May 2021 Note had a beneficial conversion feature (“BCF”) in the amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20210512__20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zowjmowmooE5" title="Debt instrument, convertible, beneficial conversion feature">15,800 which was recorded as a debt discount which was being amortized over the life of the May 2021 Note. The debt discount totaled $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210512__20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFscJ2QcGkge" title="Amortization of debt discount">1,000,000 which was being amortized over the life of the May 2021 Notes. On November 29, 2022, the May 2021 Note was exchanged for a new convertible debenture (see below). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On November 1, 2021, the Company entered into a Securities Purchase Agreement (“First November 2021 SPA”) with a related party, who is an affiliate stockholder (“First November 2021 Investor”), to purchase three convertible notes (collectively as “First November 2021 Notes”) and three accompanying warrants (collectively as “First November 2021 Warrants”), for an aggregate investment amount of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20211101__20211101__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_z4uVvm5RFfUg" title="Fair Value Adjustment of Warrants">1,000,000. The first note issued on November 1, 2021, had a principal balance of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--NoteOneMember_zOzfXbFu6erd" title="Debt Instrument, Face Amount">334,000 and accompanying warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211101__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_znM2kPL0AkPi" title="Fair value adjustment of warrants">18,251,367 shares of common stock. The second note issued on December 1, 2021, had a principal balance of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211201__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMember_zCbWZVTUEJa6" title="Debt Instrument, Face Amount">333,000 and accompanying warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211201__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwc88zkbDv8" title="Fair value adjustment of warrants">18,196,722 shares of common stock. The third note issued on January 1, 2022, had a principal balance of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--NoteThreeMember_z1s15xEm7uNb" title="Debt Instrument, Face Amount">333,000 and accompanying warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220101__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zavPQLEBfEF4" title="Fair value adjustment of warrants">18,196,722 shares of common stock. The Company received $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUPA9cCbfox6" title="Debt Instrument, Face Amount">1,000,000 in aggregate proceeds from the First November 2021 Notes. The First November 2021 Notes bore interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOVs4Ul9cTuf" title="Debt Instrument, Interest Rate, Stated Percentage">8% per annum and was to mature on November 1, 2026. The First November 2021 Warrants are exercisable at any time and expire on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20211101__20211101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ziUYi8JfSQni" title="Maturity date">November 1, 2026. The First November 2021 Warrants were initially valued at $990,048 using the relative fair value method and were recorded as debt discount which is being amortized over the life of the First November 2021 Notes. The First November 2021 Notes and First November 2021 Warrants are convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211101__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGabqmI3DpBj" title="Class of warrant or right, exercise price of warrants or rights">0.00366 per share (subject to adjustment). The First November 2021 Notes and First November 2021 Warrants included a down-round provision under which the conversion price and exercise price were reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the First November 2021 Notes and First November 2021 Warrants. On January 26, 2022, a notice and request for consent regarding a change in offering terms was sent by the Company to the First November 2021 Investor. Upon the approval of the First November 2021 Investor, <span id="xdx_907_eus-gaap--DebtInstrumentDescription_c20211101__20211101__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWwCwjttvfJ6" title="Debt description">the Company modified the terms of the First November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the First November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the First November 2021 Notes. The Company issued additional warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIvlTvFdcIv2" title="Fair value adjustment of warrants">218,579,234 shares of common stock to the First November 2021 Investor which increased the total relative fair value of all warrants in total by $<span id="xdx_90B_eus-gaap--DebtInstrumentFairValue_iI_pp0p0_c20211101__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zC36VxRrTvl2" title="Debt instrument, fair value disclosure">34,620 recorded as debt discount which is being amortized over the life of the First November 2021 Notes (see Note 8 and 9). The modification of the First November 2021 SPA did not meet the requirements of a debt extinguishment under ASC 470-50 - Debt Modifications and Exchanges; however it represented a substantial modification whereby the First November 2021 Investor received a substantial amount of additional warrants for the same principal amount of investment hence it was accounted for, in substance, as a debt modification ASC 470-50 and no gain or losses was recognized. As of September 30, 2022, the First November 2021 Notes had an outstanding principal of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_z6yr9CajErRl" title="Debt Instrument, Face Amount">1,000,000 and accrued interest of $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zNwgY7Nfdiuj" title="Interest Payable">20,164 and are included in the accompanying balance sheet at $<span id="xdx_903_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwbAY3nGCSj" title="Convertible Notes Payable, Noncurrent">140,093 as a long-term convertible note payable – related party, net of discount in the amount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zzqNhL2mFkWh" title="Debt instrument unamortized discount">859,907 (see Note 8) as of September 30, 2022. On November 29, 2022, the First November 2021 Notes were exchanged for a new convertible debenture (see below). On April 5, 2022, the Company entered into a Securities Purchase Agreement (“First April 2022 SPA”) with a related party, Matthew Schwartz, who is a member of the board of directors (“Investor”), to purchase a convertible note with a principal balance of $100,000 (“First April 2022 Note”) with accompanying warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220405__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_z16SjSTXBzFe" title="Warrants to purchase">4,201,681 shares of common stock (“First April 2022 Warrants”). The Company received net proceeds of $100,000 on March 24, 2022. The First April 2022 Warrants were valued at $89,815 using the relative fair value method and were recorded as debt discount which is being amortized over the life of the First April 2022 Note. The First April 2022 Warrants are exercisable at any time and expire on April 1, 2027. The First April 2022 Note bore interest rate of 8% per annum and was to mature on April 1, 2027. The First April 2022 Note and First April 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220405__us-gaap--DebtInstrumentAxis__custom--NoteMember_z6c4n9E8uQc" title="Class of warrant or right, exercise price of warrants or rights">0.00476 per share (subject to adjustment). The First April 2022 Note and First April 2022 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the First April 2022 Note and First April 2022 Warrants. For so long as the First April 2022 Warrants remains outstanding and until the listing by the Company or the trading of the common stock on a Qualified National Exchange (as defined in the agreement); (i) if the Company issues warrants to investors in an offering of common stock or of any equity linked security (each a “Subsequent Offering”), and such warrants equal more than 20% warrant coverage, then a number of additional shares will be added to the First April 2022 Warrants such that the First April 2022 Warrants shall equal the same percentage of the warrant coverage offered to the investors in the Subsequent Offering and; (ii) if the Company issues warrants in a Subsequent Offering which may be exercised by means of a cashless exercises, then the First April 2022 Warrants shall be exercisable by the same cashless exercise feature of the warrants issued in the Subsequent Offering. As of September 30, 2022, the First April 2022 Note had an outstanding principal balance of $100,000 and accrued interest of $3,901 and is reflected in the accompanying balance sheet at $<span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHznFX1svzkj" title="Long term convertible note payable">18,959 as a long-term convertible note payable – related party, net of discount in the amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20220930__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYZIW0SsDgw9" title="Debt discount">81,041 (see Note 8) as of September 30, 2022. On November 29, 2022, the First April 2022 Note was exchanged for a new convertible debenture (see below). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On May 9, 2022, the Company entered into a Securities Purchase Agreement (“May 2022 SPA”) with a related party, who is an affiliate stockholder (“May 2022 Investor”), to purchase four convertible notes for an aggregate investment amount of $1,000,000 (collectively as “May 2022 Notes”) and accompanying warrants to purchase shares of common stock equal to <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20220509__20220509__us-gaap--DebtInstrumentAxis__custom--NoteMember_zPVDuiCCBaqk" title="Warrants to purchase price">20% of the number of the total shares of common stock issuable upon the conversion of the May 2022 Notes (collectively as “May 2022 Warrants”). The first note issued on May 9, 2022, had a principal balance of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_pp0p0_c20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqiBJLA2ji44" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220509__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zS6ZzbfIEFHh" title="Fair value adjustment of warrants">10,504,202 shares of common stock. The second note issued on May 24, 2022, had a principal balance of $<span id="xdx_90C_eus-gaap--NotesPayable_iI_pp0p0_c20220524__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z92aF72IQaY8" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220524__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zOVDAOOAabtf" title="Fair value adjustment of warrants">10,504,202 shares of common stock. The third note issued on June 10, 2022, had a principal balance of $<span id="xdx_90C_eus-gaap--NotesPayable_iI_pp0p0_c20220610__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUweUabi5fz2" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220610__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zhsB7TCQ37pg" title="Fair value adjustment of warrants">10,504,202 shares of common stock. The fourth note issued on July 1, 2022, had a principal balance of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_pp0p0_c20220701__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMlGrSM8MBdk" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220701__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zhzq0KSfWBH8" title="Fair value adjustment of warrants">10,504,202 shares of common stock. The Company received $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20220509__20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zahQN0MWcbFd" title="Aggregate proceeds">1,000,000 in aggregate proceeds from the May 2022 Notes. The May 2022 Notes bore an interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pip0_dp_uPure_c20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBOQiLTkUMge" title="Interest rate">8% per annum and were to mature on April 1, 2027. The May 2022 Warrants are exercisable at any time and expire on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20220509__20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_z9tjjrtPT3Fa" title="Maturity date">April 1, 2027. The May 2022 Warrants were valued at $178,449 using the relative fair value method and were recorded as debt discount which is being amortized over the life of the May 2022 Notes. The May 2022 Notes and May 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220509__us-gaap--DebtInstrumentAxis__custom--NoteMember_zpiWibTMLINg" title="Class of warrant or right, exercise price of warrants or rights">0.00476 per share (subject to adjustment). The May 2022 Notes and May 2022 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the May 2022 Notes and May 2022 Warrants. For so long as the May 2022 Warrants remains outstanding and until the listing by the Company or the trading of the common stock on a Qualified National Exchange (as defined in the agreement); (i) if the Company issues warrants to investors in a Subsequent Offering, and such warrants equal more than 20% warrant coverage, then a number of additional shares will be added to the May 2022 Warrants such that the May 2022 Warrants shall equal the same percentage of the warrant coverage offered to the investors in the Subsequent Offering and; (ii) if the Company issues warrants in a Subsequent Offering which may be exercised by means of a cashless exercises, then the May 2022 Warrants shall be exercisable by the same cashless exercise feature of the warrants issued in the Subsequent Offering. As of September 30, 2022, the May 2022 Notes had an aggregate outstanding principal balance of $1,000,000 and accrued interest of $20,110 and are included in the accompanying balance sheet at $834,803 as a long-term convertible note payable – related party, net of discount in the amount of $165,197 (see Note 8) as of September 30, 2022. On November 29, 2022, the May 2022 Note was exchanged for a new convertible debenture (see below). On June 15, 2022, the Company entered into a Securities Purchase Agreement (“June 2022 SPA”) with a related party, Danica Holley, who is a member of the board of directors (“Investor”), to purchase a convertible note with principal of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220615__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_zsewjxLmTxA1" title="Debt instrument, face amount">50,000 (“June 2022 Note”) with accompanying warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220615__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_ze6WanP5PmA6" title="Warrants to purchase">2,100,840 shares of common stock (“June 2022 Warrants”). The Company received net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20220615__20220615__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_z7scRby6RQy5" title="Proceeds from issuance of debt">50,000 on June 15, 2022. The June 2022 Warrants were valued at $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220615__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_zVx8dnSndbV" title="Warrants and rights outstanding">5,924 using the relative fair value method and were recorded as debt discount which is being amortized over the life of the June 2022 Note. The June 2022 Warrants are exercisable at any time and expire on <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20220615__20220615__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_zV3W3J235qmc" title="Maturity date">April 1, 2027. The June 2022 Note bore interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220615__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_z2aV7dGqLbg6" title="Interest rate">8% per annum and was to mature on April 1, 2027. The June 2022 Note and June 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220615__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_zkPnZMYYavb9" title="Conversion price per share">0.00476 per share (subject to adjustment). The June 2022 Note and June 2022 Warrants include a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the June 2022 Note and June 2022 Warrants. For so long as the June 2022 Warrants remains outstanding and until the listing by the Company or the trading of the common stock on a Qualified National Exchange (as defined in the agreement); (i) if the Company issues warrants to investors in a Subsequent Offering, and such warrants equal more than 20% warrant coverage, then a number of additional shares will be added to the June 2022 Warrants such that the June 2022 Warrants shall equal the same percentage of the warrant coverage offered to the investors in the Subsequent Offering and; (ii) if the Company issues warrants in a Subsequent Offering which may be exercised by means of a cashless exercises, then the June 2022 Warrants shall be exercisable by the same cashless exercise feature of the warrants issued in the Subsequent Offering. As of September 30, 2022, the June 2022 Note had an outstanding principal balance of $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_zgN1JhoPQ0Gj" title="Principal balance">50,000 and accrued interest of $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_zlr47IXioy9b" title="Accrued interest">1,173. The June 2022 Note are included in the accompanying balance sheet at $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember_z6rhZFeJvnB8" title="Convertible long term notes payable">44,438 as a long-term convertible note payable – related party, net of discount in the amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementJuneTwoThousandTwentyTwoMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_z78hmUo3E6Vf" title="Net of discount">5,562 (see Note 8) as of September 30, 2022. On November 29, 2022, the June 2022 Note was exchanged for a new convertible debenture (see below). On July 29, 2022, the Company entered into a Demand Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors and a related party, for a principal balance of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zKzGbiiWYv65" title="Debt instrument, face amount">125,000, and on September 2, 2022, the Company entered into a second Demand Promissory Note Agreement with Jeffrey Busch for a principal balance of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20220802__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_z5rX4ptS5Odd" title="Debt instrument, face amount">150,000 (collectively referred to as the “Busch Notes”). The Busch Notes bore an annual interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zfjsXOW2cSOe" title="Annual interest rate">8% and were payable on demand. The outstanding principal and accrued interest on the Busch Notes were contingently convertible, in full, at the option of the lender, into the same security issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, the Busch Notes had an outstanding principal balance of $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_z2w9gA9BJet9" title="Principal balance">275,000 and accrued interest of $<span id="xdx_906_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zqqC3RjOVWvf" title="Accrued interest">2,683 and are included in the accompanying balance sheet as a short-term convertible note payable – related party. On November 29, 2022, the Busch Notes were exchanged for a new convertible debenture (see below). On August 11, 2022, the Company entered into a Demand Promissory Note Agreement with a related party, who is an affiliate stockholder, for a principal balance of $375,000. The note bore annual interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220811__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zMXWSK9KIx39" title="Annual interest rate">8% and was payable on demand. The outstanding principal and accrued interest of the note was contingently convertible, in full, at the option of the lender, into the same security issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, this note had an outstanding principal balance of $375,000 and accrued interest of $4,110 and is included in the accompanying balance sheet as a short-term convertible note payable – related party. On November 29, 2022, this note was exchanged for a new convertible debenture (see below). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On September 2, 2022, the Company entered into a Demand Promissory Note Agreement with a related party, who is an affiliate stockholder, for a principal balance of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20220902__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z03QyT5GSEH1" title="Debt instrument, face amount">350,000. The note bore an annual interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220902__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zP32gedbyM5e" title="Annual interest rate">8% and was payable on demand. The outstanding principal and accrued interest of the note was contingently convertible, in full, at the option of the lender, into the same security issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, this note had an outstanding principal balance of $<span id="xdx_90A_eus-gaap--NotesPayable_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYMoc1CpNvlk" title="Principal balance">350,000 and accrued interest of $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember__us-gaap--TypeOfArrangementAxis__us-gaap--ConvertibleDebtMember_zxZytoZUfZ46" title="Accrued interest">2,148 and is included in the accompanying balance sheet as a short-term convertible note payable – related party. On November 29, 2022, this note was exchanged for a new convertible debenture (see below). On November 1, 2022, the Company entered into a Demand Promissory Note Agreements with two related parties, who are affiliate stockholders, for a principal balance of $120,000. The notes bore an annual interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221101__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zmKwRPZuKKjg" title="Annual interest rate">8% and were payable on demand. The outstanding principal and accrued interest of the notes was contingently convertible, in full, at the option of the lender, into the same security issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. In December 2022, these short-term loans were repaid. On November 29, 2022, in connection with the Share Exchange Agreements and New Convertible Debt discussed below, the May 2021 Warrants, First November 2021 Warrants, First April 2022 Warrants, May 2022 Warrants, and June 2022 Warrants, aggregating <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zSge0rMmVnOe" title="Warrants purchase">385,441,138 warrants, were amended to reduce the exercise price to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8sypuw8bJQh" title="Exercise price of warrant">0.003 per share. Additionally, <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zMwDhcaRjz39" title="Warrants purchase">63,897,764 warrants issued in connection with Series F preferred stock were amended to reduce the exercise price to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zobuhgg2tRGj" title="Warrants exercise price">0.003 per share. In conjunction with the price reduction, the price protection feature for all these warrants was eliminated. All other terms of the warrants remained the same. As a result of the November 29, 2022 amendment to the exercise price, the Company calculated the difference between the warrants fair values on November 29, 2022, the date of the amendment, using the then current exercise price ranging from $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zUwtfIcYrKAe" title="Class of warrant or right, exercise price of warrants or rights">0.00366 to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zLUMXWuo4fn6" title="Class of warrant or right, exercise price of warrants or rights">0.00476 and the new exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zw8qN9S1SP59" title="Shares price">0.003 and determined that the difference was insignificant. Share Exchange Agreements and New Related Party Convertible Debentures and Warrants dated November 29, 2022 On November 29, 2022, the Company consummated the initial closing (the “Initial Closing”) of a private placement offering (the “Offering”) pursuant to the terms and conditions of that certain Securities Purchase Agreement, dated as of November 29, 2022 (the “Purchase Agreement”), by and among the Company, certain related party accredited investors (the “Related Party Purchasers”) and Cavalry Fund I Management LLC, a Delaware limited liability company, in its capacity as collateral agent (the “Collateral Agent”). At the Initial Closing, the Company sold the related party Purchasers (i) <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221129__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zKDu01i0JaX3" title="Annual interest rate">10% Original Issue Discount Senior Secured Convertible Debentures (the “New Related Party Debentures”) in an aggregate principal amount of $550,000 and (ii) warrants (the “New Related Party Warrants”) to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221129__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_zd1QO8Z4vvg7" title="Warrants issued to purchase of securities">157,142,857 shares of common stock of the Company (the “Common Stock”), subject to adjustments provided by the Warrants, which represents 100% warrant coverage. The Company received a total of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221129__20221129__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_zJTXZvmlEkif" title="Proceeds from intial public offerings">412,092 in net proceeds at the Initial Offering from the Related Party Purchasers, net of the Original Issue Discount of $50,000, commissions of $58,200 and other offering costs of $29,708. On November 29, 2022, the Company entered into Securities Exchange Agreements with the above related party investors, whereby the May 2021 Note, the First November 2021 Notes, the First April 2022 Note, the May 2022 Notes, the June 2022 Note, the Busch Notes, the August 11, 2022 Demand Promissory Note, and the September 2, 2022 Demand Promissory Note with an aggregate principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20220902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DemandPromissoryNotesMember_znzunkzRgHXb">4,150,000 (the “Exchanged Related Party Notes”) and accrued interest payable of $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DemandPromissoryNotesMember_zLnopChhtxxe">120,750 were exchanged for New Related Party Debentures. Additionally, on November 29, 2022, in order to induce the related party investors to exchange the respective convertible notes into the Related Party Debentures, the aggregate principal amount of the Exchanged Related Party Notes and accrued interest payable was increased by <span id="xdx_90D_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_zBBp85h8uho" title="Accrued interest payable increased percentage">15% (and the August 11, 2022 and September 2, 2022 Demand Promissory Notes were issued with <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220811__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DemandPromissoryNotesMember_zLa1Bd1XPyoc" title="Promissory notes interest rate percentage"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DemandPromissoryNotesMember_zv0jgcAGG1A8" title="Promissory notes interest rate percentage">10% OID), or $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_zczMIKEyBy9g" title="Related party convertible debt">589,505, for new Related Party Debentures with an aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_zago5Ir90Ijb">4,860,255. On November 29, 2022, the Company entered into Securities Exchange Agreements with related party preferred stockholders, whereby related party holders of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221129__20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsbQQPtKjtNd" title="Number of shares issued">1,000 shares of Series E preferred stock with a stated value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221129__20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zlBj9XF42OWe" title="Number of shares issued, value">2,000,000 and accrued dividends payable of $<span id="xdx_902_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjphw5NW4Y17" title="Dividends payable">66,630, and related party holders of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221129__20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znoA2sc5Qhec" title="Number of shares issued">500 shares of Series F preferred stock with a stated value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221129__20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zJz0QWDKjJ19" title="Number of shares issued, value">1,000,000 and accrued dividends payable of $<span id="xdx_90A_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zZi6aY7X3SU3" title="Dividends payable">33,315 were exchanged for the New Related Party Debentures. Additionally, on November 29, 2022, in order to induce the related party preferred stockholders to exchange their respective preferred shares into the New Related Party Debentures, the aggregate stated value and accrued dividends payable were increased by <span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdMbtFfp7PAa" title="Dividends payable">15%, or $464,992, for new Related Party Debentures with an aggregate principal amount of $3,564,937. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) The November 29, 2022 New Related Party Debentures mature on November 29, 2023, subject to a three-month extension at the sole discretion of the Company. The New Related Party Debentures bear interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221129__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_z9RaPwl3WOUg" title="Annual interest rate">10% per annum payable upon conversion or maturity. The New Related Party Debentures are convertible into shares of the Company’s common stock at any time after the maturity date and prior to Mandatory Conversion (as defined below) at the conversion price equal to the lesser of: (i) $0.003 per share and (ii) 70% of the average of the VWAP (as defined in the Debentures) (or 50% of the average of such VWAP if an event of default has occurred and has not been cured) of the Common Stock during the ten Trading Day (as defined in the Debentures) period immediately prior to the applicable conversion date. The New Related Party Debentures are subject to mandatory conversion (“Mandatory Conversion”) in the event the Company closes a registered public offering of its Common Stock and receives gross proceeds of not less than $5,000,000, with such offering resulting in the listing for trading of the Common Stock on a national exchange (“Qualified Offering”). The conversion price per share of Common Stock in the case of a Mandatory Conversion shall be the lesser of (i) $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221129__us-gaap--FinancialInstrumentAxis__us-gaap--ConvertibleDebtSecuritiesMember__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember_zX55OtW8BIK2" title="Conversion price">0.003 per share and (ii) <span id="xdx_908_ecustom--OfferingPricePercent_iI_pid_dp_uPure_c20221129__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember__us-gaap--FinancialInstrumentAxis__us-gaap--ConvertibleDebtSecuritiesMember_zdejGXlOe7bi" title="Offering price percent">70% of the offering price per share in the Qualified Offering (the “Qualified Offering Price”). Alternatively, upon a Mandatory Conversion, the holders of the Debentures may elect to exchange their Debentures for newly issued convertible preferred securities at a price per share equal to the Qualified Offering Price or the five-day VWAP of the Common Stock prior to the date that is 181 days after the closing of the Qualified Offering. Notwithstanding the preceding, holders of New Related Party Debentures shall have the right to require satisfaction of up to 40% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. Investors that are exchanging securityholders shall have the right to require satisfaction of up to 10% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. The New Related Party Debentures also contain certain price protection provisions providing for adjustment of the number of shares of Common Stock issuable upon conversion of the Debentures in case of certain future dilutive events or stock-splits and dividends. The Company’s obligations under the New Related Party Debentures are secured by a first priority lien on all of the assets of the Company pursuant to that certain Security Agreement, dated November 29, 2022 (the “Security Agreement”) by and among the Company, the Debenture holders and the Collateral Agent. The Purchase Agreement contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, covenants that restrict the ability of the Company without the prior written consent of the Debenture holders, to incur additional indebtedness, and repay outstanding indebtedness, create or permit liens on assets, redeem its Common Stock, settle outstanding litigation, or enter into transactions with affiliates. If the Company or any Subsidiary shall default on any of its obligations under any mortgage credit agreement or other facility indenture agreement, factoring agreement or other instrument under which there may be issued, or by which there may be secured or evidenced, any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement that (a) involves an obligation greater than $250,000, whether such indebtedness now exists or shall hereafter be created, and (b) results in such indebtedness becoming or being declared due and payable prior to the date on which it would otherwise become due and payable, the New Related Party Debenture shall be deemed in default and the default provisions shall apply. In connection with the Securities Exchange Agreements with related parties for the exchange of the convertible notes and preferred shares for the New Related Party Debentures discussed above, the Company issued an aggregate of 2,564,340,702 warrants. <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_pid_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember_zx8yoB0p5lDc" title="Warrant reason for issuing, descriptions">The New Related Party Warrants are exercisable for five years and six months from the earlier of the maturity date of the New Related Party Debentures and the closing of the Qualified Financing, at an exercise price equal to (i) in the event that a Qualified Offering is consummated prior to the exercise of the New Related Party Warrant, the price per share at which the Qualified Offering is made (“Qualified Offering Price”), or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember_z7XwxPtukBE3" title="Warrant exercise price">0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration statement covering the resale of the shares underlying the New Related Party Warrants within 180 days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum of 25%. The New Related Party Warrants contain certain price protection provisions providing for adjustment of the amount of securities issuable upon exercise of the New Related Party Warrants in case of certain future dilutive events or stock-splits and dividends. As discussed above, on November 29, 2022, in order to induce the related party investors to exchange their respective convertible notes and preferred stock into the New Related Party Debentures, the aggregate principal amount and accrued interest payable of the exchanged convertible notes, and the stated value and accrued dividends of exchanged preferred stock was increased by 15% (the August 11, 2022 and September 2, 2022 Demand Promissory Notes were issued with <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220811__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvYl4tA6P4Nf" title="Promissory notes interest rate percentage"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9ht9UzSiQva" title="Promissory notes interest rate percentage">10% OID), or an aggregate amount of $1,046,167. This inducement fee was included in loss from debt extinguishment on the accompanying unaudited statement of operations during the three months ended December 31, 2022. Additionally, the remaining debt discount on exchanged related party notes of $1,768,379 was written off and included in loss from debt extinguishment on the accompanying unaudited statement of operations during the three months ended December 31, 2022. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Convertible Debt On November 1, 2021, the Company entered into a Securities Purchase Agreement (“Second November 2021 SPA”) with an investor (“Second November 2021 Investor”) to purchase two convertible notes (collectively as “Second November 2021 Notes”) and two accompanying warrants (collectively as “Second November 2021 Warrants”), for an aggregate investment amount of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20211027__20211101__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementSecondNovemberTwoThousandTwentyOneMember_zQBoWAaIJEr" title="Aggregate investment amount">500,000. The first note, issued on November 1, 2021, had a principal balance of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20211101__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--DebtInstrumentAxis__custom--NoteOneMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zeQXPV5df75e" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zEMKE6zQ8lal" title="Warrants purchase">13,661,203 shares of common stock. The second note issued on December 1, 2021, had a principal balance of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20211201__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmousqEySeX" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211201__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFoLEkgzGc6" title="Warrants purchase">13,661,203 shares of common stock. The Company received $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_c20211125__20211201__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcKVfGEBWL2" title="Proceeds from convertible debt">500,000 in aggregate proceeds from the Second November 2021 Notes. The Second November 2021 Notes bore an interest rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211201__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWlo2Cbitbdk" title="Interest rate">8% per annum and was to mature on November 1, 2026. The Second November 2021 Warrants are exercisable at any time and expire on November 1, 2026. The Second November 2021 Warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFW6Y6ut1xd7" title="Warrants purchase">27,322,406 shares of common stock were valued at $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20211125__20211201__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK5Xar6KcZs1" title="Fair value">495,560 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the Second November 2021 Notes. The Second November 2021 Notes and Second November 2021 Warrants are convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211201__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQS2HzAmRoy4" title="Conversion price">0.00366 per share (subject to adjustment). The Second November 2021 Notes and Second November 2021 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the Second November 2021 Notes and Second November 2021 Warrants. The conversion and exercise price of the Second November 2021 Notes and Second November 2021 Warrants are reduced equal to the lower conversion and exercise price of the new issuance or amended securities. At the election of the Second November 2021 Investor, the Second November 2021 Notes was convertible in whole or in part at any time and from time to time. On January 26, 2022, a notice and request for consent regarding a change in offering terms was sent by the Company to the Second November 2021 Investor. Upon the approval of the Second November 2021 Investor, <span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20220124__20220126__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZP31IhaRmbf" title="Debt instrument description">the Company modified the terms of the Second November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the Second November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the Second November 2021 Notes. The Company issued additional warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220126__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGVCMamiXpF8" title="Warrants purchase, shares">109,289,616 shares of common stock to the Second November 2021 Investor which increased the total relative fair value of all warrants in total by $<span id="xdx_906_eus-gaap--DebtInstrumentFairValue_iI_c20220126__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zJMQntiTkUVc" title="Fair value">22,429. This was recorded as debt discount which is being amortized over the life of the Second November 2021 Notes (see Note 9). The modification of the Second November 2021 SPA did not meet the requirements of a debt extinguishment under ASC 470-50 - Debt Modifications and Exchanges; however it represented a substantial modification whereby the Second November 2021 Investor received a substantial amount of additional warrants for the same principal amount of investment hence it was accounted for, in substance, as a debt modification ASC 470-50 and no gain or losses was recognized. As of September 30, 2022, the Second November 2021 Notes had an outstanding principal balance of $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20211001__20220930__us-gaap--DebtInstrumentAxis__custom--SecondNovemberTwoThousnadAndTwentyOneNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4NMPDiKK8of" title="Principal balance">500,000 and accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--SecondNovemberTwoThousnadAndTwentyOneNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4Nb4A7KMsVc" title="Accrued interest">34,520. The Second November 2021 Notes are included in the accompanying balance sheet at $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--SecondNovemberTwoThousnadAndTwentyOneNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z57CWKkkH9Hk" title="Long term convertible note payable">69,417 as a long-term convertible note payable, net of discount in the amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--SecondNovemberTwoThousnadAndTwentyOneNotesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhi0KW1OQZz4" title="Net of discount">430,583 as of September 30, 2022. On November 29, 2022, the Second November 2021 Notes were exchanged for a new convertible debenture (see below). On November 1, 2021, the Company entered into a Securities Purchase Agreement (“Third November 2021 SPA”) with an investor (“Third November 2021 Investor”) to purchase two convertible notes (collectively as “Third November 2021 Notes”) and two accompanying warrants (collectively as “Third November 2021 Warrants”), for an aggregate investment amount of $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20211027__20211101__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgsGWA2K4iad" title="Aggregate investment amount">500,000. The first note issued on November 1, 2021, had a principal balance of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20211101__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--DebtInstrumentAxis__custom--NoteOneMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z6XfNKVOiEVl" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zslpA161iNg" title="Warrants purchase">13,661,203 shares of common stock. The second note issued on December 1, 2021, had a principal balance of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20211201__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFIUjN8RPV6a" title="Principal balance">250,000 and accompanying warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211201__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqLzdGDpDhYd" title="Warrants purchase">13,661,203 shares of common stock. The Company received $<span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_c20211125__20211201__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z2If1ZHrzLTh" title="Proceeds from convertible debt">500,000 in aggregate proceeds from the Third November 2021 Notes. The Third November 2021 Notes bore an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211201__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zyyrJQu7QRRj" title="Interest rate">8% per annum was to mature on November 1, 2026. The Third November 2021 Warrants are exercisable at any time and expire on November 1, 2026. The Third November 2021 Warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfirAcjkaRL9" title="Warrants purchase">27,322,406 shares of common stock were valued at $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20211027__20211101__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOenWZeY8By2" title="Fair value">495,560 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the Third November 2021 Notes. The Third November 2021 Notes and Third November 2021 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrLbqHi3qW17" title="Conversion price">0.00366 per share (subject to adjustment). The Third November 2021 Notes and Third November 2021 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the Third November 2021 Notes and Third November 2021 Warrants. The conversion and exercise price of the Third November 2021 Notes and Third November 2021 Warrants are reduced equal to the lower conversion and exercise price of the new issuance or amended securities. At the election of the Third November 2021 Investor, the Third November 2021 Notes were convertible in whole or in part at any time and from time to time. On January 26, 2022, a notice and request for consent regarding a change in offering terms was sent by the Company to the Third November 2021 Investor. <span id="xdx_900_eus-gaap--DebtInstrumentDescription_c20220124__20220126__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z8hLz7QtIBc1" title="Debt instrument description">Upon the approval of the Third November 2021 Investor, the Company modified the terms of the Third November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the Third November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the Third November 2021 Notes. The Company issued additional warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220126__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zee69RW5Vxse" title="Warrants purchase">109,289,616 shares of common stock to the Third November 2021 Investor which increased the total relative fair value of all warrants in total by $<span id="xdx_90E_eus-gaap--DebtInstrumentFairValue_iI_c20220126__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPOeb6REr9S1" title="Fair value">22,429. This was recorded as debt discount which is being amortized over the life of the Third November 2021 Notes (see Note 9). The modification of the Third November 2021 SPA did not meet the requirements of a debt extinguishment under ASC 470-50 - Debt Modifications and Exchanges; however it represented a substantial modification whereby the Third November 2021 Investor received a substantial amount of additional warrants for the same principal amount of investment, hence it was accounted for, in substance, as a debt modification ASC 470-50 and no gain or losses was recognized. As of September 30, 2022, the Third November 2021 Notes had an outstanding principal balance of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsgw5nSKgGEg" title="Principal balance">500,000 and accrued interest of $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVVauvJwgYc" title="Accrued interest">34,411 and are included in the accompanying balance sheet at $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zkZbSjchQH84" title="Convertible long term notes payable">69,417 as a long-term convertible note payable, net of discount in the amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__srt--TitleOfIndividualAxis__custom--ThirdInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z6jxtE62mnp4" title="Net of discount">430,583 as of September 30, 2022. On November 29, 2022, the Third November 2021 Notes were exchanged for a new convertible debenture (see below). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On January 27, 2022, the Company entered into a Securities Purchase Agreement (“First January 2022 SPA”) with an investor (“First January 2022 Investor”) to purchase a convertible note with a principal balance of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5vIrtMhtjvj" title="Debt principal balance">500,000 (“First January 2022 Note”) with the Company receiving $<span id="xdx_908_eus-gaap--ProceedsFromConvertibleDebt_c20220127__20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBWKl26FcOQ6" title="Proceeds from convertible debt">500,000 in proceeds and accompanying warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zk1oAKxNZ2Uh" title="Purchase of warrants">136,612,022 shares of common stock (“First January 2022 Warrants”). The First January 2022 Note bore an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztLdQIwHvbda">8% per annum and was to mature on November 1, 2026. The First January 2022 Warrants are exercisable at any time and expire on November 1, 2026. The First January 2022 Warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zowdw0GhPjDb">136,612,022 shares of common stock were valued at $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20220127__20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zB2gD5jc5KQg">498,428 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the First January 2022 Note. The First January 2022 Note and First January 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220127__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUsUgbpcmNIh">0.00366 per share (subject to adjustment). The First January 2022 Note and First January 2022 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the First January 2022 Note and First January 2022 Warrants include. The conversion and exercise price of the First January 2022 Note and First January 2022 Warrants are reduced equal to the lower conversion and exercise price of the new issuance or amended securities. At the election of the First January 2022 Investor, the First January 2022 Note was convertible in whole or in part at any time and from time to time. As of September 30, 2022, the First January 2022 Note had an outstanding principal balance of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z54gE1pQkU3j">500,000 and accrued interest of $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVf8eSZONIQ5">26,959 and is included in the accompanying balance sheet at $<span id="xdx_909_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5vHz9jaly04">72,081 as a long-term convertible note payable, net of discount in the amount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__srt--TitleOfIndividualAxis__custom--FirstInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhOcnbsAoIt2">427,919 as of September 30, 2022. On November 29, 2022, the First January 2022 Note was exchanged for a new convertible debenture (see below). On January 31, 2022, the Company entered into a Securities Purchase Agreement (“Second January 2022 SPA”) with an investor (“Second January 2022 Investor”) to purchase a convertible note with principal balance of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQmqZ79JRpFb">500,000 (“Second January 2022 Note”) with the Company receiving $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_c20220130__20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zW18Kg8sQIif" title="Proceeds from convertible debt">500,000 in proceeds and accompanying warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5G9WNDJKGYf">136,612,022 shares of common stock (“Second January 2022 Warrants”). The Second January 2022 Note bore an interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zR8fBOfoTTl1">8% per annum and was to mature on November 1, 2026. The Second January 2022 Warrants are exercisable at any time and expire on November 1, 2026. The Second January 2022 Warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z11vAyO04RJe">136,612,022 shares of common stock were valued at $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20220130__20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrev2n60FXQ7">498,428 using the relative fair value method and recorded as a debt discount which was being amortized over the life of the Second January 2022 Note. The Second January 2022 Note and Second January 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220131__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbR10N925cc8">0.00366 per share (subject to adjustment). The Second January 2022 Note and Second January 2022 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the Second January 2022 Note and Second January 2022 Warrants. The conversion and exercise price of the Second January 2022 Note and Second January 2022 Warrants are reduced equal to the lower conversion and exercise price of the new issuance or amended securities. At the election of the Second January 2022 Investor, the Second January 2022 Note was convertible in whole or in part at any time and from time to time. As of September 30, 2022, the Second January 2022 Note had an outstanding principal balance of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1aRoNQr0Gjj">500,000 and accrued interest of $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMkjmgd6SGJl">26,520 and is included in the accompanying balance sheet at $<span id="xdx_907_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSc4b5s6ISe6">71,221 as a long-term convertible note payable, net of discount in the amount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__srt--TitleOfIndividualAxis__custom--SecondInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmApNIR9IRRf">428,779. On November 29, 2022, the Second January 2022 Note was exchanged for a new convertible debenture (see below). During April 2022, the Company entered into a Securities Purchase Agreement (“Second April 2022 SPA”) with various investors (“Investors”), to purchase convertible notes for an aggregate investment amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20220430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrAOLhOVJWEl" title="Aggregate investment amount">425,000 (collectively as “Second April 2022 Notes”) with the Company receiving $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20220401__20220430__us-gaap--DebtInstrumentAxis__custom--NoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zOJWPruH25C4" title="Proceeds from issuance of debt">425,000 of proceeds and accompanying warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfOJCCoTeXB5" title="Warrants purchase">17,857,144 shares of common stock (collectively as “Second April 2022 Warrants”). The Second April 2022 Warrants were valued at $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20220401__20220430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9smQTezarU8" title="Fair value of warrant">335,593 using the relative fair value method and were recorded as debt discount which was being amortized over the life of the Second April 2022 Notes. The Second April 2022 Notes bore an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZS9cKuIny4l" title="Interest rate">8% per annum and was to matures on <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20220430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zq5HptDYyrn3" title="Maturity date">April 1, 2027. The Second April 2022 Warrants are exercisable at any time and expire on April 1, 2027. The Second April 2022 Notes and Second April 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z8AeychgLYRg" title="Conversion price">0.00476 per share (subject to adjustment). The Second April 2022 Notes and Second April 2022 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the Second April 2022 Notes and Second April 2022 Warrants. The conversion and exercise price of the Second April 2022 Notes and Second April 2022 Warrants are reduced equal to the lower conversion and exercise price of the new issuance or amended securities. For so long as the Second April 2022 Warrants remains outstanding and until the listing by the Company or the trading of the common stock on a Qualified National Exchange (as defined in the agreement); (i) if the Company issues warrants to investors in a Subsequent Offering, and such warrants equal more than 20% warrant coverage, then a number of additional shares will be added to the Second April 2022 Warrants such that the Second April 2022 Warrants shall equal the same percentage of the warrant coverage offered to the investors in the Subsequent Offering and; (ii) if the Company issues warrants in a Subsequent Offering which may be exercised by means of a cashless exercises, then the Second April 2022 Warrants shall be exercisable by the same cashless exercise feature of the warrants issued in the Subsequent Offering. At the election of the Investors, the Second April 2022 Notes was convertible in whole or in part at any time and from time to time. As of September 30, 2022, the Second April 2022 Notes had an aggregate outstanding principal balance of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zgV4B01ldsp6" title="Principal balance">425,000 and accrued interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZIiKhRw1IH5" title="Accrued interest">15,710 and are included in the accompanying balance sheet at $<span id="xdx_90E_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsWot3kbzFFi" title="Convertible long term notes payable">120,808 as a long-term convertible note payable, net of discount in the amount of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXCd62Q2V3d5" title="Net of discount">304,192 as of September 30, 2022. On November 29, 2022, the Second April 2022 Notes were exchanged for a new convertible debenture (see below). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On July 1, 2022, the Company entered into a Securities Purchase Agreement with an investor (“July 2022 Investor”), to purchase a convertible note for a principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220702__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zg2kOpWnUBn6" title="Aggregate investment amount">50,000 (“July 2022 Note”) with the Company receiving $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20220627__20220702__us-gaap--DebtInstrumentAxis__custom--NoteMember__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4cq7zMmurak" title="Proceeds from issuance of debt">50,000 of proceeds and accompanying warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220702__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVJaZh8JFNpb">2,100,840 shares of common stock (“July 2022 Warrants”). The July 2022 Note bore an interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20220702__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zCW23q4QJwl2" title="Interest rate">8% per annum and was to mature on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220627__20220702__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLldRwraUtr8" title="Maturity date">April 1, 2027. The July 2022 Warrants are exercisable at any time and expire on April 1, 2027. The July 2022 Warrants were valued at $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20220627__20220702__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHahcIO0ZEG2" title="Principal balance">7,037 using the relative fair value method and was recorded as debt discount to be amortized over the life of the July 2022 Note. The July 2022 Note and July 2022 Warrants were convertible and exercisable, respectively, into shares of the Company’s common stock at a price equal to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220702__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zCAQQhfU1Khf" title="Conversion price">0.00476 per share (subject to adjustment). The July 2022 Note and July 2022 Warrants included a down-round provision under which the conversion price and exercise price are reduced if the Company sells or issues any securities including options, convertible securities, with the exception of exempt issuance (as defined in the agreements), or amended outstanding securities, at a lower conversion or exercise price than that of the July 2022 Note and July 2022 Warrants. The conversion and exercise price of the July 2022 Note and July 2022 Warrants are reduced equal to the lower conversion and exercise price of the new issuance or amended securities. For so long as the July 2022 Warrants remains outstanding and until the listing by the Company or the trading of the common stock on a Qualified National Exchange (as defined in the agreement); (i) if the Company issues warrants to investors in a Subsequent Offering, and such warrants equal more than 20% warrant coverage, then a number of additional shares will be added to the July 2022 Warrants such that the July 2022 Warrants shall equal the same percentage of the warrant coverage offered to the investors in the Subsequent Offering and; (ii) if the Company issues warrants in a Subsequent Offering which may be exercised by means of a cashless exercises, then the July 2022 Warrants shall be exercisable by the same cashless exercise feature of the warrants issued in the Subsequent Offering. As of September 30, 2022, the July 2022 Note had an outstanding principal balance of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20211001__20220930__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zV1ArIjbAjO4" title="Principal balance">50,000 and accrued interest of $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUDQN58Cj192" title="Accrued interest">953 and is included in the accompanying balance sheet at $<span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvauH9tQqrxg" title="Convertible long term notes payable">43,337 as a long-term convertible note payable, net of discount in the amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__srt--TitleOfIndividualAxis__custom--JulyInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfkujWp2Oaih" title="Net of discount">6,663. On November 29, 2022, the July 2022 Note was exchanged for a new convertible debenture (see below). On October 22, 2022, the Company issued a new convertible note for $200,000 to an existing investor for the settlement of claims (the “Settlement Note”). In connection with issuance of the Settlement Note, the Company recorded settlement expense of $200,000. On November 29, 2022, the Settlement Note was exchanged for a new convertible debenture (see below). On November 29, 2022, in connection with the Share Exchange Agreements and New Convertible Debentures discussed below, the Second November 2021 Warrants, Third November 2021 Warrants, January 2022 Warrants, Second January 2022 Warrants, Second April 2022 Warrants, and the July 2022 Warrants, aggregating <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember_z070USDSsNEl" title="Warrants purchase">566,406,072 warrants, were amended to reduce the exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zInQUBs5WT96" title="Warrant exercise price per share">0.003 per share. Additionally, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zB86jE4LUzl1" title="Warrants purchase">16,393,443 warrants issued to a placement agent in January 2022 were amended to reduce the exercise price to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zETgz7VLZgXc" title="Warrant exercise price per share">0.003 per share. In conjunction with the price reduction, the price protection feature for all these warrants was eliminated. All other terms of the warrants remained the same. As a result of the November 29, 2022 amendment to the exercise price, the Company calculated the difference between the warrants fair values on November 29, 2022, the date of the amendment, using the then current exercise price ranging from $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zXgCriNymaVd" title="Exercise price of warrants">0.00366 to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zme6viwDmNK1" title="Exercise price of warrants">0.00476 and the new exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zt1BTcPvAsH2" title="Exercise price of warrants">0.003 and determined that the difference was insignificant. Share Exchange Agreements and New Convertible Debentures and Warrants dated November 29, 2022 On November 29, 2022, the Company consummated the Initial Closing of the Offering pursuant to the terms and conditions of the Purchase Agreement, by and among the Company, certain accredited investors (the “Purchasers”) and Cavalry Fund I Management LLC, a Delaware limited liability company, in its capacity as collateral agent (the “Collateral Agent”). At the Initial Closing, the Company sold the Purchasers (i) <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zYXGQfTcK5N9" title="Annual interest rate">10% Original Issue Discount Senior Secured Convertible Debentures (the “New Debentures”) in an aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zuSj6y8KVwBi" title="Principal balance">2,805,000 and (ii) warrants (the “Warrants” and together with the New Debentures, the “Underlying Securities”) to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zZ0MmG6yEsfd" title="Warrants issued to purchase of securities">801,428,569 shares of common stock of the Company (the “Common Stock”), subject to adjustments provided by the Warrants, which represents <span id="xdx_905_ecustom--WarrantCoveragePercentage_iI_pid_dp_uPure_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zW0CCeN2Cyq6" title="Warrant coverage percentage">100% warrant coverage. The Company received a total of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_z8ySBpC1Y0Qh" title="Proceeds from intial public offerings">2,095,288 in net proceeds at the Initial Offering, net of the Original Issue Discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zbHIEAKlADj6" title="Original debt issue discount">255,000, commissions of $<span id="xdx_90A_eus-gaap--PaymentsForCommissions_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_z6FsWTsM09gj" title="Payments for commissions">296,800 and other offering costs of $<span id="xdx_902_eus-gaap--DeferredOfferingCosts_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zRcGQUaQdyq9" title="Offering costs">157,912. The Purchase Agreement contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, covenants that restrict the ability of the Company without the prior written consent of the Debenture holders, to incur additional indebtedness, and repay outstanding indebtedness, create or permit liens on assets, redeem its Common Stock, settle outstanding litigation, or enter into transactions with affiliates. On November 29, 2022, the Company entered into Securities Exchange Agreements with the above investors, whereby the Second November 2021 Notes, the Third November 2021 Notes, the First January 2022 Note, the Second January 2022 Note, the Second April 2022 Notes, the July 2022 Note, and the Settlement Note, with an aggregate principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--ExchangedConvertibleNotesMember_zBuMNWMtb5v4" title="Debt instrument, face amount">2,675,000 (the “Exchanged Convertible Notes”) and accrued interest payable of $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--ExchangedConvertibleNotesMember_zKcxbQsToA5j" title="Accrued interest payable">173,375 were exchanged for New Debentures. Additionally, on November 29, 2022, in order to induce the investors to exchange their respective convertible notes into the New Debentures, the aggregate principal amount and accrued interest payable was increased by <span id="xdx_909_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember_zClhSy9Mgoi3" title="Interest payable">15%, or $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNotesMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zmMSV5epQWec" title="Original issue discount">427,256, for the New Debentures with an aggregate principal amount of $3,275,631. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On November 29, 2022, the Company entered into Securities Exchange Agreements with preferred stockholders, whereby holders of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zZTYoAW0DiLk" title="Number of shares issued">902 shares of Series C-1 preferred stock with a stated value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221129__20221129__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zm1WfOs7caS5" title="Number of shares issued, value">372,303, and holders of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221129__20221129__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zopNdyw4HCs3" title="Number of shares issued">3,037 shares of Series C-2 preferred stock with a stated value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221129__20221129__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_z5A4aY1932Bc" title="Number of shares issued, value">1,245,935 were exchanged for the New Debentures. Additionally, on November 29, 2022, in order to induce the preferred stockholders to exchange their respective preferred shares into the New Debentures, the aggregate stated value of the preferred shares was increased by <span id="xdx_909_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zlXtAvc63LR8" title="Dividends payable">15%, or $<span id="xdx_909_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_z5msuqt6yXr9" title="Dividends payable">242,736, for New Debentures with an aggregate principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zD8JjHNRwAij" title="Principal balance">1,860,974. The New Debentures mature on November 29, 2023, subject to a three-month extension at the sole discretion of the Company. The New Debentures bear interest at 10% per annum payable upon conversion or maturity. The New Debentures are convertible into shares of Common Stock at any time after the maturity date and prior to Mandatory Conversion at the conversion price equal to the lesser of: (i) $0.003 per share and (ii) 70% of the average of the VWAP (as defined in the Debentures) (or 50% of the average of such VWAP if an event of default has occurred and has not been cured) of the Common Stock during the ten Trading Day (as defined in the Debentures) period immediately prior to the applicable conversion date. The New Debentures are subject to Mandatory Conversion in the event the Company closes a Qualified Offering. The conversion price per share of Common Stock in the case of a Mandatory Conversion shall be the Qualified Offering Price. Alternatively, upon a Mandatory Conversion, the holders of the New Debentures may elect to exchange their Debentures for newly issued convertible preferred securities at a price per share equal to the Qualified Offering Price or the five-day VWAP of the Common Stock prior to the date that is 181 days after the closing of the Qualified Offering. Notwithstanding the preceding, holders of New Debentures shall have the right to require satisfaction of up to 40% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. Investors that are exchanging securityholders shall have the right to require satisfaction of up to 10% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. The New Debentures also contain certain price protection provisions providing for adjustment of the number of shares of Common Stock issuable upon conversion of the New Debentures in case of certain future dilutive events or stock-splits and dividends. The Company’s obligations under the New Debentures are secured by a first priority lien on all of the assets of the Company pursuant to that certain Security Agreement, dated November 29, 2022 (the “Security Agreement”) by and among the Company, the Purchasers and the Collateral Agent. The Company had the right to hold one or more subsequent closings at any time prior to December 31, 2022, unless otherwise extended, to sell additional Underlying Securities in an aggregate principal amount up to $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__srt--RangeAxis__srt--MaximumMember_zRcPzmobrQmb" title="Principal balance">6,600,000, which was subject to adjustment. The subsequent closing deadline was extended, and a subsequent raise was consummated on January 27, 2023 (See Note 11). If the Company or any Subsidiary shall default on any of its obligations under any mortgage credit agreement or other facility indenture agreement, factoring agreement or other instrument under which there may be issued, or by which there may be secured or evidenced, any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement that (a) involves an obligation greater than $250,000, whether such indebtedness now exists or shall hereafter be created, and (b) results in such indebtedness becoming or being declared due and payable prior to the date on which it would otherwise become due and payable, the New Debenture shall be deemed in default and the default provisions shall apply. In connection with the Securities Exchange Agreements with investors for the exchange of the convertible notes and preferred shares for the New Debentures discussed above, the Company issued an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zpDy8sWH1YO9" title="Warrants issued">2,269,030,092 warrants to investors. <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_pid_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zD9w8znFej4h" title="Warrant reason for issuing, descriptions">The Warrants are exercisable for five years and six months from the earlier of the maturity date of the New Debentures and the closing of the Qualified Financing, at an exercise price equal to (i) in the event that a Qualified Offering is consummated prior to the exercise of the Warrant, the Qualified Offering Price, or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zCvKFegG8sDa" title="Warrant exercise price">0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration statement covering the resale of the shares underlying the Warrants within 180 days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum of 25%. The Warrants contain certain price protection provisions providing for adjustment of the amount of securities issuable upon exercise of the Warrants in case of certain future dilutive events or stock-splits and dividends. As discussed above, on November 29, 2022, in order to induce the investors to exchange their respective convertible notes and preferred stock into the New Debentures, the aggregate principal amount and accrued interest payable of the exchanged convertible notes, and the stated value of exchanged preferred stock was increased by <span id="xdx_902_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zPBxMHmUnh4b" title="Interest payable">15%, or an aggregate amount of $669,992. This inducement fee was included in loss from debt extinguishment on the accompanying unaudited statement of operations during the three months ended December 31, 2022. Additionally, the remaining debt discount on Exchanged Convertible Notes of $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember_zIzaMYA2N2l4" title="Principal balance">1,949,909 was written off and included in loss from debt extinguishment on the accompanying unaudited statement of operations during the three months ended December 31, 2022. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) In connection with the Initial Closing of the private placement, the Company and Joseph Gunnar & Co. LLC, a U.S. registered broker-dealer (“Gunnar”), entered into a placement agency agreement (the “Placement Agency Agreement”), pursuant to which Gunnar agreed to act as the placement agent for the Offering (the “Placement Agent”). Pursuant to the terms of the Placement Agency Agreement, the Company agreed to (i) pay Gunnar a cash placement fee of 10% of the gross cash proceeds raised in the Offering, and (ii) issue to Gunnar warrants (the “PA Warrants”) on the terms identical to the Warrants sold in the Offering in an amount equal to 10% of the Underlying Securities sold to investors. As a result of the foregoing, the Company paid Gunnar an aggregate commission of $<span id="xdx_901_eus-gaap--PaymentsForCommissions_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__srt--TitleOfIndividualAxis__custom--GunnarMember_zhP4vPEqZvc8" title="Commission payable">305,000 in connection with the Initial Closing. The Company also paid $<span id="xdx_907_eus-gaap--PaymentsForLegalSettlements_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__srt--TitleOfIndividualAxis__custom--GunnarMember_zkCFD7WC7tm8" title="Legal fees payable">50,000 in fees to Gunnar’s legal counsel and paid Gunnar a financial advisory fee of $<span id="xdx_907_eus-gaap--PaymentsForFees_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__srt--TitleOfIndividualAxis__custom--GunnarMember_z4RWuKQwttzj" title="Advisory fee payable">50,000. In addition, Gunner received <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__srt--TitleOfIndividualAxis__custom--GunnarMember_z6RLCbP7dhMi" title="Warrant received">124,489,795 warrants. Additionally, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgpB4NSNAz18">16,000,000 warrants to a consultant in connection with the private placement offering. Analysis of Exchange Agreements, Related Party Debenture and New Debentures, and Related Warrants In accordance with ASC 470-50, Debt Modifications and Extinguishments, the Company performed an assessment of whether the Exchange Agreement transactions with related parties and investors was deemed to be new debt, a modification of existing debt, or an extinguishment of existing debt. The Company evaluated the November 29, 2022 Exchange Agreements for debt modification and concluded that the debt exchanges qualified for debt extinguishment. The Company determined the transactions were considered a debt extinguishment because the change in debt, the inducement premiums (related parties and third parties) discussed previously totaling $<span id="xdx_906_eus-gaap--ExtinguishmentOfDebtAmount_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__us-gaap--DebtInstrumentAxis__custom--RelatedPartyDebentureAndNewDebenturesMember_z9Da6FWZT9Rb" title="Extinguishment of debt,amount">1,724,489, and the issuance of new warrants was substantial. Upon extinguishment, the Company had an aggregate of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__us-gaap--DebtInstrumentAxis__custom--RelatedPartyDebentureAndNewDebenturesMember_zFb4zWbBh44b" title="Unamortized discount">3,718,288 of unamortized initial debt discount recorded which was written off and included in loss on debt extinguishment on the accompanying unaudited statement of operations during the three months ended December 31, 2022. Derivative Liabilities Pursuant to Related Party Debentures and New Debentures and Related Warrants Pursuant to the provisions of ASC 815-40 – Derivatives and Hedging – Contracts in an Entity’s Own Stock, the New Related Party Debentures, the New Debenture, and the New warrants issued in connection with the Exchange Agreements were analyzed and it was determined that the terms of the New Related Party Debentures, New Debentures and the related warrants contained terms that were considered derivatives due to the variable conversion of the Debentures and exercise price of the warrants, and other provisions which includes events not within the control of the Company. In accordance with ASC 815-40, the embedded conversion option contained in the Notes and the Warrants were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion options and warrants was determined using the Binomial Lattice valuation model. At the end of each period and on the date notes convert or are repaid, the Company revalues the derivative liabilities resulting from the embedded options and warrants. In connection with the issuance of the New Related Party Debentures and the New Debentures and related warrants, on November 29, 2022, the initial measurement date, the aggregate fair values of the embedded conversion option derivatives and warrant derivatives of $<span id="xdx_902_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_c20221129__us-gaap--DebtInstrumentAxis__custom--RelatedPartyDebentureAndNewDebenturesMember_zhGTawAPLH38" title="Derivative instruments liabilities">41,961,095 was recorded as derivative liabilities and was attributable to the following: 1) $<span id="xdx_90F_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_c20221129__us-gaap--LongtermDebtTypeAxis__custom--NewRelatedPartyDebenturesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmFaJ7Qcwf1" title="Derivative instruments liabilities">21,986,653 of derivative liabilities was attributable to the New Related Party Debentures and related warrants which was allocated to debt discount up to the net principal amount of the New Related Party Debentures of $8,837,284, with the remainder of $13,149,369 charged to current period operations as initial derivative expense, and 2) $<span id="xdx_90B_eus-gaap--DerivativeInstrumentsAndHedgesLiabilities_iI_c20221129__us-gaap--LongtermDebtTypeAxis__custom--NewDebenturesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJUNeMrpG9C3" title="Derivative instruments liabilities">19,974,442 of derivative liabilities was attributable to the New Debentures and related warrants which was allocated to debt discount up to the net principal amount of the New Debentures of $7,231,894, with the remainder of $12,742,548 charged to current period operations as initial derivative expense. At the end of the period, the Company revalued the embedded conversion option derivative liabilities and warrant derivative liabilities and recorded a derivative expense of $505,158. In connection with the revaluation and the initial derivative expense, the Company recorded an aggregate derivative expense of $26,397,075 during the three months ended December 31, 2022. The Company uses the Binomial Valuation Model to determine the fair value of its conversion options and new stock warrants which requires the Company to make several key judgments including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the value of the Company’s common stock;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the expected life of issued stock warrants;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the expected volatility of the Company’s stock price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the expected dividend yield to be realized over the life of the stock warrants; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the risk-free interest rate over the expected life of the stock warrants.</td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) <p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zAGKkg16k7Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 29, 2022 (the Exchange Agreement date) and December 31, 2022, the fair value of the embedded options and stock warrants were estimated at issuance using the Binomial Valuation Model with the following assumptions: SCHEDULE OF FAIR VALUE OF EMBEDDED OPTIONS AND STOCK WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2023</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%; text-align: left">Dividend rate</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Term (in years)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1 to 6.5 years</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Volatility</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zOPb88JgDbH7" title="Volatility minimum">270.0% to <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zi4UMkzAC7q4" title="Volatility maximum">364.2</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Risk—free interest rate</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z1gpeuajbeB4" title="Risk free interest rate minimum">3.92% to <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zDU5QVyDKzxi" title="Risk free interest rate maximum">4.78</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> The Company’s computation of the expected life of issued stock warrants was based on the simplified method as the Company does not have adequate exercise experience to determine the expected term. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock. During the three months ended December 31, 2022 and 2021, amortization of debt discounts related to the convertible notes payable and Debentures amounted to $1,602,646 and $92,019, respectively, which has been included in interest expense on the accompanying unaudited statements of operations. Notes Payable - Related Party On October 21, 2021, the Company entered into a Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors and a related party, for a principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20211021__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_z6Nwa4fY5BBe" title="Principal amount">150,000. The Company received proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20211021__20221021__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zZYHappcaoKa" title="Gross proceeds from debt">150,000. The note bore an annual interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211021__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_z3BVOXYsMYQh" title="Annual interest rate">1%, matured on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20211021__20221021__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zkniFHnZHYXf" title="Maturity date">December 1, 2021 and could have been prepaid in whole or in part without penalty. Pursuant to the note, the Company has a 90-day grace period following the maturity date after which the lender was permitted to charge a late payment fee equal to <span id="xdx_902_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20211021__20211021__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zBkPqlWxfAGj" title="Debt interest rate">1% of the outstanding principal balance and cost of collection, including legal fees. During the year ended September 30, 2022, the Company fully paid the outstanding balance on the note. As of September 30, 2022, the note had no outstanding balance (see Note 8). On April 26, 2021, the Company entered into a Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors and a related party, for a principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20210426__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zAyKaDEj1VQ4" title="Principal amount">100,000. The Company received proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfDebt_c20210425__20220426__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_z8w5DU9Mq1K9" title="Gross proceeds from debt">100,000. The note bears an annual interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210426__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zmkBGRoYA33d" title="Annual interest rate">1%, matures on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210426__20220426__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zOFJHlCiLUEj" title="Maturity date">April 1, 2022 and can be prepaid in whole or in part without penalty. Pursuant to the note, the Company has a 90-day grace period following the maturity date after which the lender was permitted charge a late payment fee equal to <span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_c20210426__20210426__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zRkL7f0XOaRc" title="Debt interest rate">1% of the outstanding principal balance and cost of collection, including legal fees. On May 5, 2022, the Company and Jeffrey Busch (collectively as “Parties”) amended the April 26, 2021 note with principal amount of $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20220505__20220505__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zLPuM5SjSTjb" title="Original amount">100,000 (“Original Note”) pursuant to which the Parties increased the principal amount to $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20210505__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zgseg23IIuF2" title="Principal amount">350,000 (“New Note”) with the Company receiving an additional $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20210505__20220505__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zrTh4hZDlK1d" title="Gross proceeds from debt">250,000 of proceeds and added a contingent conversion feature. The New Note bears an annual interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210505__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_z17rLZTX1Up" title="Annual interest rate">1% (which shall increase to <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20210505__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__srt--RangeAxis__srt--MaximumMember_za7Ajsx23Y93" title="Annual interest rate">2% in an event of a default) and matures on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210505__20220505__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zNTggjbCWDH9" title="Maturity date">May 5, 2024. The New Note may not be prepaid and is only convertible upon an occurrence of a public offering. The outstanding principal plus any unpaid accrued interest (“Conversion Amount”) of the New Note is convertible into shares of common stock at the price for which the common stock was sold in the public offering. Pursuant to ASC 470-50 - Debt Modifications and Exchanges, the amendment was accounted for as a debt extinguishment because the contingent conversion feature added to the New Note resulted in a substantial modification of the Original Note. No gain or loss was recognized in connection with the debt extinguishment. As of December 31, 2022, the New Note had an outstanding principal balance of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zlkLxjO4pHR9" title="Principal amount">350,000, reflected as notes payable – related party in the accompanying unaudited balance sheet since the conditions for its contingent conversion has not yet been met, and accrued interest of $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zlVwn9MrZKIc" title="Accrued interest">3,356 (see Note 8). As of September 30, 2022, the New Note had an outstanding principal balance of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zna1VYnJQNE6" title="Principal amount">350,000, reflected as notes payable – related party in the accompanying balance sheet since the conditions for its contingent conversion has not yet been met, and accrued interest of $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartyMember__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember_zABaxmkjQJNc" title="Accrued interest">2,474 (see Note 8). Note Payable In September 2017, the Company entered into a note agreement with a third-party investor. Pursuant to the note, the Company borrowed a principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20170930__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zvtqnzsCLKxe" title="Principal amount">1,000. The note bears an annual interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20170930__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zD9FcHhUOhBi" title="Interest rate">33.3%, is unsecured and in default due to non-payment of the balance pursuant to the repayment terms. As of December 31, 2022, the note had principal and accrued interest balances of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_z4pxaUFYnhDd" title="Principal amount">1,000 and $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zWRsJPH7Rry3" title="Accrued interest">1,772, respectively. As of September 30, 2022, the note had principal and accrued interest balances of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zD7fxiuvHag9" title="Principal amount">1,000 and $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zSguVZqbWdj9" title="Accrued interest">1,689, respectively. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED)

On December 31, 2022 and September 30, 2022, convertible notes payable (third parties and related parties) consisted of the following: SCHEDULE OF CONVERTIBLE NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_499_20221231_zXmF692npZB1" style="font-family: Times New Roman, Times, Serif; text-align: center">1 </td><td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_492_20220930_zIBBHE3UYJG8" style="font-family: Times New Roman, Times, Serif; text-align: center"> 2</td><td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_maCDNz70j_zJiYdl2Nxaoh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Principal amount</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">7,941,605</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">2,475,000</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_msCDNz70j_zAoH14vrOxf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: debt discount</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(7,265,021</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(2,028,719</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iTI_pp0p0_mtCDNz70j_maCDz2Xu_zdjPSWXFZ056" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes payable, net</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">676,584</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">446,281</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayableCurrent_iNI_pp0p0_di_zAIVNoAgbzLg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: current portion of convertible notes payable - related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(676,584</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_zTeuszMrsxJ5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Convertible notes payable, net – long-term</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">446,281</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DebtInstrumentFaceAmountRelatedParty_iI_pp0p0_maCDRPz1E9_zjPQz0ANKQdl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Principal amount – related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">8,975,192</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4,150,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DebtInstrumentUnamortizedDiscountRelatedParty_iNI_pp0p0_di_msCDRPz1E9_zLvrLOFkiWYb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: debt discount – related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(8,203,748</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,844,186</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ConvertibleDebtRelatedParty_iI_pp0p0_mtCDRPz1E9_maCDz2Xu_z9O5gQd1O086" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Convertible notes payable - related parties, net</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">771,444</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,305,814</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ConvertibleDebtRelatedPartyCurrent_iNI_pp0p0_di_zdpTNeeO7aTi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: current portion of convertible notes payable - related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(771,444</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(1,000,000</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ConvertibleDebtRelatedPartyNonCurrent_iI_pp0p0_zVCBrORAYEWa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Convertible notes payable - related parties, net – long-term</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,305,814</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebt_iTI_pp0p0_mtCDz2Xu_z4cgb0JAf9m6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total convertible notes payable, net</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,448,028</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,752,095</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7941605

2475000

7265021

2028719

676584

446281

676584

446281

8975192 4150000 8203748 1844186 771444 2305814 771444 1000000 1305814

1448028

2752095

63897764

1000000

0.08

2026-05-12

333334

333333

0.00313

1000000

20164

267521

732479

0.00313

2026-05-12

984200

15800

1000000

334000

18251367

333000

18196722

333000

18196722

1000000

0.08

2026-11-01

990048

0.00366

the Company modified the terms of the First November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the First November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the First November 2021 Notes.

218579234

34620

1000000

20164

140093

859907

100000

4201681

100000

89815

2027-04-01

0.08

0.00476

100000

3901

18959

81041

1000000

0.20

250000

10504202

250000

10504202

250000

10504202

250000

10504202

1000000

0.08

2027-04-01

178449

0.00476

1000000

20110

834803

165197

50000

2100840

50000

5924

2027-04-01

0.08

0.00476

50000

1173

44438

5562

125000

150000

0.08

275000

2683

375000

0.08

375000

4110

350000

0.08

350000

2148

120000

0.08

385441138

0.003

63897764

0.003

0.00366

0.00476

0.003

0.10

550000

157142857

412092

50000

58200

29708

4150000

120750

0.15

0.10

589505

4860255

1000

2000000

66630

500

1000000

33315

0.15

464992

3564937

2023-11-29

0.10

0.003

0.70

0.50

5000000

0.003

0.70

Notwithstanding the preceding, holders of New Related Party Debentures shall have the right to require satisfaction of up to 40% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. Investors that are exchanging securityholders shall have the right to require satisfaction of up to 10% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing.

250000

2564340702

The New Related Party Warrants are exercisable for five years and six months from the earlier of the maturity date of the New Related Party Debentures and the closing of the Qualified Financing, at an exercise price equal to (i) in the event that a Qualified Offering is consummated prior to the exercise of the New Related Party Warrant, the price per share at which the Qualified Offering is made (“Qualified Offering Price”), or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration statement covering the resale of the shares underlying the New Related Party Warrants within 180 days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum of 25%

0.003

0.15

0.10

1046167

1768379

500000

250000

13661203

250000

13661203

500000

0.08

27322406

495560

0.00366

the Company modified the terms of the Second November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the Second November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the Second November 2021 Notes

109289616

22429

500000

34520

69417

430583

500000

250000

13661203

250000

13661203

500000

0.08

27322406

495560

0.00366

Upon the approval of the Third November 2021 Investor, the Company modified the terms of the Third November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the Third November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the Third November 2021 Notes

109289616

22429

500000

34411

69417

430583

500000

136612022

0.08

136612022

498428

0.00366

500000

26959

72081

427919

500000

136612022

0.08

136612022

498428

0.00366

500000

26520

71221

428779

425000

17857144

335593

0.08

2027-04-01

0.00476

425000

15710

120808

304192

50000

2100840

0.08

2027-04-01

7037

0.00476

50000

953

43337

6663

200000

566406072

0.003

16393443

0.003

0.00366

0.00476

0.003

0.10

2805000

801428569

2095288

255000

296800

157912

2675000

173375

0.15

427256

3275631

902

372303

3037

1245935

0.15

242736

1860974

2023-11-29

0.10

0.003

0.70

0.50

Notwithstanding the preceding, holders of New Debentures shall have the right to require satisfaction of up to 40% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. Investors that are exchanging securityholders shall have the right to require satisfaction of up to 10% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing.

6600000

250000

2269030092

The Warrants are exercisable for five years and six months from the earlier of the maturity date of the New Debentures and the closing of the Qualified Financing, at an exercise price equal to (i) in the event that a Qualified Offering is consummated prior to the exercise of the Warrant, the Qualified Offering Price, or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration statement covering the resale of the shares underlying the Warrants within 180 days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum of 25%

0.003

0.15

669992

1949909

In connection with the Initial Closing of the private placement, the Company and Joseph Gunnar & Co. LLC, a U.S. registered broker-dealer (“Gunnar”), entered into a placement agency agreement (the “Placement Agency Agreement”), pursuant to which Gunnar agreed to act as the placement agent for the Offering (the “Placement Agent”). Pursuant to the terms of the Placement Agency Agreement, the Company agreed to (i) pay Gunnar a cash placement fee of 10% of the gross cash proceeds raised in the Offering, and (ii) issue to Gunnar warrants (the “PA Warrants”) on the terms identical to the Warrants sold in the Offering in an amount equal to 10% of the Underlying Securities sold to investors

305000

50000

124489795

16000000

1724489

3718288

41961095

21986653

8837284

13149369

19974442

7231894

12742548

505158

26397075

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zAGKkg16k7Xj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 29, 2022 (the Exchange Agreement date) and December 31, 2022, the fair value of the embedded options and stock warrants were estimated at issuance using the Binomial Valuation Model with the following assumptions: SCHEDULE OF FAIR VALUE OF EMBEDDED OPTIONS AND STOCK WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2023</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%; text-align: left">Dividend rate</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right">—</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Term (in years)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1 to 6.5 years</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Volatility</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zOPb88JgDbH7" title="Volatility minimum">270.0% to <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zi4UMkzAC7q4" title="Volatility maximum">364.2</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Risk—free interest rate</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z1gpeuajbeB4" title="Risk free interest rate minimum">3.92% to <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zDU5QVyDKzxi" title="Risk free interest rate maximum">4.78</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> </table>

P1Y

P6Y6M

270.0

364.2

3.92

4.78

1602646

92019

150000

0.01

2021-12-01

0.01

100000

0.01

2022-04-01

0.01

100000

350000

250000

0.01

0.02

2024-05-05

350000

3356

350000

2474

1000

0.333

1000

1772

1000

1689

NOTE 7 –LEASE LIABILITIES Financing Lease Right-of-Use (“ROU”) Assets and Financing Lease Liabilities Effective November 2018, the Company entered into a financing agreement with the first lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $<span id="xdx_901_eus-gaap--PaymentsForRent_c20181101__20181130__srt--TitleOfIndividualAxis__custom--FirstLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z6WAi0cTzgLe" title="Monthly payment">379 for a period of <span id="xdx_909_eus-gaap--LesseeFinanceLeaseDescription_c20181101__20181130__srt--TitleOfIndividualAxis__custom--FirstLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zd5z8FumzMYa" title="Finance lease description"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtM_c20181130__srt--TitleOfIndividualAxis__custom--FirstLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z8evmIoIwwvl" title="Finance lease term">60 months commencing in November 2018 through October 2023. At the effective date of the financing agreement, the Company recorded a financing lease payable of $<span id="xdx_90B_eus-gaap--FinanceLeasePrincipalPayments_c20181101__20181130__srt--TitleOfIndividualAxis__custom--FirstLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjjfe5m0mDs1" title="Financing lease payable">16,065. Effective November 2018, the Company entered into a financing agreement with a second lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20181101__20181130__srt--TitleOfIndividualAxis__custom--SecondLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z0BEgb2iqWHg" title="Monthly payment">1,439 for a period of <span id="xdx_909_eus-gaap--LesseeFinanceLeaseDescription_c20181101__20181130__srt--TitleOfIndividualAxis__custom--SecondLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zUOdJLkuVFP6" title="Finance lease description"><span id="xdx_90E_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtM_c20181130__srt--TitleOfIndividualAxis__custom--SecondLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zkA02lWRIMvk" title="Finance lease term">60 months commencing in November 2018 through October 2023. At the effective date of the financing agreement, the Company recorded a financing lease payable of $<span id="xdx_90A_eus-gaap--FinanceLeasePrincipalPayments_c20181101__20181130__srt--TitleOfIndividualAxis__custom--SecondLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zj6QG7fPODmj" title="Financing lease payable">62,394. Effective March 2019, the Company entered into a financing agreement with a third lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20190301__20190331__srt--TitleOfIndividualAxis__custom--ThirdLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zeK6vBgmHgo1" title="Monthly payment">1,496 for a period of <span id="xdx_905_eus-gaap--LesseeFinanceLeaseDescription_c20190301__20190331__srt--TitleOfIndividualAxis__custom--ThirdLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zdfg6cn278fd" title="Finance lease description"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtM_c20190331__srt--TitleOfIndividualAxis__custom--ThirdLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zniGjWEpebN2" title="Finance lease term">60 months commencing in March 2019 through February 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $<span id="xdx_90D_eus-gaap--FinanceLeasePrincipalPayments_c20190301__20190331__srt--TitleOfIndividualAxis__custom--ThirdLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_znfr0OWENnof" title="Financing lease payable">64,940. Effective August 2019, the Company entered into a financing agreement with a fourth lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $<span id="xdx_909_eus-gaap--PaymentsForRent_c20190801__20190831__srt--TitleOfIndividualAxis__custom--FourthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zQAwzZz4ka8" title="Monthly payment">397 for a period of <span id="xdx_906_eus-gaap--LesseeFinanceLeaseDescription_c20190801__20190831__srt--TitleOfIndividualAxis__custom--FourthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zal3uZW73O9j" title="Finance lease description"><span id="xdx_909_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtM_c20190831__srt--TitleOfIndividualAxis__custom--FourthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zcDNSRcqTC93" title="Finance lease term">60 months commencing in August 2019 through July 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $<span id="xdx_902_eus-gaap--FinanceLeasePrincipalPayments_c20190801__20190831__srt--TitleOfIndividualAxis__custom--FourthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zm0vg3QO3fI" title="Financing lease payable">19,622. Effective January 2020, the Company entered into a financing agreement with a fifth lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make a monthly payment of $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20200101__20200131__srt--TitleOfIndividualAxis__custom--FifthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zNEJDVFfupwl" title="Monthly payment">1,395 for a period of <span id="xdx_90C_eus-gaap--LesseeFinanceLeaseDescription_c20200101__20200131__srt--TitleOfIndividualAxis__custom--FifthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zCgOL6ie8vJg" title="Finance lease description"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseTermOfContract1_iI_dtM_c20200131__srt--TitleOfIndividualAxis__custom--FifthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPeCfReOTke4" title="Finance lease term">60 months commencing in January 2020 through December 2025. At the effective date of the financing agreement, the Company recorded a financing lease payable of $<span id="xdx_906_eus-gaap--FinanceLeasePrincipalPayments_c20200101__20200131__srt--TitleOfIndividualAxis__custom--FifthLessorMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zT7YvpeDbvu6" title="Financing lease payable">68,821. The significant assumption used to determine the present value of the financing lease payables was the discount rate which ranged from 8% and 15% based on the Company’s estimated effective rate pursuant to the financing agreements. Financing lease right-of-use assets (“Financing ROU”) is summarized below: SCHEDULE OF FINANCIAL LEASE RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231_zU3CGMsas3Y4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220930_zkeMjUyOTcr8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maFLROUzpTr_zY1VdPXEcWD4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify">Financing ROU assets</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msFLROUzpTr_zEvWajLBkYt4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(178,479</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(166,887</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_mtFLROUzpTr_zz6pvLRLYVP7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance of Financing ROU assets</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">53,362</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">64,954</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the three months ended December 31, 2022 and 2021, depreciation expense related to Financing ROU assets amounted to $11,592 and $11,592, respectively. <p id="xdx_890_ecustom--ScheduleOfFinancingLeaseLiabilityRelatedToFinancingRightOfUseAssetsTableTextBlock_z6DPoh3wJ6L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financing lease liability related to the Financing ROU assets is summarized below: SCHEDULE OF FINANCING LEASE LIABILITY RELATED TO FINANCING RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_z2G2Yj2jUS0h" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220930_zUfLndA3X1lg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40B_ecustom--FinancingLeasePayablesForEquipment_iI_maCzQDc_zpsU4Ygeulxe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify; padding-bottom: 1.5pt">Financing lease payables for equipment</td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FinancingLeasePayables_iTI_maCzeiy_mtCzQDc_zmqf5zeQUwAl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total financing lease payables</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PaymentsOfFinancingLeaseLiabilities_iI_maCzeiy_zwYaEn3Qxff3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Payments of financing lease liabilities</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(156,335</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(143,456</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iTI_mtCzeiy_zweCSLDOrKgi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">75,506</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">88,385</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zTQaaWUn0XRg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less: short term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(52,037</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(53,995</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z8pyr1lz62z1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Long term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">23,469</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">34,390</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Future minimum lease payments under the financing lease agreements on December 31, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER FINANCING LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Years ending December 31,</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zK6UHbrSdZEl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Amount</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzwQK_zEyANUZhm19d" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%; text-align: center">2023</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right">57,631</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzwQK_z1iWBnxHY4vd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">2024</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">24,403</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtCzwQK_z6Z3GKYgDB2a" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">Total minimum financing lease payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">82,034</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQS3ZFFyEcT" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: discount to fair value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(6,528</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiability_iI_zOXs1GQtcCf3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financing lease payable on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">75,506</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Operating Lease Right-of-Use (“ROU”) Asset and Operating Lease Liabilities In December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025. Pursuant to the lease agreement, the lease requires the Company to pay a monthly base rent of; (i) $<span id="xdx_907_eus-gaap--PaymentsForRent_c20191201__20191231__srt--StatementScenarioAxis__custom--FirstYearMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZMqtTKL0Mo2" title="Monthly base rent">4,878 in the first year; (ii) $<span id="xdx_901_eus-gaap--PaymentsForRent_c20191201__20191231__srt--StatementScenarioAxis__custom--SecondYearMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zpkpPMJ40VX6" title="Monthly base rent">5,026 in the second year; (iii) $<span id="xdx_904_eus-gaap--PaymentsForRent_c20191201__20191231__srt--StatementScenarioAxis__custom--ThirdYearMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zXLtMkYzZsA6" title="Monthly base rent">5,179 in the third year; (iv) $<span id="xdx_90B_eus-gaap--PaymentsForRent_c20191201__20191231__srt--StatementScenarioAxis__custom--FourthYearMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zb5WchVppmch" title="Monthly base rent">5,335 in the fourth year and; (v) $<span id="xdx_905_eus-gaap--PaymentsForRent_c20191201__20191231__srt--StatementScenarioAxis__custom--FifthYearMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zShzGBS1GSQl" title="Monthly base rent">5,495 in the fifth year, plus a pro rata share of operating expenses beginning February 2020. In February 2020, pursuant to ASC 842 – Leases, the Company calculated the present value of the total lease payments using a discount rate of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20200229__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_zhxzdRQvqPY5" title="Operating discount rates">12% which was based on the Company’s estimated incremental borrowing rate. The Company recorded an operating right-of-use asset and lease liability of $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20200229__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_z0utP98UozT5" title="Operating lease right of use asset"><span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_c20200229__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_zDcrKUK22oI4" title="Operating lease liability">231,337 in connection with the lease. On June 10, 2021, the Company entered into an amendment to its existing Warehouse Lease (the “Lease Amendment”), effective October 3, 2021, for its laboratory facility in Golden, CO (see Note 10). The Lease Amendment provided for: (i) an extension to the term of the original lease to five years following the completion of the Company’s improvements to the Expansion Premises (defined below); (ii) an expansion of the premises to include the premises located at Unit 404, Building F, 15000 West 6th Avenue, Golden, Colorado 80401, consisting of approximately 4,734 rentable square feet (the “Expansion Premises”); (iii) an annual base rent modification; (iv) an increase to the security deposit; (v) tenant improvement allowance; (vi) additional parking and; (vii) two renewal options, each for five year terms, for a total of ten years. Pursuant to the Lease Amendment, the Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893 for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394 for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve; (13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen. In October 2021, pursuant to ASC 842 – Leases, the Company wrote off the balances of the operating asset of $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211031__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_zWcr88ZHzoRh" title="Operating asset">168,664 and operating liability of $<span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_c20211031__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_zFJzQlg9Qnsa" title="Operating lease, liability">176,893 related to the original lease and recognized a gain on lease modification in the amount of $<span id="xdx_907_eus-gaap--OperatingLeaseLeaseIncome_c20211001__20211031__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_zSAhnTTR1Swc" title="Gain on lease modification">8,229, which was included in general and administrative expense in the accompanying statement of operation. The Company calculated the present value of the total lease payments in the Lease Amendment using a discount rate of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211031__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_z4k1QFwWrSWh" title="Operating discount rates">8% which was based on the Company’s incremental borrowing rate at the effective date and recorded an operating right-of-use asset and an operating lease liability of $<span id="xdx_90A_ecustom--OperatingOfficeLeaseLiability_iI_c20211031__srt--CumulativeEffectPeriodOfAdoptionAxis__us-gaap--AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember_zhzzWcIb8YTc" title="Operating office lease">1,212,708. For the three months ended December 31, 2022, lease costs related to operating lease ROU asset and operating lease liabilities amounted to $50,311 which included base lease costs of $29,554 and other expenses such as common area maintenance and taxes of $20,757, all of which were expensed during the period and included in general and administrative expenses on the accompanying statements of operations. For the three months ended December 31, 2021, lease costs amounted to $56,867, which included base lease costs of $28,690 and other expenses of $28,177, all of which were expensed during the period and included in general and administrative expenses on the accompanying statements of operations. Operating Right-of-use asset (“ROU”) is summarized below: SCHEDULE OF OPERATING RIGHT-OF-USE ASSET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zMkeIJJhp87j" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220930_zRfKA8MoynA7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_ecustom--OperatingOfficeLeaseLiability_iI_pp0p0_msOLROUz1Ma_zxvnaMSFbvhe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify">Operating office lease</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetAccumulatedReduction_iI_pp0p0_maOLROUz1Ma_zbQwsPdnKukf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less accumulated reduction</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(70,289</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(57,847</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pp0p0_mtOLROUz1Ma_zPeQd6PglyT4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance of Operating ROU asset</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,142,419</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,154,861</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Operating lease liability related to the ROU asset is summarized below: SCHEDULE OF OPERATING LEASE LIABILITY RELATED TO RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zXUl05SRPA13" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220930_zuMezWOA21V" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_408_ecustom--OperatingOfficeLeaseLiability_iI_pp0p0_maOLLzElS_zulB4mQGF8Q3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating office lease</td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseLiabilities_iTI_pp0p0_mtOLLzElS_maOLLzok0_zlQNfhCdOk01" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total operating lease liability</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ReductionOfOperatingLeaseLiability_iI_pp0p0_maOLLzok0_zU5lt52TpiZi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Reduction of operating lease liability</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(35,324</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(29,396</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzok0_zQG3tkiKWmc7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,177,384</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,183,312</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z0bvUmXu7Xbk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less: short term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(26,960</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(25,551</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zycVV2124e44" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Long term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,150,424</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,157,761</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Future base lease payments under the non-cancellable operating lease on December 31, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS OF OPERATING LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Years ending December 31,</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zxV0Mis4zWl9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Amount</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzZLB_z62xU64j3S5k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%; text-align: center">2023</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right">120,199</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzZLB_zqr31GZ5XxS6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">2024</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">123,806</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzZLB_zZ42EckzQmw4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">2025</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">127,520</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzZLB_zDYgY0Lmk7l9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">2026</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">131,871</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzZLB_zJnGAAHVO6Nk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">2027 and thereafter</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,515,340</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzZLB_zVKIzE9ghakl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total minimum non-cancellable operating lease payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,018,736</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zKyCECQJhYs4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: discount to fair value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(841,352</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_zSCmkzlk30O" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total operating lease liability on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,177,384</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

379

60 months commencing in November 2018 through October 2023

P60M

16065

1439

60 months commencing in November 2018 through October 2023

P60M

62394

1496

60 months commencing in March 2019 through February 2024

P60M

64940

397

60 months commencing in August 2019 through July 2024

P60M

19622

1395

60 months commencing in January 2020 through December 2025

P60M

68821

0.08

0.15

Financing lease right-of-use assets (“Financing ROU”) is summarized below: SCHEDULE OF FINANCIAL LEASE RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20221231_zU3CGMsas3Y4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220930_zkeMjUyOTcr8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maFLROUzpTr_zY1VdPXEcWD4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify">Financing ROU assets</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msFLROUzpTr_zEvWajLBkYt4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(178,479</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(166,887</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_mtFLROUzpTr_zz6pvLRLYVP7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance of Financing ROU assets</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">53,362</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">64,954</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

231841

178479

166887

53362

64954

11592 11592 <p id="xdx_890_ecustom--ScheduleOfFinancingLeaseLiabilityRelatedToFinancingRightOfUseAssetsTableTextBlock_z6DPoh3wJ6L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financing lease liability related to the Financing ROU assets is summarized below: SCHEDULE OF FINANCING LEASE LIABILITY RELATED TO FINANCING RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_z2G2Yj2jUS0h" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220930_zUfLndA3X1lg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40B_ecustom--FinancingLeasePayablesForEquipment_iI_maCzQDc_zpsU4Ygeulxe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify; padding-bottom: 1.5pt">Financing lease payables for equipment</td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--FinancingLeasePayables_iTI_maCzeiy_mtCzQDc_zmqf5zeQUwAl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total financing lease payables</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">231,841</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PaymentsOfFinancingLeaseLiabilities_iI_maCzeiy_zwYaEn3Qxff3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Payments of financing lease liabilities</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(156,335</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(143,456</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iTI_mtCzeiy_zweCSLDOrKgi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">75,506</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">88,385</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zTQaaWUn0XRg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less: short term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(52,037</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(53,995</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z8pyr1lz62z1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Long term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">23,469</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">34,390</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 231841 231841 231841 231841 -156335 -143456

75506

88385

52037

53995

23469

34390

Future minimum lease payments under the financing lease agreements on December 31, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER FINANCING LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Years ending December 31,</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zK6UHbrSdZEl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Amount</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzwQK_zEyANUZhm19d" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%; text-align: center">2023</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right">57,631</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzwQK_z1iWBnxHY4vd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">2024</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">24,403</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtCzwQK_z6Z3GKYgDB2a" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">Total minimum financing lease payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">82,034</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQS3ZFFyEcT" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: discount to fair value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(6,528</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiability_iI_zOXs1GQtcCf3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financing lease payable on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">75,506</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

57631

24403

82034

6528

75506

The lease is for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025

4878

5026

5179

5335

5495

0.12

231337

4734

the Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893 for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394 for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve; (13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen.

168664

176893

8229

0.08

1212708

50311

29554

20757

56867

28690

28177

Operating Right-of-use asset (“ROU”) is summarized below: SCHEDULE OF OPERATING RIGHT-OF-USE ASSET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20221231_zMkeIJJhp87j" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220930_zRfKA8MoynA7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_ecustom--OperatingOfficeLeaseLiability_iI_pp0p0_msOLROUz1Ma_zxvnaMSFbvhe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify">Operating office lease</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OperatingLeaseRightOfUseAssetAccumulatedReduction_iI_pp0p0_maOLROUz1Ma_zbQwsPdnKukf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less accumulated reduction</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(70,289</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(57,847</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pp0p0_mtOLROUz1Ma_zPeQd6PglyT4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance of Operating ROU asset</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,142,419</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,154,861</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1212708 1212708 -70289 -57847

1142419

1154861

Operating lease liability related to the ROU asset is summarized below: SCHEDULE OF OPERATING LEASE LIABILITY RELATED TO RIGHT-OF-USE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_zXUl05SRPA13" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220930_zuMezWOA21V" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_408_ecustom--OperatingOfficeLeaseLiability_iI_pp0p0_maOLLzElS_zulB4mQGF8Q3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify; padding-bottom: 1.5pt">Operating office lease</td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseLiabilities_iTI_pp0p0_mtOLLzElS_maOLLzok0_zlQNfhCdOk01" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total operating lease liability</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,212,708</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ReductionOfOperatingLeaseLiability_iI_pp0p0_maOLLzok0_zU5lt52TpiZi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Reduction of operating lease liability</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(35,324</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(29,396</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzok0_zQG3tkiKWmc7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,177,384</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,183,312</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z0bvUmXu7Xbk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less: short term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(26,960</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(25,551</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zycVV2124e44" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Long term portion</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,150,424</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,157,761</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1212708 1212708 1212708 1212708 -35324 -29396

1177384

1183312

26960

25551

1150424

1157761

Future base lease payments under the non-cancellable operating lease on December 31, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS OF OPERATING LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Years ending December 31,</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zxV0Mis4zWl9" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Amount</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzZLB_z62xU64j3S5k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%; text-align: center">2023</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right">120,199</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzZLB_zqr31GZ5XxS6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">2024</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">123,806</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzZLB_zZ42EckzQmw4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">2025</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">127,520</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzZLB_zDYgY0Lmk7l9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: center">2026</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">131,871</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzZLB_zJnGAAHVO6Nk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">2027 and thereafter</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,515,340</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzZLB_zVKIzE9ghakl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total minimum non-cancellable operating lease payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,018,736</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zKyCECQJhYs4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less: discount to fair value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(841,352</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_zSCmkzlk30O" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total operating lease liability on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,177,384</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

120199

123806

127520

131871

1515340

2018736

841352

1177384

NOTE 8 – RELATED-PARTY TRANSACTIONS   Effective January 1, 2021, the Company entered into a consulting agreement with Mr. Kucharchuk, a member of the Board of Directors, to serve as a strategic advisor. The agreement was effective for a period of twelve months, commencing on January 1, 2021 and shall renew on a month-to month basis, subject to the right of the Company and Mr. Kucharchuk to terminate the agreement in accordance with the agreement. Pursuant to the agreement, Mr. Kucharchuk shall be paid $2,000 per month. As of December 31, 2022 and September 30, 2022, the Company had an accounts payable – related party balance of $6,000 and $12,000 related to this consulting agreement, respectively. On April 26, 2021, the Company entered into a Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors, for a principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20210426__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember_zphIyYJbz80b">100,000 (see Note 6). On May 5, 2022, the parties amended the April 26, 2021 note into the New Note with the Company receiving an additional $250,000 of proceeds and added a conversion feature. The New Note bears an annual interest rate of 1% (which shall increase to <span id="xdx_90F_ecustom--DebtInstrumentDefaultInterestRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--RelatedPartyTransactionAxis__srt--BoardOfDirectorsChairmanMember_zPVOGeaXzTyb" title="Debt instrument default interest rate">2% in an event of a default) and matures on May 5, 2024. As of December 31, 2022, the New Note had an outstanding principal balance of $350,000, reflected as notes payable – related party in the accompanying unaudited balance sheet since the conditions for its contingent conversion has not yet been met, and accrued interest of $3,356 (see Note 6). As of September 30, 2022, the New Note had an outstanding principal balance of $350,000, reflected as notes payable – related party in the accompanying balance sheet since the conditions for its contingent conversion has not yet been met, and accrued interest of $2,474 (see Note 6). On May 12, 2021, the Company and the May 2021 Investor entered into a May 2021 SPA to purchase a convertible May 2021 Note and with principal value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20210512__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_ze0rUdcjncvb" title="Principal value">1,000,000 and accompanying May 2021 Warrants (see Note 6). In connection with the Company’s obligations under the May 2021 Note, the Company entered into a security agreement with the May 2021 Investor as agent, pursuant to which the Company granted a lien on the laboratory equipment of the Company, for the benefit of the related party. As of September 30, 2022, the May 2021 Note had an outstanding principal balance of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_zSHaTWCn2jq4" title="Principal balance">1,000,000 and accrued interest of $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_zXphbNFem0s2" title="Accrued interest">20,164. On November 29, 2022, the May 2021 Note was exchanged for a new convertible debenture (see Note 6). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On October 21, 2021, the Company entered into a Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors and a related party, for a principal balance of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20211021__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteAgreementMember_zMQYpjlLdxef" title="Principal value">150,000. During the year ended September 30, 2022, the Company fully paid the outstanding balance on the note. As of September 30, 2022, the note had no outstanding balance (see Note 6). On November 1, 2021, pursuant to the First November 2021 SPA the First November 2021 Investor purchased three notes with aggregate principal of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20211101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_zRTXVulwcQZ6" title="Principal balance">1,000,000 with accompanying First November 2021 Warrants to purchase up to an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20211101__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_z2r1vEcpiUp2" title="Warrants purchase">54,644,811 shares of common stock. As of September 30, 2022, the First November 2021 Notes had an outstanding principal balance of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_z2YhIA5EBgCi" title="Principal balance">1,000,000 and accrued interest of $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_zEsLwTGZroKc" title="Accrued interest">20,164. On November 29, 2022, the First November 2021 Notes were exchanged for a new convertible debenture (see Note 6). On January 26, 2022, a notice and request for consent regarding a change in offering terms was sent by the Company to the First November 2021 Investor. Upon the approval of the First November 2021 Investor, <span id="xdx_90E_eus-gaap--DebtInstrumentDescription_c20220126__20220126__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_zGGurhcRoRL" title="Debt description">the Company modified the terms of the First November 2021 SPA which increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the First November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion of the First November 2021 Notes. The Company issued additional warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220126__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_z0e556NERY8c" title="Fair value adjustment of warrants">218,579,234 shares of common stock to the First November 2021 Investor which increased the total relative fair value of all warrants in total by $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220126__20220126__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--FirstNovemberTwoThousandTwentyOneSecuritiesPurchaseAgreementMember_zXUZC6knTV7c" title="Fair value">34,630 recorded as debt discount which is being amortized over the life of the First November 2021 Notes (see Note 6 and 9). On April 5, 2022, pursuant to the First April 2022 SPA, Matthew Schwartz, a member of the Board of Directors and a related party, purchased a convertible note with principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20220405__us-gaap--TypeOfArrangementAxis__custom--FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember_zEfexJbIsqA9" title="Debt instrument, face amount">100,000 with accompanying First April 2022 Warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220405__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember__us-gaap--TypeOfArrangementAxis__custom--FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_zvKGQsJosvxi" title="Warrants to purchase">4,201,681 shares of common stock. The Company received net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_c20220323__20220324__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember__us-gaap--TypeOfArrangementAxis__custom--FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_zfr6A9UXGVK2" title="Proceeds from issuance of debt">100,000 on March 24, 2022. As of September 30, 2022, the First April 2022 Note had an outstanding principal balance of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember_zyRevJaGStOj" title="Principal balance">100,000 and accrued interest of $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--FirstAprilTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MatthewSchwartzMember_zqSmkhzDxyai" title="Accrued interest">3,901. On November 29, 2022, the First April 2022 Note was exchanged for a new convertible debenture (see Note 6). On May 9, 2022, pursuant to the May 2022 SPA the May 2022 Investor purchased four convertible notes for an aggregate investment amount of $<span id="xdx_90B_eus-gaap--Investments_iI_c20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--FourConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_z2J0K2d4rHI8" title="Aggregate investment amount">1,000,000 with accompanying May 2022 Warrants to purchase shares of common stock equal to <span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20220509__20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--FourConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_zBSEz2ZUApzf" title="Warrants to purchase price">20% of the number of the total shares of common stock issuable upon the conversion of the May 2022 Notes. During the year ended September 30, 2022, the Company received an aggregate of $<span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_c20220509__20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--FourConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_zYNWRawTPrRh" title="Aggregate proceeds">1,000,000 of proceeds and issued an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220509__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--FourConvertibleNotesMember_zxPwWERhzijk" title="Aggregate proceeds, shares">42,016,808 of the May 2022 Warrants. As of September 30, 2022, the May 2022 Notes had an aggregate outstanding principal balance of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--FourConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_zxbbXnOyCZlk" title="Principal balance">1,000,000 and accrued interest of $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--FourConvertibleNotesMember__us-gaap--TypeOfArrangementAxis__custom--MayTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember_z2DgcBEQy4Mb" title="Accrued interest">20,110. On November 29, 2022, the May 2022 Note was exchanged for a new convertible debenture (see Note 6). On June 15, 2022, pursuant to the June 2022 SPA, Danica Holley, a member of the Board of Directors and a related party, purchased a convertible note with principal of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220615__us-gaap--TypeOfArrangementAxis__custom--JuneTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DanicaHolleyMember_zvBUPNQljKvk" title="Debt instrument, face amount">50,000 with accompanying June 2022 Warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220615__us-gaap--TypeOfArrangementAxis__custom--JuneTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DanicaHolleyMember_zjM9q6460HPj" title="Warrants to purchase">2,100,840 shares of common stock. As of September 30, 2022, the June 2022 Note had an outstanding principal balance of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--JuneTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DanicaHolleyMember_zsxQz59e4NC9" title="Principal balance">50,000 and accrued interest of $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--JuneTwoThousandTwentyTwoSecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DanicaHolleyMember_zwK2R4SgCEA7" title="Accrued interest">1,173. On November 29, 2022, the June 2022 Note was exchanged for a new convertible debenture (see Note 6). On July 29, 2022, the Company entered into a Demand Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors and a related party, for a principal balance of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20220729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zRUiY8Um5Gjl" title="Principal balance">125,000, and on September 2, 2022, the Company entered into a second Demand Promissory Note Agreement with Jeffrey Busch for a principal balance of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220902__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--SecondDemandPromissoryNoteAgreementMember_ze5k5tTuI7v3" title="Principal balance">150,000 (collectively referred to as called the “Busch Notes”). The Busch Notes bear an annual interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220729__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zaYapC42osO7" title="Annual interest rate">8% and are payable on demand. The outstanding principal and accrued interest on the Busch Note is contingently convertible, in full, at the option of the lender, into the same security which is being issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, the Busch Notes had an outstanding principal balance of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zqkH1jtCmrQ1" title="Principal balance">275,000 and accrued interest of $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zUHnnLZnJ9A5" title="Accrued interest">2,683 and are reflected in the accompanying balance sheet as a short-term convertible note payable – related party. On November 29, 2022, the Busch Notes were exchanged for a new convertible debenture (see Note 6). On August 11, 2022, the Company entered into a Demand Promissory Note Agreement with a related party, who is an affiliate stockholder, for a principal balance of $375,000. The note bears an annual interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220811__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zqONaEJkLIc7" title="Annual interest rate">8% and is payable on demand. The outstanding principal and accrued interest of the note is contingently convertible, in full, at the option of the lender, into the same security which is being issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, this note had an outstanding principal balance of $375,000 and accrued interest of $4,110 and is reflected in the accompanying balance sheet as a short-term convertible note payable – related party. On November 29, 2022, this note was exchanged for a new convertible debenture (see Note 6). On September 2, 2022, the Company entered into a Demand Promissory Note Agreement with a related party, who is an affiliate stockholder, for a principal balance of $350,000. The note bears an annual interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220902__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementOneMember_z78YEs3QbzU1" title="Annual interest rate">8% and is payable on demand. The outstanding principal and accrued interest of the note is contingently convertible, in full, at the option of the lender, into the same security which is being issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, this note had an outstanding principal balance of $350,000 and accrued interest of $2,148 and is reflected in the accompanying balance sheet as a short-term convertible note payable – related party. On November 29, 2022, this note was exchanged for a new convertible debenture (see Note 6). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) During the year ended September 30, 2022, the Company advanced a total of $13,883 to a related party, which is an affiliate entity and a majority shareholder of the Company. During the year ended September 30, 2022, the Company recorded bad debt expense of $35,594 related to the write off of related party advances. As of December 31, 2022 and September 30, 2022, the Company had related party receivable balances of $0. On November 1, 2022, the Company entered into a Demand Promissory Note Agreements with two related parties, who are affiliate stockholders, for a principal balance of $120,000. The notes bore an annual interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221101__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNoteAgreementMember_zPw6Mfxn3Onc" title="Annual interest rate">8% and were payable on demand. The outstanding principal and accrued interest of the notes was contingently convertible, in full, at the option of the lender, into the same security issued by the Company in its next private placement of equity or equity backed securities at any time after the inception date. In December 2022, these short-term loans were repaid. On November 29, 2022, in connection with the Share Exchange Agreements and New Related Party Convertible Debentures discussed in Note 6, the May 2021 Warrants, First November 2021 Warrants, First April 2022 Warrants, May 2022 Warrants, and June 2022 Warrants, aggregating <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z3uyYnFj6Ii7" title="Warrants purchase">385,441,138 warrants, were amended to reduce the exercise price to $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zomUonhYxBwc" title="Shares price">0.003 per share. Additionally, <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zvq5EbDbWUkk" title="Warrants purchase">63,897,764 warrants issued in connection with Series F preferred stock were amended to reduce the exercise price to $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20221129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zicvJBhmrrQh" title="Shares price">0.003 per share. In conjunction with the price reduction, the price protection feature for all these warrants was eliminated. All other terms of the warrants remained the same. (See Note 6). On November 29, 2022, the Company consummated the Initial Closing of the Offering pursuant to the terms and conditions of the Purchase Agreement, by and among the Company the Related Party Purchasers and the Collateral Agent. At the Initial Closing, the Company sold the related party Purchasers (i) the New Related Party Debentures in an aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20221129__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zU24ruT0iOk4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,000 and (ii) the New Related Party Warrants to purchase up to 157,142,857 shares of Common Stock, subject to adjustments provided by the Warrants, which represents 100% warrant coverage. The Company received a total of $412,092 in net proceeds at the Initial Offering from the Related Party Purchasers, net of the Original Issue Discount of $50,000, commissions of $58,200 and other offering costs of $29,708. (See Note 6). On November 29, 2022, the Company entered into Securities Exchange Agreements with the Exchanged Related Party Notes and accrued interest payable of $120,750 were exchanged for New Related Party Debentures. Additionally, on November 29, 2022, in order to induce the related party investors to exchange the respective convertible notes into the Related Party Debentures, the aggregate principal amount of the Exchanged Related Party Notes and accrued interest payable was increased by <span id="xdx_907_eus-gaap--ShortTermDebtInterestRateIncrease_dp_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZIZPPH8qfOg" title="Accrued interest payable increased percentage">15% (those issued for the August 11, 2022 and September 2, 2022 Demand Promissory Notes were issued with <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220902__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNotesMember_zrCM0kgoLyKh" title="Promissory notes interest rate percentage"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220811__us-gaap--TypeOfArrangementAxis__custom--DemandPromissoryNotesMember_zY9eR334TCZ6" title="Promissory notes interest rate percentage">10% OID), or $589,505, for new Related Party Debentures with an aggregate principal amount of $4,860,255. (See Note 6). On November 29, 2022, the Company entered into Securities Exchange Agreements with related party preferred stock holders, whereby related party holders of <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYlpuKJuGrdd" title="Preferred stock, shares authorized">1,000 shares of Series E preferred stock with a stated value of $<span id="xdx_904_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfRPs1ewYkyg" title="Principal balance">2,000,000 and accrued dividends payable of $<span id="xdx_90B_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zlp9TjbzcDp3" title="Dividends payable">66,630, and related party holders of 500 shares of Series F preferred stock with a stated value of $<span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z3Vjj5ibVVHb" title="Principal balance">1,000,000 and accrued dividends payable of $<span id="xdx_908_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxdnfJmU3ei9" title="Principal balance">33,315 were exchanged for the New Related Party Debentures. Additionally, on November 29, 2022, in order to induce the related party preferred stockholders to exchange their respective preferred shares into the New Related Party Debentures, the aggregate stated value and accrued dividends payable were increased by <span id="xdx_90A_eus-gaap--ShortTermDebtInterestRateIncrease_pid_uPure_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zTrZ4mnZJxu3" title="Dividends payable">15%, or $464,992, for new Related Party Debentures with an aggregate principal amount of $3,564,937. (See Note 6). As of December 31, 2022 and September 30, 2022, the Company owed several executives and directors for expense reimbursements and consulting fees in the aggregate amount of $6,000 and $16,223, respectively, which is reflected on the accompanying balance sheet as accounts payable – related parties. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On December 31, 2022 and September 30, 2022, net amount due to related parties consisted of the following: SCHEDULE OF RELATED PARTIES TRANSACTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zCDOtqgbz6q2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220930_zzjkG9Mrv6zf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40B_ecustom--ConvertibleNotePrincipalRelatedParty_iI_maDTRPCzGRh_zCKkn3cLgmjb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify">Convertible notes principal – related parties</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">8,975,192</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">4,150,000</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DebtInstrumentUnamortizedDiscountRelatedParty_iNI_di_msDTRPCzGRh_zt8um4PhdL7l" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Discount on convertible notes - related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(8,203,748</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(1,844,186</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_maDTRPCzGRh_z1wF0mcpWnkj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Note payable principal – related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">350,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">350,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedLiabilitiesRelatedParties_iI_maDTRPCzGRh_zlb8j7GLiGe9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Accrued liabilities - related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">82,043</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">76,927</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_maDTRPCzGRh_zZFaAoF2qXg8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Accounts payable – related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">6,000</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">16,223</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DueToRelatedPartiesCurrent_iTI_mtDTRPCzGRh_zk0OIJARRLnb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,209,487</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,748,964</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2000

6000

12000

100000

250000

0.01

0.02

2024-05-05

350000

3356

350000

2474

1000000

20164

150000

1000000

54644811

1000000

20164

218579234

34630

100000

4201681

100000

3901

1000000

0.20

1000000

42016808

1000000

20110

50000

2100840

50000

1173

125000

150000

0.08

275000

2683

375000

0.08

375000

4110

350000

0.08

350000

2148

13883

35594

120000

0.08

385441138

0.003

63897764

0.003

550000

157142857

412092

50000

58200

29708

120750

0.15

0.10

589505

4860255

1000

2000000

66630

500

1000000

33315

0.15

464992

3564937

6000

16223

On December 31, 2022 and September 30, 2022, net amount due to related parties consisted of the following: SCHEDULE OF RELATED PARTIES TRANSACTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zCDOtqgbz6q2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220930_zzjkG9Mrv6zf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40B_ecustom--ConvertibleNotePrincipalRelatedParty_iI_maDTRPCzGRh_zCKkn3cLgmjb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify">Convertible notes principal – related parties</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">8,975,192</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">4,150,000</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DebtInstrumentUnamortizedDiscountRelatedParty_iNI_di_msDTRPCzGRh_zt8um4PhdL7l" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Discount on convertible notes - related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(8,203,748</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(1,844,186</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_maDTRPCzGRh_z1wF0mcpWnkj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Note payable principal – related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">350,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">350,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedLiabilitiesRelatedParties_iI_maDTRPCzGRh_zlb8j7GLiGe9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Accrued liabilities - related parties</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">82,043</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">76,927</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_maDTRPCzGRh_zZFaAoF2qXg8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Accounts payable – related parties</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">6,000</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">16,223</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DueToRelatedPartiesCurrent_iTI_mtDTRPCzGRh_zk0OIJARRLnb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify">Total</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,209,487</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,748,964</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8975192 4150000 8203748 1844186

350000

82043 76927

6000

16223

1209487

2748964

NOTE 9 – STOCKHOLDERS’ DEFICIT Shares Authorized On September 22, 2020, the Company filed with the Nevada Secretary of State, an amendment to its Articles of Incorporation to change its name from “OncBioMune Pharmaceutical, Inc.” to “Theralink Technologies, Inc.” and increase its authorized shares of common stock from 6,666,667 shares of common stock at $0.0001 per share par value to 12,000,000,000 shares of common stock at $0.0001 per share par value, effective September 24, 2020. On July 1, 2022, the Company filed with the Nevada Secretary of State, an amendment to its Articles of Incorporation to increase its authorized shares of common stock from 12,000,000,000 shares to 100,000,000,000 shares of common stock at $0.0001 per share par value. Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,333 shares of the authorized 26,667 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action. As of December 31, 2022 and September 30, 2022, there were <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcrsQQI0Lp31" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgKC3Vjt4GAf" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220930__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdKSriampnq8" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20220930__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfHNukXI6LE5" title="Preferred stock, shares outstanding">667 shares of the Company’s Series A Preferred Stock issued and outstanding held by a former member of the Board of Directors. Series C-1 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series C-1 Preferred Stock (the “Series C-1 Certificate of Designation”), as amended on June 9, 2021, with the Nevada Secretary of State to designate 3,000 shares of its previously authorized preferred stock as Series C-1 Preferred Stock, par value $0.0001 per share and a stated value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z7s5upA3tG8h" title="Preferred stock, par or stated value per share">4,128.42 per share. The Series C-1 Certificate of Designation and its filing was approved by the Company’s Board of Directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series C-1 Preferred Stock have the following preferences and rights: On June 9, 2021, the Company filed an Amendment (the “CoD Amendment”) to the Series C-1 Certificate of Designation with the Nevada Secretary of State. The filing of the CoD Amendment was approved by the Board on June 8, 2021, and by the holders of the majority of the outstanding shares of Series C-1 Preferred Stock on June 8, 2021. The CoD Amendment sets the triggering price for the anti-dilution price protection at $0.00275 per share, the same price as the Series C-2 Certificate of Designation. All other terms of the Series C-1 Certificate of Designation remain unchanged and in full force and effect. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holders of shares of Series C-1 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors.</td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each share of Series C-1 Preferred Stock is convertible into shares of common stock any time after the Initial Issuance Date at a conversion price of $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9IOOEBfSIg7" title="Conversion price">0.0275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) the conversion amount (determined by the sum of the stated value thereof plus any additional amount thereon which consist of all dividends, whether declared or not) of such share of Series C-1 by (y) the conversion price of $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxfNDDr4ZgJf" title="Conversion price">0.0275 per share (subject to temporary adjustment upon a triggering event as defined by the Series C-1 Certificate of Designation, to <span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionRatio_iI_pid_dp_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0qvaoiB6bj" title="Conversion percentage">80% of the conversion price). The adjusted conversion price is only in effect until the triggering event is cured. The convertibility of shares of Series C-1 Preferred Stock is limited such that a holder of Series C-1 Preferred Stock may not convert Series C-1 Preferred Stock to common stock to the extent that the number of shares of common stock to be issued pursuant to such conversion, when aggregated with all other shares of common stock owned by the holder at such time, would result in the holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) more than <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20200514__20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2PlQ5jlgPm3" title="Common stock outstanding, percentage">4.99% of all of the Company’s common stock outstanding. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series C-1 Certificate of Designation), at a price of or with an exercise price or conversion price of less than $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zJ2RbOymnNuj" title="Conversion price">0.0275 per share (see amendment discussed above), then upon such issuance or sale, the Series C-1 Preferred Stock conversion price shall be reduced to the sale price, the exercise price or conversion price of the securities sold. In addition, these preferred shareholders have the right to participate in future equity offerings from the company for twenty-four months from the effective date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series C-1 Preferred Stock shall be entitled to receive, in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (“Liquidation Funds”) before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Series C-1 Certificate of Designation) then outstanding, an amount per shares of the Series C-1 Preferred Stock equal to the greater of (A) the conversion amount thereof on the date of such payment or (B) the amount per share such holder of Series C-1 Preferred Stock would receive if such holder converted such Series C-1 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the holders of Series C-1 Preferred Stock and holders of the shares of Parity Stock, then each holder of Series C-1 Preferred Stock and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such holder of Series C-1 Preferred Stock and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series C-1 Preferred Stock and all holders of Parity Stock.</td></tr> </table> During the year ended September 30, 2022, various holders of the Series C-1 Preferred Stock converted an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211001__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember_zt7K1u7do5Wc" title="Number of shares issued for conversion of convertible securities">1,923 shares of Series C-1 Preferred Stock into <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20211001__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaqiTEq4sIt2" title="Common stock issued upon conversion">288,637,529 shares of the Company’s common stock (see below – Common Stock Issued Upon Conversion of Series C-1 Preferred Stock). On November 29, 2022, the Company entered into Securities Exchange Agreements with preferred stockholders, whereby holders of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember_zZEMKGVuhd1e" title="Number of shares conversion of convertible securities">902 shares of Series C-1 preferred stock with a stated value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember_zltY9swwjDYl" title="Stock issued during period, value, conversion of units">372,303 were exchanged for the New Debentures (See Note 6). As of December 31, 2022 and September 30, 2022, the Company had <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember_zbmj2X2lqo1i" title="Preferred stock, shares outstanding">141 and <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember_zgWKR1JnJaw6" title="Preferred stock, shares outstanding">1,043 shares of Series C-1 Preferred Stock issued and outstanding, respectively. Series C-2 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series C-2 Preferred Stock (the “Series C-2 Certificate of Designation”) with the Nevada Secretary of State to designate 6,000 shares of its previously authorized preferred stock as Series C-2 Preferred Stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zZ2ZaOr6aPVc" title="Preferred stock par or stated value per share">0.0001 per share and a stated value of $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zhEaORIhEKm7" title="Preferred stock par or stated value per share">410.27 per share. The Series C-2 Certificate of Designation and its filing was approved by the Company’s Board of Directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series C-2 Preferred Stock have the following preferences and rights: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holders of shares of Series C-2 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors.</td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each share of Series C-2 Preferred Stock is convertible into shares of common stock any time after the initial issuance date at a conversion price of $0.00275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) the conversion amount (determined by the sum of the stated value thereof plus any additional amount thereon) of such share of Series C-2 by (y) the conversion price of $0.00275 per share (subject to temporary adjustment upon a triggering event as defined by the Series C-2 Certificate of Designation to <span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionRatio_iI_pid_dp_c20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zqqO19r3Ghv2" title="Conversion percentage">80% of the conversion price). The adjusted conversion price is only in effect until the triggering event is cured. The convertibility of shares of Series C-2 Preferred Stock is limited such that a holder of Series C-2 Preferred Stock may not convert Series C-2 Preferred Stock to common stock to the extent that the number of shares of common stock to be issued pursuant to such conversion, when aggregated with all other shares of common stock owned by the holder at such time, would result in the holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) more than <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20200514__20200518__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zvUzhGv4IuS3" title="Common stock outstanding, percentage">4.99% of all of the Company’s common stock outstanding.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series C-2 Certificate of Designation), at a price of or with an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series C-2 Preferred Stock conversion price shall be reduced to the sale price, the exercise price or conversion price of the securities sold. In addition, these preferred shareholders have the right to participate in future equity offerings from the company for twenty-four months from the effective date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series C-2 Preferred Stock shall be entitled to receive, in cash out of the Liquidation Funds before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Series C-2 Certificate of Designation) then outstanding, an amount per shares of the Series C-2 Preferred Stock equal to the greater of (A) the conversion amount thereof on the date of such payment or (B) the amount per share such holder would receive if such holder converted such Series C-2 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the holders of Series C-2 Preferred Stock and holders of the shares of Parity Stock, then each holder of Series C-2 Preferred Stock and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such holder of Series C-2 Preferred Stock and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series C-2 Preferred Stock and all holders of Parity Stock.</td></tr> </table> During the year ended September 30, 2022, a holder of the Series C-2 Preferred Stock converted <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_pid_c20211001__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zwF9g94XScXg" title="Conversion of stock shares converted">1,880 shares of Series C-1 Preferred Stock into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_c20211001__20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesCOnePreferredStockMember_zP3UaaCDjmCb" title="Conversion of stock shares converted">280,475,491 shares of the Company’s common stock (see below – Common Stock Issued Upon Conversion of Series C-2 Preferred Stock). On November 29, 2022, the Company entered into Securities Exchange Agreements with preferred stockholders, whereby holders of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zlPEemunPhVj" title="Number of shares conversion of convertible securities">3,037 shares of Series C-2 preferred stock with a stated value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_z8i8ZxiHmRFc" title="Stock issued during period, value, conversion of units">1,245,935 were exchanged for the New Debentures (See Note 6). As of December 31, 2022 and September 30, 2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zfoeFNFCIsHd" title="Preferred stock, shares issued::XDX::-"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_doxL_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zjctqgQUWHT1" title="Preferred stock, shares outstanding::XDX::-">0 and <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20220930__us-gaap--StatementClassOfStockAxis__custom--SeriesCTwoPreferredStockMember_zOCOfguwv8Ij" title="Preferred stock, shares outstanding">3,037 shares of Series C-2 Preferred Stock, respectively, issued and outstanding. Series E Preferred Stock On September 15, 2020, the Company filed a Certificate of Designation, Preferences and Rights of Series E Preferred Stock (the “Series E Certificate of Designation”) with the Nevada Secretary of the State to designate 2,000 shares of its previously authorized preferred stock as Series E Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series E Certificate of Designation and its filing were approved by the Company’s Board of Directors without stockholder approval as provided for in the Company’s Articles of Incorporation and under Nevada law. The holders of shares of Series E Preferred Stock have the following preferences and rights: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">From the initial issuance date, cumulative dividends on each share of Series E shall accrue, on a quarterly basis in arrears (with any partial quarter calculated on a pro-rata basis), at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200915__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zGzVxGouMRR6" title="Debt interest rate">8% per annum on the stated value, plus any additional amount thereon. Dividends shall be paid within 15 days after the end of each fiscal quarter (“Dividend Payment Date”), at the option of the Holder in cash or through the issuance of shares of common stock. In the event that the Holder elects to receive its dividends in shares of common stock the number of shares of common stock to be issued to each applicable Holder shall be determined by dividing the total dividend outstanding to such Holder by the average closing price of the common stock during the five trading days on the principal market prior to the dividend payment date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holders of shares of Series E Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors.</td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"><span id="xdx_90A_eus-gaap--PreferredStockConversionBasis_c20200912__20200915__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zhAhRSSAd7Ng" title="Preferred stock, conversion basis">Each share of Series E Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the conversion price which is the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation including a price protection provision for offerings below the conversion price, provided, however, the conversion price shall never be less than $0.0021. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number by the conversion price.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with, (i) a Change of Control of the Company or (ii) on the closing of, a Qualified Public Offering by the Company, all of the outstanding shares of Series E (including any fraction of a share) shall automatically convert into an aggregate number of shares of common stock (including any fraction of a share) by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number (including any fraction of a share) by the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation including a price protection provision for offerings below the conversion price. However, the conversion price shall never be less than $0.0021. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series E shall be deemed to have been converted into shares of Common Stock immediately prior to the closing of such transaction or Qualified Public Offering.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series E Certificate of Designation), at a price, an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series E Preferred Stock conversion price shall be reduced to the sale price or the exercise price or conversion price of the securities sold.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holders of Series E Preferred Stock have no voting rights.</td></tr> </table> On September 16, 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with an affiliated investor, who is a beneficial shareholder, to purchase an aggregate amount of <span id="xdx_901_eus-gaap--TemporaryEquitySharesIssued_iI_c20200916__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDvof18lppM4" title="Stock issued">1,000 shares of the newly created Series E Convertible Preferred Stock of the Company (the “Series E Preferred”) for an aggregate investment amount of $<span id="xdx_908_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pp0p0_c20200916__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbvNoAKBHWN9" title="Aggregate investment amount">2,000,000. Pursuant to the Series E Certificate of Designation, Series E Preferred Stock is redeemable at the option of the holder in the event that the Company is prohibited from issuing shares of common stock to a holder upon any conversion due to insufficient shares of common stock available (“Authorized Failure Shares”) and therefore meets the criteria of a contingently redeemable instrument in accordance with ASC 480-10-25-7 – Distinguishing Liabilities from Equity. The Series E Preferred Stock is contingently redeemable upon the occurrence of an event that is outside of the issuer’s control and is classified as temporary equity pursuant to ASC 480-10-S99. Further the Series E Preferred Stock is an equity host instrument since it has more features that align with an equity instrument than a debt instrument pursuant to ASC 815-15-25-17A – Derivatives and Hedging, which states in part that “the nature of the host contract depends on the economic characteristics and risks of the entire hybrid financial instrument.” All of the contractual and implied terms of the preferred share, such as the existence of a redemption feature or conversion option, should be considered when determining the nature of the host instrument as debt or equity. The Series E Preferred Stock embedded conversion feature (call option) is considered clearly and closely related to the equity host. Accordingly, further analysis under ASC 815-40-15 is not necessary and the embedded conversion feature should not be bifurcated from the host instrument. The Series E Preferred Stock redemption feature (put option) does not meet all the criteria under ASC 815-10-15-83, therefore it does not qualify as a derivative. To determine whether the Series E Preferred Stock contains a BCF, we compared the effective conversion price and the Company’s stock price on the commitment date. The effective conversion price was calculated by dividing the proceeds from Series E Preferred Stock by the number of common shares issuable upon conversion of the Series E Preferred Stock. The BCF is measured as the difference between the commitment date stock price and the effective conversion price multiplied by the number of common stock issuable upon conversion of Series E. The BCF is limited to the total cash proceeds received if the amount of the BCF exceeds the cash proceeds received. In connection with the issuance of Series E Preferred Stock, during the year ended September 30, 2020, the Company recognized a beneficial conversion feature in the amount of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20191001__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z9NTasyrGNv8" title="Beneficial conversion feature amount">2,000,000 which was accounted for as a deemed dividend. During the year ended September 30, 2021, the issuance of Series F Preferred Stock triggered the price protection clause in the Series E Preferred Stock. Thus, the conversion price of the Series E Preferred Stock was reduced from $<span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20210930__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zitJINmM2m82" title="Conversion price">0.00375 to $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20210930__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zuEP2cGiuzkc" title="Conversion price">0.00313 on that date. On November 29, 2022, the Company entered into Securities Exchange Agreements with related party preferred stockholders, whereby related party holders of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zVA92gFM6Zah" title="Number of shares convertible securities">1,000 shares of Series E preferred stock with a stated value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20221129__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zUbaa03gxX38" title="Stock issued during period, value, conversion of convertible securities">2,000,000 and accrued dividends payable of $<span id="xdx_90D_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zx25CFCr7WT3" title="Dividends payable">66,630 were exchanged for the New Related Party Debentures. (See Note 6). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) During the three months ended December 31, 2022 and 2021, the Company incurred $<span id="xdx_90D_eus-gaap--DividendsPreferredStockStock_pp0p0_c20221001__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_znlLAFEQyNMk" title="Sereis E preferred stock dividend">26,301 and $<span id="xdx_908_eus-gaap--DividendsPreferredStockStock_pp0p0_c20211001__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zxloVraH8f1a" title="Sereis E preferred stock dividend">40,329 of Series E dividends. As of December 31, 2022 and September 30, 2022, dividend payable balances were $0 and $40,329, respectively, reflected in the accompanying unaudited balance sheets as accrued liabilities instead of temporary equity. As of December 31, 2022 and September 30, 2022, the Company had <span id="xdx_90E_eus-gaap--TemporaryEquitySharesIssued_iI_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zW5t4BgpdEg3" title="Temporary equity, shares issued::XDX::-"><span id="xdx_90B_eus-gaap--TemporaryEquitySharesOutstanding_iI_doxL_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zphosl2NChGa" title="Temporary equity, shares outstanding::XDX::-">0 and 1,000 shares of Series E Preferred Stock issued and outstanding classified as temporary equity in the accompanying unaudited balance sheets, respectively. Series F Preferred Stock On July 30, 2021, the Company filed a Certificate of Designation, Preferences and Rights of Series F Preferred Stock (the “Series F Certificate of Designation”), with the Nevada Secretary of State to designate 1,000 shares of its previously authorized preferred stock as Series F Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series F Certificate of Designation and its filing were approved by the Company’s Board of Directors without stockholder approval as provided for in the Company’s Articles of Incorporation and under Nevada law. The holders of shares of Series F Preferred Stock have the following preferences and rights: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">From the Initial Issuance Date, cumulative dividends on each share of Series F shall accrue, on a monthly basis in arrears (with any partial month being made on a pro-rata basis), at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210730__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z4Mtk2UouPf8" title="Debt interest rate">8% per annum on the stated value, plus any additional amount thereon. Dividends shall be paid within 15 days after the end of each month (“Dividend Payment Date”), at the option of the Holder in cash or through the issuance of shares of common stock. In the event that the Holder elects to receive its dividends in shares of common stock the number of shares of common stock to be issued to each applicable Holder shall be determined by dividing the total dividend payable to such Holder by the average closing price of the common stock during the five trading days on the principal market prior to the dividend payment date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holders of shares of Series F Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90F_eus-gaap--PreferredStockConversionBasis_c20210730__20210730__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zo1xKz6xfj7l" title="Preferred stock, conversion basis">Each share of Series F Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the conversion price which is the lesser of: (i) $0.00313 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series F Certificate of Designation including a price protection provision for offerings below the conversion price, provided, however, the conversion price shall never be less than $0.0016. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus additional amount by the conversion price.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with, (i) a Change of Control of the Company or (ii) on the closing of, a Qualified Public Offering by the Company, all of the outstanding shares of Series F Preferred Stock (including any fraction of a share) shall automatically convert along with the additional amount into an aggregate number of shares of common stock (including any fraction of a share) as is determined by dividing the number of shares of Series F Preferred Stock (including any fraction of a share) by the automatic conversion price then in effect. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series F Preferred Stock shall be deemed to have been converted into shares of common stock immediately prior to the closing of such transaction or Qualified Public Offering.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series F Certificate of Designation), at a price, an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series F Preferred Stock conversion price shall be reduced to the sale price, or the exercise price or conversion price of the securities sold.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Series F Preferred Stock shall rank pari passu with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company with the Series C-1 Preferred Stock of the Company, the Series C-2 Preferred Stock of the Company, and the Series E Preferred Stock of the Corporation (the “Parity Stock”), and all other shares of capital stock of the Company shall be junior in rank to all Series F shares with respect to the preferences as to dividends (except for the common stock, which shall be pari passu as provided in the Series F Certificate of Designation), distributions and payments upon the liquidation, dissolution and winding up of the Company (such junior stock is referred to herein collectively as “Junior Stock”). The rights of all such Junior Stock shall be subject to the rights, powers, preferences and privileges of the Series F Preferred Stock. Without limiting any other provision of the Series F Certificate of Designation, without the prior express consent of the Required Holder, the Company shall not hereafter authorize or issue any additional or other shares of capital stock that is (i) of senior rank to the Series F Preferred Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company (collectively, the “Senior Preferred Stock”), or (ii) Parity Stock. Except as provided for in the Certificate of Designation, in the event of the merger or consolidation of the Company into another corporation, the Series F Preferred Stock shall maintain their relative rights, powers, designations, privileges and preferences provided for in the Certificate of Designation for a period of at least two years following such merger or consolidation and no such merger or consolidation shall cause result inconsistent therewith.</td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On July 30, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with an affiliated investor, who is a beneficial shareholder, to purchase an aggregate amount of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z0SmKS3dfq95" title="Sale of stock shares issued in transaction">500 shares of Series F Convertible Preferred Stock (the “Series F Preferred”) with accompanying warrant for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjsWdZLqOppg" title="Number of shares convertible securities">63,897,764 of common stock (the “Warrant”), for total proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPGHtxEl8pw1">1,000,000 (see Note 9). The Series F Preferred Stock has a stated value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zKf9JnOvkVM4" title="Preferred stock, par value">2,000 per share and shall accrue monthly in arrears, dividends at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znhbQarcVNWj" title="Debt Insterest rate">8% per annum on the stated value. The dividends shall be paid monthly at the option of the holder of the Series F Preferred in either cash or shares of common stock of the Company. <span id="xdx_904_eus-gaap--PreferredStockConversionBasis_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmsztvQV4z7l" title="Preferred stock conversion description">The number of shares of common stock issuable upon conversion of the Series F Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00313 and (ii) 75% of the average closing price of the Company’s common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0016. In addition, the investor was issued a Warrant to purchase an amount of common stock equal to 20% of the shares of common stock issuable upon conversion of the Series F Preferred at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until July 30, 2026. The Warrants are exercisable for cash at any time. The 63,897,764 Warrant was valued using the relative fair value method at $957,192 and the Series F Preferred stock had a grant date fair value $42,808 which was recorded as a BCF. In accordance with ASC 470 – Debt, the proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhjEoMcephg9">1,000,000 was allocated based on the relative fair values of the Series F preferred stock and the Warrant of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_ztbfiDxGMR5e">42,808 and $<span id="xdx_907_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFUsTvojhC9">957,192, respectively. Although ASC 470 is for debt instruments issued with warrants, preferred shares issued with warrants should be accounted for in a similar manner. Pursuant to the Series F Certificate of Designation, Series F Preferred Stock is redeemable at the option of the holder in the event that the Company is prohibited from issuing shares of common stock to a holder upon any conversion due to insufficient shares of common stock available (“Authorized Failure Shares”) and therefore meets the criteria of a contingently redeemable instrument in accordance with ASC 480-10-25-7 – Distinguishing Liabilities from Equity. The Series F Preferred Stock is contingently redeemable upon the occurrence of an event that is outside of the issuer’s control and should be classified as temporary equity pursuant to ASC 480-10-S99. Further the Series F Preferred Stock is an equity host instrument since it has more features that align with an equity instrument than a debt instrument pursuant to ASC 815-15-25-17A – Derivatives and Hedging, which states in part that “the nature of the host contract depends on the economic characteristics and risks of the entire hybrid financial instrument.” All of the contractual and implied terms of the preferred share, such as the existence of a redemption feature or conversion option, should be considered when determining the nature of the host instrument as debt or equity. The Series F Preferred Stock embedded conversion feature (call option) is considered clearly and closely related to the equity host. Accordingly, further analysis under ASC 815-40-15 is not necessary and the embedded conversion feature should not be bifurcated from the host instrument. The Series F Preferred Stock redemption feature (put option) does not meet all the criteria under ASC 815-10-15-83, therefore it does not qualify as a derivative. To determine whether the Series F Preferred Stock contains a BCF, we compared the effective conversion price and the Company’s stock price on the commitment date. The effective conversion price was calculated by dividing the proceeds from Series F Preferred Stock by the number of common shares issuable upon conversion of the Series F Preferred Stock. The BCF is measured as the difference between the commitment date stock price and the effective conversion price multiplied by the number of common stock issuable upon conversion of Series F. The BCF is limited to the total cash proceeds received if the amount of the BCF exceeds the cash proceeds received. In connection with the issuance of Series F Preferred Stock, during the year ended September 30, 2021, the Company recognized a BCF in the amount of $<span id="xdx_90F_ecustom--BeneficialConversionFeatureAmount_pp0p0_c20201001__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zkYtn3mDqYw2" title="Beneficial conversion feature amount">42,808 which was accounted for as a deemed dividend. The relative fair value of the warrant of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLkQYstKIpE1" title="Fair value of warrants">957,192 was recorded as a discount associated with the Series F preferred stock and was fully amortized immediately because the Series F preferred stock was convertible on the date of issuance. The Company recorded the $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210730__20210730__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ziqhMels5ZA3" title="Beneficial conversion feature amount">957,192 as deemed dividend. On November 29, 2022, the Company entered into Securities Exchange Agreements with related party preferred stockholders, whereby related party holders of 500 shares of Series F preferred stock with a stated value of $1,000,000 and accrued dividends payable of $33,315 were exchanged for the New Related Party Debentures (See Note 6). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) During the three months ended December 31, 2022 and September 30, 2022, the Company also recorded dividends related to the Series F Preferred Stock in the amount of $13,151 and $20,164. As of December 31, 2022 and September 30, 2022, dividend payable balances were $0 and $20,164, respectively, reflected in the accompanying unaudited balance sheets as accrued liabilities instead of temporary equity. As of December 31, 2022 and September 30, 2022, the Company had <span id="xdx_902_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvRg7eIBkcIa" title="Temporary equity, shares issued"><span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6QGmDLtiE52" title="Temporary equity, shares outstanding">0 and <span id="xdx_906_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zsxdpk4QFm9e" title="Temporary equity, shares issued"><span id="xdx_903_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYMlwz0PPbHf" title="Temporary equity, shares outstanding">500 shares of Series F Preferred Stock issued and outstanding classified as temporary equity in the accompanying unaudited balance sheets, respectively. Stock Options On April 28, 2020, the Board approved the 2020 Equity Incentive Plan (“2020 Plan”), as amended on May 29, 2020. On April 18, 2022, the Board terminated the 2020 Plan and any shares reserved thereunder are no longer subject to reservation and the Company had no options issued and outstanding under the 2020 Plan. On April 18, 2022, the Company’s Board and the shareholders approved the 2022 Equity Incentive Plan (“2022 Plan”) at which time the plan became effective. Upon the effective date of the 2022 Plan, <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220418__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwWYMxsmugec" title="Common stock capital shares reserved for future issuance">1,915,000,000 shares of the Company’s common stock were reserved for issuance under the 2022 Plan (“Reserved Share Amount”), subject to the adjustments described in the 2022 Plan, and such Reserved Share Amount, when issued in accordance with the 2022 Plan, shall be validly issued, fully paid, and non-assessable. Pursuant to the 2022 Plan, the option price of each incentive stock option (except those that constitute substitute awards) shall be at least the fair market value of a share on the grant date; provided, however, that in the event that a grantee is a ten percent stockholder as of the grant date, the option price of an incentive stock option shall be not less than <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220417__20220418__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbjXHQCdNHU4" title="Fair market value, percentage">110% of the fair market value of a share on the grant date, in no case shall the option price of any option be less than the par value of a share. On May 26, 2022, the Company’s Board of Directors (“Board”) approved the future granting of stock options under the 2022 Equity Incentive Plan, to various employees and consultants. On August 16, 2022, the Company granted stock options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220816__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyTwentyTwoPlanMember_zLXREcYA0QHh" title="Maximum number of shares issuance during the period">1,901,410,519 common shares of the Company to various employees and consultants with an exercise price of $0.0036 per share. The options expire on August 15, 2032 and vest over varying vesting terms through August 2026. The fair value of these option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of 0%; expected volatility of 365.1%; risk-free interest rate of 2.82%; and an estimated holding period of 10 years. The Company valued these stock option at a fair value of $7,985,924 and will record stock-based compensation expense over the vesting periods. During the three months ended December 31, 2022, in connection with the accretion of stock-based option expense over the vesting period, the Company recorded stock option expense of $612,173. As of December 31, 2022, there were 1,901,410,519 options outstanding and 1,380,407,725 options vested, subject to the filing of a registration on Form S-8 for the registration of the shares underlying such options. As of December 31, 2022, there was $1,358,129 of unvested stock-based compensation expense to be recognized through August 2026. The aggregate intrinsic value on December 31, 2022 was $0 and was calculated based on the difference between the quoted share price on December 31, 2022 of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zImUmvfiY5ri" title="Exercise price">0.0034 and the exercise price of the underlying options. Stock option activities for the three months ended December 31, 2022 are summarized as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of Options</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify">Balance Outstanding September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20221001__20221231_zh1jE65Ja9Nf" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Options, Beginning Outstanding">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231_zGusdtBXtH04" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted-average Exercise Price, Beginning Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zLwadr06KF0i" title="Weighted-average Remaining Contractual Term">9.88</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231_zkvX2z27KJAe" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Beginning">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Granted</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231_zPA5BjnsmXn3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231_zwxpGYgCGSE" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance Outstanding December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20221001__20221231_z4Ug4xh40mkb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Ending Outstanding">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231_z3qKj0Z2AC41" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Ending Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_zIk5v43Zzdo2" title="Weighted-average Remaining Contractual Term">9.63</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231_znuGFwilFIf8" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Ending">0</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Exercisable, December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20221001__20221231_fKGEp_zcAT4hHU7hq3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Exercisable">1,380,407,725</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">(a)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20221001__20221231_zNbnNfGU6ORh" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Exercisable">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20221231_z3sqkif0Hqu" title="Weighted-average Remaining Contractual Term, Exercisable">9.63</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20221001__20221231_z3n6aah22Gal" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Exercisable">0</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance Non-vested on September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20221001__20221231_zcdsoJEUm5Na" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, non vested and expected to vest, beginning balance">547,666,344</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20221001__20221231_z1X2Q2SUNBMj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Beginning Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zqtPtCp3CGy7" title="Weighted-average Remaining Contractual Term">9.88</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231_zlVY0OlLLoT4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Beginning">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Granted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231_ziYva9SUMb13" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231_zCXuZHGa7C7d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Vested during the period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20221001__20221231_zSvyYLISaOWf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Vested during the period">(26,663,550</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20221001__20221231_zXVULpNGJw9d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Vested during the period">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance Non-vested on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20221001__20221231_zgdw7oYrE43l" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, non vested and expected to vest, ending balance">521,002,794</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20221001__20221231_zCjxOvPBP9ik" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Ending Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20221231_zGn5yDOInZ13" title="Weighted-average Remaining Contractual Term">9.63</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231_z7G8INoiAJc5" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Ending">0</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These vested options are only exercisable upon the company filing an S-8 to register the underlying shares.</td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Warrants Legacy Warrants On May 12, 2021, in connection with the issuance of a convertible note, the Company issued a Warrant to purchase up to 63,897,764 shares of common stock at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until May 12, 2026 (see Note 6). The Warrants are exercisable for cash at any time. The Warrant was valued at $984,200 using the relative fair value method was recorded as debt discount which was being amortized over the life of the convertible note. On July 30, 2021, the Company, in connection with the issuance of 500 shares of Series F preferred stock, issued a Warrant to purchase up to 63,897,764 shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210730__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zGSWRO5ocI3l" title="Warrant exercise price">0.00313 per share (subject to adjustment as provided therein) until July 30, 2026. The Warrants are exercisable for cash at any time. The Warrant was valued at $957,192 using the relative fair value method and was recorded as deemed dividend. On November 1, 2021, the Company issued the First November 2021 Warrants to purchase an aggregate of 54,644,811 shares of common stock. The First November 2021 Warrants are exercisable at any time at a price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211101__us-gaap--AwardTypeAxis__custom--FirstNovemberTwoThousandTwentyOneMember_zmx0E7V2oCv5" title="Warrants exercisable">0.00366 per share (subject to adjustment) until November 1, 2026. The First November 2021 Warrants were valued at $990,048 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the First November 2021 Notes (see Note 6 and Note 8). On November 1, 2021, the Company issued the Second November 2021 Warrants to purchase an aggregate of 27,322,406 shares of common stock. The Second November 2021 Warrants are exercisable at any time at a price equal to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211101__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandTwentyOneMember_zMwMwCtswBoi" title="Warrants exercisable">0.00366 per share (subject to adjustment) until November 1, 2026. The Second November 2021 Warrants were valued at $495,560 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the Second November 2021 Notes (see Note 6). On November 1, 2021, the Company issued the Third November 2021 Warrants to purchase an aggregate of 27,322,406 shares of common stock. The Third November 2021 Warrants are exercisable at any time at a price equal to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211101__us-gaap--AwardTypeAxis__custom--ThirdNovemberTwoThousandTwentyOneMember_zYgWou0aShXh" title="Warrants exercisable">0.00366 per share (subject to adjustment) until November 1, 2026. The Third November 2021 Warrants were valued at $495,560 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the Third November 2021 Notes (see Note 6). On January 26, 2022, the Company, upon the approval of the First November 2021 Investor, amended the First November 2021 SPA whereby the Company issued additional cashless-exercisable warrants to purchase 218,579,234 shares of common stock. As a result, the total relative fair value of all warrants in total increased by $34,630, recorded as debt discount, which was being amortized over the life of the First November 2021 Notes (see Note 6). These warrants were exercisable at a price equal to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220126__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandTwentyOneMember_zgQyw8vL18t4" title="Warrants exercisable per share">0.00366 per share (subject to adjustment) until November 1, 2026. On January 26, 2022, the Company, upon the approval of the Second November 2021 Investor, amended the Second November 2021 SPA whereby the Company issued additional cashless-exercisable warrants to purchase 109,289,616 shares of common stock. As a result, the total relative fair value of all warrants in total increased by $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20220126__20220126__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandTwentyOneMember_zSoMA4LiQ4sc" title="Fair value adjustment of warrants">22,429, recorded as debt discount, which was being amortized over the life of the Second November 2021 Notes (see Note 6). These warrants were exercisable at a price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220126__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandTwentyOneMember_zLldcAogblp2" title="Warrants exercisable per share">0.00366 per share (subject to adjustment) until November 1, 2026. On January 26, 2022, the Company, upon the approval of the Third November 2021 Investor, amended the Third November 2021 SPA whereby the Company issued additional cashless-exercisable warrants to purchase 109,289,616 shares of common stock. As a result, the total relative fair value of all warrants in total increased by $22,429, recorded as debt discount, which was being amortized over the life of the Third November 2021 Notes (see Note 6). These warrants were exercisable at a price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220126__us-gaap--AwardTypeAxis__custom--ThirdNovemberTwoThousandTwentyOneMember_zNt8clZeQ4l1" title="Warrants exercisable per share">0.00366 per share (subject to adjustment) until November 1, 2026. On January 27, 2022, the Company issued the First January 2022 Warrants to purchase an aggregate of 136,612,022 shares of common stock. The First January 2022 Warrants are exercisable at any time at a price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220127__us-gaap--AwardTypeAxis__custom--FirstJanuaryTwoThousandTwentyTwoMember_zzP5CDKJaKgg" title="Warrants exercisable">0.00366 per share (subject to adjustment) until November 1, 2026. The First January 2022 Warrants were valued at $472,403 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the First January 2022 Note (see Note 6). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On January 31, 2022, the Company issued the Second January 2022 Warrants to purchase an aggregate of 136,612,022 shares of common stock. The Second January 2022 Warrants are exercisable at any time at a price equal to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__us-gaap--AwardTypeAxis__custom--SecondJanuaryTwoThousandTwentyTwoMember_zTHdNXe2bx21" title="Warrants exercisable">0.00366 per share (subject to adjustment) until November 1, 2026. The Second January 2022 Warrants were valued at $469,810 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the Second January 2022 Note (see Note 6). On January 31, 2022, the Company issued to two consultants an aggregate of <span id="xdx_903_eus-gaap--SharesIssued_iI_c20220131__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcUUtlrpnpqd" title="Shares issued">16,393,443 warrants as a placement fee in connection with the First January 2022 Note and Second January 2022 Note (collectively as “January 2022 Notes”) (see Note 6). These warrants are exercisable at a price equal to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220131__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zodzFkcMB4C3" title="Warrants exercisable">0.00366 per share until November 1, 2024. These warrants were valued at $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20220131__20220131__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhxhgIPRWVk7" title="Fair value adjutment of warrants">54,595 using the relative fair value method and were recorded as a debt discount which was being amortized over the life of the January 2022 Note. On April 5, 2022, the Company issued the First April 2022 Warrants to purchase 4,201,681 shares of common stock. The First April 2022 Warrants are exercisable at any time at a price equal to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220405__us-gaap--AwardTypeAxis__custom--FirstAprilTwoThousandTwentyTwoMember_zdMGl5Ml8FS1" title="Warrants exercisable">0.00476 per share (subject to adjustment) until April 1, 2027. The First April 2022 Warrants were valued at $89,815 using the relative fair value method and was recorded as debt discount which was being amortized over the life of the First April 2022 Note (see Note 6 and Note 8). During April 2022, the Company issued the Second April 2022 Warrants to purchase an aggregate of 17,857,144 shares of common stock. The Second April 2022 Warrants are exercisable at any time at price equal to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220430__us-gaap--AwardTypeAxis__custom--SecondAprilTwoThousandTwentyTwoMember_zeNIycxXwuBk" title="Warrants exercisable">0.00476 per share (subject to adjustment) until April 1, 2027. The Second April 2022 Warrants were valued at $335,593 using the relative fair value method and were recorded as debt discount which was being amortized over the life of the Second April 2022 Notes (see Note 6). On May 9, 2022, the Company issued the May 2022 Warrants to purchase an aggregate of 42,016,808 shares of common stock. The May 2022 Warrants are exercisable at any time at a price equal to $0.00476 per share (subject to adjustment) until April 1, 2027. The May 2022 Warrants were valued at $178,449 using the relative fair value method and were recorded as debt discount which was being amortized over the life of the May 2022 Notes (see Note 6 and Note 8). On June 15, 2022, the Company issued the June 2022 Warrants to purchase 2,100,840 shares of common stock. The June 2022 Warrants are exercisable at any time at a price equal to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220615__us-gaap--AwardTypeAxis__custom--JuneTwoThousandTwentyTwoMember_zfahGSBJjCrg" title="Warrants exercisable per share">0.00476 per share (subject to adjustment) until April 1, 2027. The June 2022 Warrants were valued at $5,924 using the relative fair value method and were recorded as debt discount which is being amortized over the life of the June 2022 Note (see Note 6 and Note 8). On July 1, 2022, the Company issued the July 2022 Warrants to purchase an aggregate of 2,100,840 shares of common stock. The July 2022 Warrants are exercisable at any time at a price equal to $0.00476 per share (subject to adjustment) until April 1, 2027. The July 2022 Warrants were valued at $8,190 using the relative fair value method and were recorded as debt discount which was being amortized over the life of the July 2022 Notes (see Note 6). On November 29, 2022, in connection with the Share Exchange Agreements and New Convertible Debt discussed below, the May 2021 Warrants, First November 2021 Warrants, First April 2022 Warrants, May 2022 Warrants, and June 2022 Warrants, aggregating <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221129__us-gaap--AwardTypeAxis__custom--FirstNovemberTwoThousandAndTwentyOneMember_zPX8fX6fIOsl" title="Number of warrants or rights outstanding">385,441,138 warrants, were amended to reduce the exercise price to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221129__us-gaap--AwardTypeAxis__custom--FirstNovemberTwoThousandAndTwentyOneMember_zxYTiTFGaroe" title="Number of warrants exercise price per share">0.003 per share. Additionally, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zbJvx7U6ypI7" title="Number of securities called by warrant">63,897,764 warrants issued in connection with Series F preferred stock were amended to reduce the exercise price to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zM9c5l2NO0Og" title="Number of warrants exercise price per share">0.003 per share. All other terms of the warrants remained the same. As a result of the November 29, 2022 amendment to the exercise price, the Company calculated the difference between the warrants fair values on November 29, 2022, the date of the amendment, using the then current exercise price ranging from $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221129__20221129__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--CurrentExercisePriceMember_zbccoJUIfj26" title="Share-based payment arrangement, option, exercise price range, lower range limit">0.00366 to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221129__20221129__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--CurrentExercisePriceMember_z8vxdKrQ6rx7" title="Share-based payment arrangement, option, exercise price range, upper range limit">0.00476 and the new exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221129__20221129__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--NewExercisePriceMember_zsAyDcPAVaI" title="Share-based payment arrangement, option, exercise price range, upper range limit">0.003 and determined that the difference was insignificant. (See Note 6). On November 29, 2022, in connection with the Share Exchange Agreements and New Convertible Debentures discussed in Note 6, the Second November 2021 Warrants, Third November 2021 Warrants, January 2022 Warrants, Second January 2022 Warrants, Second April 2022 Warrants, and the July 2022 Warrants, aggregating <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221129__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandAndTwentyOneMember_zBTorT4nhQAk" title="Number of warrants or rights outstanding">566,406,072 warrants, were amended to reduce the exercise price to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221129__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandAndTwentyOneMember_z3UIIlM8X6c4" title="Number of warrants exercise price per share">0.003 per share. Additionally, 16,393,443 warrants issued to a placement agent in January 2022 were amended to reduce the exercise price to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221129__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zNuKunwela9a" title="Number of warrants exercise price per share">0.003 per share. In conjunction with the price reduction, the price protection feature for all these warrants was eliminated. All other terms of the warrants remained the same. As a result of the November 29, 2022 amendment to the exercise price, the Company calculated the difference between the warrants fair values on November 29, 2022, the date of the amendment, using the then current exercise price ranging from $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221129__20221129__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandAndTwentyOneMember_zScRtdlejX1c" title="Share-based payment arrangement, option, exercise price range, lower range limit">0.00366 to $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221129__20221129__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandAndTwentyOneMember_zr4DZfu2YX7" title="Share-based payment arrangement, option, exercise price range,upper range limit">0.00476 and the new exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221129__20221129__us-gaap--AwardTypeAxis__custom--SecondNovemberTwoThousandAndTwentyOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--NewExercisePriceMember_zkqxOxspXDDe" title="Share-based payment arrangement, option, exercise price range,upper range limit">0.003 and determined that the difference was insignificant. (See Note 6). THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) New Warrants In connection with the Securities Exchange Agreements with related parties for the exchange of the convertible notes and preferred shares for the New Related Party Debentures, as discussed in Note 6, the Company issued an aggregate of <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsIssuedInConnectionWithIssuedInConnectionWithANewRelatedPartyDebentures_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCfUndSt8Ne8" title="Share based compensation, New related party debentures">2,564,340,702 warrants. The Warrants are exercisable for five years and six months from the earlier of the maturity date of the New Related Party Debentures and the closing of the Qualified Financing, at an exercise price equal to (i) <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9npXd9udwPf" title="Warrant or right, reason for issuance, description">in the event that a Qualified Offering is consummated prior to the exercise of the Warrant, the Qualified Offering Price, or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration statement covering the resale of the shares underlying the Warrants within 180 days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum of 25%. The Warrants contain certain price protection provisions providing for adjustment of the amount of securities issuable upon exercise of the Warrants in case of certain future dilutive events or stock-splits and dividends. In connection with the Securities Exchange Agreements with investors for the exchange of the convertible notes and preferred shares for the New Debentures, as discussed in Note 6, the Company issued an aggregate of <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsIssuedInConnectionWithIssuedInConnectionWithANewRelatedPartyDebentures_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zVgtgzpTFU71" title="Share based compensation, New related party debentures">2,269,030,092 warrants to investors. The Warrants are exercisable for five years and six months from the earlier of the maturity date of the New Debentures and the closing of the Qualified Financing, at an exercise price equal to (i) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20221001__20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zpqLXHNckq2e" title="Warrant or right, reason for issuance, description">in the event that a Qualified Offering is consummated prior to the exercise of the Warrant, the Qualified Offering Price, or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration statement covering the resale of the shares underlying the Warrants within 180 days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum of 25%. The Warrants contain certain price protection provisions providing for adjustment of the amount of securities issuable upon exercise of the Warrants in case of certain future dilutive events or stock-splits and dividends. In connection with the Initial Closing of the private placement, the Company and Gunnar, entered into the Placement Agency Agreement, pursuant to which Gunnar agreed to act as the Placement Agent. Pursuant to the terms of the Placement Agency Agreement, Gunner received <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember_zXjOXWHdCWrl" title="Number of warrants">124,489,795 warrants. Additionally, the Company issued <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z4JvvBMoYyok" title="Number of warrants">16,000,000 warrants to a consultant in connection with the private placement offering. Warrants activities for the three months ended December 31, 2022 is summarized as follows: SCHEDULE OF WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Average</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Contractual</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Aggregate</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Exercise</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Term</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Intrinsic</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Years)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify">Balance Outstanding on September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23ct0V5PgYk" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Warrants, Outstanding Beginning balance">1,888,813,005</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcqpMQ2r8ia" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning balance">0.003</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB88icWQpUD8" title="Weighted Average Remaining Contractual Term (Years), Beginning Balance Outstanding">3.26</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValueBalance_iS_pdp0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zse6gsy1lPQb" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance Outstanding">1,140,362</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Issued in connection with a New Related Party Debentures (see Note 6)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsIssuedInConnectionWithIssuedInConnectionWithANewRelatedPartyDebentures_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh1HVXk5U504" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Issued in connection with a New Related Party Debentures (see Note 6)">2,564,340,702</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInConnectionWithANewRelatedPartyDebenturesWeightedAverageGranted_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8gbul4ZBKs" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued in connection with a New Related Party Debentures (see Note 6)">0.003</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Issued in connection with a New Debentures (see Note 6)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsIssuedInConnectionWithIssuedInConnectionWithANewDebentures_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXns1PGNp2r7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Issued in connection with a New Debentures (see Note 6)">2,269,030,092</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInConnectionWithANewDebenturesWeightedAverageGranted_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoTXYjLg7TCk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued in connection with a New Debentures (see Note 6)">0.003</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Issued to placement agent and consultant in connection with New Related Party and New Debentures (see Note 6)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedToPlacementAgentAndConsultantInConnectionWithNewRelatedPartyAndNewDebentures_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcXOghC2LqZ3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Issued to placement agent and consultant in connection with New Related Party and New Debentures (see Note 6)">140,489,795</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedToPlacementAgentAndConsultantInConnectionWithNewRelatedPartyAndNewDebenturesWeightedAverageGranted_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvBUgST9DJr1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price,Issued to placement agent and consultant in connection with New Related Party and New Debentures (see Note 6)">0.003</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance Outstanding on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNVhqMxwhOvl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding Ending balance">6,862,673,594</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zApu4dOWrcwj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending balance">0.0025</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPegUvwrnee9" title="Weighted Average Remaining Contractual Term (Years), Ending Balance Outstanding">5.48</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValueBalance_iE_pdp0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwIRSjWRr3Ki" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending Balance Outstanding">8,731,840</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Exercisable on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmNY2xgIgH68" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable">6,662,673,594</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZrh5PulMVHc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.0025</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYsidbHnTph" title="Weighted Average Remaining Contractual Term (Years), Exercisable">5.56</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pdp0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zstozCiUhRHk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable">8,551,840</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED)

6666667

0.0001

12000000000

0.0001

12000000000

100000000000

0.0001

1333

26667

Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.

667

3000

0.0001

4128.42

0.00275

0.0275

0.80

0.0499

0.0275

1923

288637529

902

372303

141

1043

6000

0.0001

410.27

0.00275

0.80

0.0499

1880

280475491

3037

1245935

3037

2000

0.0001

2000

0.08

Each share of Series E Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the conversion price which is the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation including a price protection provision for offerings below the conversion price, provided, however, the conversion price shall never be less than $0.0021. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number by the conversion price.

In connection with, (i) a Change of Control of the Company or (ii) on the closing of, a Qualified Public Offering by the Company, all of the outstanding shares of Series E (including any fraction of a share) shall automatically convert into an aggregate number of shares of common stock (including any fraction of a share) by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number (including any fraction of a share) by the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation including a price protection provision for offerings below the conversion price. However, the conversion price shall never be less than $0.0021. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series E shall be deemed to have been converted into shares of Common Stock immediately prior to the closing of such transaction or Qualified Public Offering.

1000

2000000

0.00375

0.00313

1000

2000000

66630

26301

40329

1000

0.0001

2000

0.08

Each share of Series F Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the conversion price which is the lesser of: (i) $0.00313 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series F Certificate of Designation including a price protection provision for offerings below the conversion price, provided, however, the conversion price shall never be less than $0.0016. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus additional amount by the conversion price.

In connection with, (i) a Change of Control of the Company or (ii) on the closing of, a Qualified Public Offering by the Company, all of the outstanding shares of Series F Preferred Stock (including any fraction of a share) shall automatically convert along with the additional amount into an aggregate number of shares of common stock (including any fraction of a share) as is determined by dividing the number of shares of Series F Preferred Stock (including any fraction of a share) by the automatic conversion price then in effect. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series F Preferred Stock shall be deemed to have been converted into shares of common stock immediately prior to the closing of such transaction or Qualified Public Offering.

500

63897764

1000000

2000

0.08

The number of shares of common stock issuable upon conversion of the Series F Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00313 and (ii) 75% of the average closing price of the Company’s common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0016. In addition, the investor was issued a Warrant to purchase an amount of common stock equal to 20% of the shares of common stock issuable upon conversion of the Series F Preferred at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until July 30, 2026. The Warrants are exercisable for cash at any time. The 63,897,764 Warrant was valued using the relative fair value method at $957,192 and the Series F Preferred stock had a grant date fair value $42,808 which was recorded as a BCF.

1000000

42808

957192

42808

957192

500

1000000

33315

13151

20164

500

1915000000

1.10

1901410519

0.0036

3.651

0.0282

7985924

612173

1901410519

1380407725

1358129

0.0034

Stock option activities for the three months ended December 31, 2022 are summarized as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of Options</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (Years)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify">Balance Outstanding September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20221001__20221231_zh1jE65Ja9Nf" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Options, Beginning Outstanding">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231_zGusdtBXtH04" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted-average Exercise Price, Beginning Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zLwadr06KF0i" title="Weighted-average Remaining Contractual Term">9.88</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231_zkvX2z27KJAe" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Beginning">-</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Granted</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231_zPA5BjnsmXn3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20221231_zwxpGYgCGSE" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance Outstanding December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20221001__20221231_z4Ug4xh40mkb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Ending Outstanding">1,901,410,519</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231_z3qKj0Z2AC41" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Ending Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20221231_zIk5v43Zzdo2" title="Weighted-average Remaining Contractual Term">9.63</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231_znuGFwilFIf8" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Ending">0</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Exercisable, December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20221001__20221231_fKGEp_zcAT4hHU7hq3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Exercisable">1,380,407,725</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">(a)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20221001__20221231_zNbnNfGU6ORh" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Exercisable">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20221231_z3sqkif0Hqu" title="Weighted-average Remaining Contractual Term, Exercisable">9.63</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20221001__20221231_z3n6aah22Gal" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Exercisable">0</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance Non-vested on September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20221001__20221231_zcdsoJEUm5Na" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, non vested and expected to vest, beginning balance">547,666,344</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20221001__20221231_z1X2Q2SUNBMj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Beginning Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211001__20220930_zqtPtCp3CGy7" title="Weighted-average Remaining Contractual Term">9.88</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20221231_zlVY0OlLLoT4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Beginning">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Granted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20221231_ziYva9SUMb13" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20221231_zCXuZHGa7C7d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Granted">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Vested during the period</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20221001__20221231_zSvyYLISaOWf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Vested during the period">(26,663,550</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20221001__20221231_zXVULpNGJw9d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Vested during the period">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Balance Non-vested on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20221001__20221231_zgdw7oYrE43l" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, non vested and expected to vest, ending balance">521,002,794</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20221001__20221231_zCjxOvPBP9ik" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted-average Exercise Price, Ending Outstanding">0.0036</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20221231_zGn5yDOInZ13" title="Weighted-average Remaining Contractual Term">9.63</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20221231_z7G8INoiAJc5" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Outstanding-Aggregate Intrinsic Value, Ending">0</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These vested options are only exercisable upon the company filing an S-8 to register the underlying shares.</td></tr> </table>

1901410519

0.0036

P9Y10M17D

1901410519

0.0036

P9Y7M17D

1380407725

0.0036

P9Y7M17D

547666344

0.0036

P9Y10M17D

26663550

0.0036

521002794

0.0036

P9Y7M17D

63897764

0.00313

984200

500

63897764

0.00313

957192

54644811

0.00366

990048

27322406

0.00366

495560

27322406

0.00366

495560

218579234

34630

0.00366

109289616

22429

0.00366

109289616

22429

0.00366

136612022

0.00366

472403

136612022

0.00366

469810

16393443

0.00366

54595

4201681

0.00476

89815

17857144

0.00476

335593

42016808

0.00476

178449

2100840

0.00476

5924

2100840

0.00476

8190

385441138

0.003

63897764

0.003

0.00366

0.00476

0.003

566406072

0.003

16393443

0.003

0.00366

0.00476

0.003

2564340702

in the event that a Qualified Offering is consummated prior to the exercise of the Warrant, the Qualified Offering Price, or (ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $0.003 per share and (B) an amount equal to 70% of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice.

2269030092

124489795

16000000

Warrants activities for the three months ended December 31, 2022 is summarized as follows: SCHEDULE OF WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Average</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Contractual</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Aggregate</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Number of</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Exercise</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Term</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Intrinsic</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Warrants</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Price</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">(Years)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Value</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: justify">Balance Outstanding on September 30, 2022</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z23ct0V5PgYk" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Warrants, Outstanding Beginning balance">1,888,813,005</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcqpMQ2r8ia" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning balance">0.003</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB88icWQpUD8" title="Weighted Average Remaining Contractual Term (Years), Beginning Balance Outstanding">3.26</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValueBalance_iS_pdp0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zse6gsy1lPQb" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning Balance Outstanding">1,140,362</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Issued in connection with a New Related Party Debentures (see Note 6)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsIssuedInConnectionWithIssuedInConnectionWithANewRelatedPartyDebentures_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh1HVXk5U504" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Issued in connection with a New Related Party Debentures (see Note 6)">2,564,340,702</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInConnectionWithANewRelatedPartyDebenturesWeightedAverageGranted_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8gbul4ZBKs" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued in connection with a New Related Party Debentures (see Note 6)">0.003</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify">Issued in connection with a New Debentures (see Note 6)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsIssuedInConnectionWithIssuedInConnectionWithANewDebentures_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXns1PGNp2r7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Issued in connection with a New Debentures (see Note 6)">2,269,030,092</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInConnectionWithANewDebenturesWeightedAverageGranted_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoTXYjLg7TCk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Issued in connection with a New Debentures (see Note 6)">0.003</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Issued to placement agent and consultant in connection with New Related Party and New Debentures (see Note 6)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedToPlacementAgentAndConsultantInConnectionWithNewRelatedPartyAndNewDebentures_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcXOghC2LqZ3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants Issued to placement agent and consultant in connection with New Related Party and New Debentures (see Note 6)">140,489,795</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedToPlacementAgentAndConsultantInConnectionWithNewRelatedPartyAndNewDebenturesWeightedAverageGranted_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvBUgST9DJr1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price,Issued to placement agent and consultant in connection with New Related Party and New Debentures (see Note 6)">0.003</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance Outstanding on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNVhqMxwhOvl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Outstanding Ending balance">6,862,673,594</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zApu4dOWrcwj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending balance">0.0025</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPegUvwrnee9" title="Weighted Average Remaining Contractual Term (Years), Ending Balance Outstanding">5.48</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValueBalance_iE_pdp0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwIRSjWRr3Ki" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending Balance Outstanding">8,731,840</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Exercisable on December 31, 2022</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmNY2xgIgH68" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercisable">6,662,673,594</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZrh5PulMVHc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.0025</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYsidbHnTph" title="Weighted Average Remaining Contractual Term (Years), Exercisable">5.56</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_pdp0_c20221001__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zstozCiUhRHk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable">8,551,840</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1888813005

0.003 P3Y3M3D 1140362 2564340702 0.003 2269030092 0.003 140489795 0.003

6862673594

0.0025 P5Y5M23D 8731840 6662673594 0.0025 P5Y6M21D 8551840

NOTE 10 – COMMITMENTS AND CONTINGENCIES Employment Agreements Michael Ruxin, M.D. On June 5, 2020, the Company and Dr. Michael Ruxin entered into an employment agreement (the “Ruxin Employment Agreement”) for Dr. Ruxin to serve as the Company’s Chief Executive Officer, President and a director. The Ruxin Employment Agreement provides that Dr. Ruxin will be employed for a five-year term commencing on June 5, 2020. The term will be automatically extended for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement provides at least sixty (60) days’ advance written notice to the other party that the employment period will not be extended. Dr. Ruxin will be entitled to receive an annual base salary of $<span id="xdx_90C_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20200603__20200605__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_z6P42ZcP53y7" title="Annual base salary">300,000 and will be eligible for an annual discretionary bonus of <span id="xdx_907_ecustom--AnnualDecretionaryBonusPercentage_iI_pid_dp_uPure_c20200605__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_z3v2pREBMBTc" title="Annual decretionary bonus percentage">150% of such base salary. In the Ruxin Employment Agreement, Dr. Ruxin is entitled to, subject to the approval of the Board or a committee thereof, and under the 2022 Plan (i) a one-time grant of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200603__20200605__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_zX4x8e4afTy7" title="Restricted stock, shares">49,047,059 Restricted Stock Units (“RSUs”) and (ii) a one-time grant of options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200603__20200605__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_zEOUdPJjJQji" title="Stock options granted">420,691,653 shares of common stock, In lieu of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200603__20200605__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_zVwIRBetokel" title="Restricted stock, shares">49,047,059 RSU’s, on August 16, 2022, the Company granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220816__20220816__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_z9GrwfBbzoTd" title="Restricted stock, shares">49,047,059 stock option plus the one-time grant of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220816__20220816__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_z7gqxyzGDpP9" title="Stock options granted">420,691,653 stock options for an aggregate amount of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220816__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_zJo5OxFVinSh" title="Stock options aggregate">469,738,712 stock options with an exercise price of $<span id="xdx_902_eus-gaap--StockOptionExercisePriceIncrease_c20220816__20220816__srt--TitleOfIndividualAxis__custom--DrMichaelRuxinMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--RuxinEmploymentAgreementMember_zsTJoFMcHYua" title="Stock options exercise price">0.0036 and an expiration date of August 15, 2032 and subject to vesting terms. Ruxin is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. For the period of May 2021 through November 2021 and from August 15, 2022 to September 30, 2022, Dr. Ruxin deferred 50% of his salary. As of December 31, 2022 and September 30, 2022, the Company had accrued payroll related to Dr. Ruxin’s salary deferment of $125,000 and $112,500, respectively. Dr. Ruxin is an “at-will” employee and his employment may be terminated by the Company at any time, with or without cause. In the event Dr. Ruxin’s employment is terminated by the Company without Cause (as defined in the Ruxin Employment Agreement), with Good Reason (as defined in the Ruxin Employment Agreement) or as a result of a non-renewal of the term of employment under the Ruxin Employment Agreement, Dr. Ruxin shall be entitled to receive the sum of (I) the Severance Multiple (as defined below), multiplied by his base salary immediately prior to such termination and (II) a pro-rata portion of his bonus for the year in which such termination occurs equal to (a) his bonus for the most recently completed calendar year (if any), multiplied by (b) a fraction, the numerator of which is the number of days that have elapsed from the beginning of such calendar year through the date of termination and the denominator of which is the total number of days in such calendar year. “Severance Multiple” shall mean 3.0; provided, however, that if the date of termination occurs on or at any time during the twelve (12)-month period following a Change in Control, the Severance Multiple shall mean 4.0. In addition, the Company shall accelerate the vesting of any outstanding, unvested equity awards granted to Dr. Ruxin prior to the date of termination. Dr. Ruxin shall be entitled to reimbursement of any COBRA payment made during the 18-month period following the date of termination. The Ruxin Employment Agreement also contains covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination, for a period of one year thereafter, (b) prohibiting the executive from disclosing confidential information regarding the Company, and (c) soliciting employees, customers and prospective customers during the term of the employment agreement and for a period of one year thereafter. Jeffrey Busch On June 5, 2020, the Company and Jeffrey Busch entered into an employment agreement (the “Busch Employment Agreement”) for Mr. Busch to serve as the Company’s Chairman of the Company and in such other positions as may be assigned from time to time by the board of directors. The Busch Employment Agreement provides that Mr. Busch will be employed for a five-year term commencing on June 5, 2020. The term will be automatically extended for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement provides at least sixty (60) days’ advance written notice to the other party that the employment period will not be extended. Mr. Busch will be entitled to receive an annual base salary of $<span id="xdx_901_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20200603__20200605__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zkpQgjaHcUPh" title="Annual base salary">60,000 and will be eligible for an annual discretionary bonus. In the Busch Employment Agreement, Mr. Busch is entitled to, subject to the approval of the Board or committee thereof, and under the 2020 Plan (i) a one-time grant of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200603__20200605__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zeYWT4xhBq2b" title="Restricted stock, shares">49,047,059 Restricted Stock (“RSUs”) and (ii) a one-time grant of options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200603__20200605__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zoaVdOlq0HM3" title="Stock options granted">420,691,653 shares of common stock. In lieu of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200603__20200605__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zGv2jU3vldtb" title="Restricted stock, shares">49,047,059 RSU’s, on August 16, 2022, the Company granted <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220816__20220816__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zUmj21C0DhQa" title="Restricted stock, shares">49,047,059 stock option plus the one-time grant of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220816__20220816__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zoiNnYtlj5fe" title="Stock options granted">420,691,653 stock options for an aggregate amount of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20200605__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_pdd" title="Stock options aggregate">469,738,712 stock options with an exercise price of $<span id="xdx_90D_eus-gaap--StockOptionExercisePriceIncrease_c20200603__20200605__srt--TitleOfIndividualAxis__custom--JeffreyBuschMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyEquityIncentivePlanMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_pdd" title="Stock options exercise price">0.0036 and an expiration date of August 15, 2032 and subject to vesting terms. Mr. Busch is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. As of December 31, 2022 and September 30, 2022, the Company had accrued director compensation of $<span id="xdx_909_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zdkwyR5DGm7g" title="Accrued director compensation">207,500 and $<span id="xdx_901_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_pp0p0_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--BuschEmploymentAgreementMember_zOEYZwNg8oD5" title="Accrued director compensation">192,500, respectively. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Mr. Busch is an “at-will” employee and his employment may be terminated by the Company at any time, with or without cause. In the event Mr. Busch’s employment is terminated by the Company without Cause (as defined in the Busch Employment Agreement), with Good Reason (as defined in the Busch Employment Agreement) or as a result of a non-renewal of the term of employment under the Busch Employment Agreement, Mr. Busch shall be entitled to receive the sum of (I) the Severance Multiple (as defined below), multiplied by his base salary immediately prior to such termination and (II) a pro-rata portion of his bonus for the year in which such termination occurs equal to (a) his bonus for the most recently completed calendar year (if any), multiplied by (b) a fraction, the numerator of which is the number of days that have elapsed from the beginning of such calendar year through the date of termination and the denominator of which is the total number of days in such calendar year. “Severance Multiple” shall mean 3.0; provided, however, that if the date of termination occurs on or at any time during the twelve (12)-month period following a Change in Control, the Severance Multiple shall mean 4.0. In addition, the Company shall accelerate the vesting of any outstanding, unvested equity awards granted to Mr. Busch prior to the date of termination. The Busch Employment Agreement also contains covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination, for a period of one year thereafter, (b) prohibiting the executive from disclosing confidential information regarding the Company, and (c) soliciting employees, customers and prospective customers during the term of the employment agreement and for a period of one year thereafter. Thomas E. Chilcott, III On September 24, 2020, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. The Company entered into an offer letter with Mr. Chilcott which provides that his base salary will be $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20200923__20200924__srt--TitleOfIndividualAxis__custom--ThomasEChilcottThreeMember__us-gaap--TypeOfArrangementAxis__custom--OfferLetterMember_z3tihyFNlvQ8" title="Annual base salary">225,000 per year. <span id="xdx_90F_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20200923__20200924__srt--TitleOfIndividualAxis__custom--ThomasEChilcottThreeMember__us-gaap--TypeOfArrangementAxis__custom--OfferLetterMember_zygrDu292Ey6" title="Deferred compensation arrangements overall description">Mr. Chilcott is entitled to participate in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock which were granted on August 16, 2022 with an exercise price of $<span id="xdx_904_eus-gaap--StockOptionExercisePriceIncrease_c20200923__20200924__srt--TitleOfIndividualAxis__custom--ThomasEChilcottThreeMember__us-gaap--TypeOfArrangementAxis__custom--OfferLetterMember_zvzJOZogLgIk" title="Stock options exercise price">0.0036 and an expiration date of August 15, 2032 and subject to vesting terms. On December 31, 2021, the Company’s Board approved an increase in the base salary of Thomas E. Chilcott, III, the Company’s Chief Financial Officer, from $225,000 to $<span id="xdx_907_eus-gaap--SalariesWagesAndOfficersCompensation_c20211230__20211231__srt--TitleOfIndividualAxis__custom--ThomasEChilcottThreeMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Annual base salary">300,000 per year. The increase was effective January 1, 2022. <span id="xdx_909_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20211230__20211231__srt--TitleOfIndividualAxis__custom--ThomasEChilcottThreeMember" title="Deferred compensation arrangements overall description">The Board also approved two new bonuses for which Mr. Chilcott was eligible: (i) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $1,000,000; and (ii) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $2,000,000 in the aggregate. On December 6, 2022, the Board approved a bonus compensation plan pursuant to which Thomas E. Chilcott, III, the Company’s Chief Financial Officer, was eligible for: (i) a $150,000 bonus payable upon the successful filing of the Company’s report on Form 10-K for the annual period ended September 30, 2022 (the “ Annual Report ”) on or before December 29, 2022; or (ii) a $100,000 bonus payable upon the successful filing of the Company’s Annual Report on or before January 13, 2023 (collectively, the “Bonus”). During the three months ended December 31, 2022, an aggregate bonus of $<span id="xdx_90C_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20221001__20221231__srt--TitleOfIndividualAxis__custom--ThomasEChilcottThreeMember__srt--RangeAxis__srt--MinimumMember_zSdTFCsINbsg" title="Annual base salary">150,000 was paid to Mr. Chilcott. Faith Zaslavsky On December 5, 2022, the Company appointed Faith Zaslavsky, age 48, as President and Chief Operating Officer of the Company, effective December 5, 2022 (the “Effective Date”). In connection with her appointment, on December 5, 2022, the Company and Ms. Zaslavsky entered into an offer letter (the “Offer Letter”) which provides that Ms. Zaslavsky’s base salary will be $400,000 per year, and that beginning in calendar year 2023 she will be eligible to receive an annual incentive cash bonus of up to 35% of base salary at the discretion of the Board for the achievement of certain milestones to be agreed upon by Ms. Zaslavsky and the Company within 90 days of the Effective Date. Upon the Company’s creation of a new equity incentive plan or an increase in the number of shares available under the Company’s existing equity incentive plan, Ms. Zaslavsky will be granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20221205__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__custom--ZaslavskyMember_zEn6hufhKQXh" title="Sharebased compensation available for grant">150,000,000 employee stock options vesting at <span id="xdx_900_eus-gaap--DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_pid_dp_c20221205__20221205__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__custom--ZaslavskyMember_z2PLp6LtWVbi" title="Vesting percentage">20% annually, beginning on the Effective Date. The employee stock options will have a strike price equal to the closing price of the Company’s common stock on the day that the Board approves Ms. Zaslavsky’s stock option package. Ms. Zaslavsky is eligible to participate in the benefit plans and programs generally available to the Company’s employees. Ms. Zaslavsky will also be entitled to reimbursement of reasonable business expenses incurred or paid by her in the performance of her duties and responsibilities for the Company, subject to any restrictions set by the Company from time to time and to such reasonable substantiation and documentation as may be specified by the Company from time to time. Ms. Zaslavsky’s employment with the Company is “at-will”, and either party can terminate the employment relationship at any time, for or without cause, with or without notice. The Offer Letter also contains standard restrictive covenants prohibiting Ms. Zaslavsky from engaging in competition with the Company within the United States during her employment and for a period of 24 months following the termination of her employment with the Company. Consulting Agreements On July 5, 2020, the Company and a consultant entered into a Scientific Advisory Board Service Agreement (“Scientific Advisory Agreement”) which provides for; (i) $<span id="xdx_90E_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_pp0p0_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAdvisoryBoardServiceAgreementMember_zHiqU5Nmgnz6" title="Compensation fees">2,000 monthly compensation; (ii) <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoPlanMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAdvisoryBoardServiceAgreementMember_z1jpZ4HLinP1" title="Stock options granted">88,786,943 stock options under the 2022 Plan, which were granted on August 16, 2022 with an exercise price of $<span id="xdx_90C_eus-gaap--StockOptionExercisePriceIncrease_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoPlanMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAdvisoryBoardServiceAgreementMember_zmEQBlDhUh23" title="Stock options exercise price">0.0036 and an expiration date of August 15, 2032 and subject to vesting terms and; (iii) $<span id="xdx_90C_eus-gaap--PaymentsForFees_pp0p0_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAdvisoryBoardServiceAgreementMember_zWnb94izAHFc" title="Payments for fees">1,500 per day for any special project requiring more than six hours of advisory service in a single day performed upon a written request from the Company. Either party may terminate the Scientific Advisory Agreement at any time upon ten days’ written notice to the other party unless either party neglects or fails to perform its obligations under the Scientific Advisory Agreement; then the termination notice shall be effective upon receipt of the same. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) On July 5, 2020, the Company and a consultant entered into a Pathology Advisory Board Service Agreement (the “Pathology Advisory Agreement”) which provides for; (i) $<span id="xdx_909_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--PathologyAdvisoryBoardServiceAgreementMember_pp0p0" title="Compensation fees">272 monthly compensation; (ii) <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoPlanMember__us-gaap--TypeOfArrangementAxis__custom--PathologyAdvisoryBoardServiceAgreementMember_zJBSr4X6oQo4" title="Stock options granted">77,972,192 stock options under the 2022 Plan, which were granted on August 16, 2022 with an exercise price of $<span id="xdx_90A_eus-gaap--StockOptionExercisePriceIncrease_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwentyTwoPlanMember__us-gaap--TypeOfArrangementAxis__custom--PathologyAdvisoryBoardServiceAgreementMember_zl2hNC7Jejzj" title="Stock options exercise price">0.0036 and an expiration date of August 15, 2032 and subject to vesting terms and; (iii) $<span id="xdx_90D_eus-gaap--PaymentsForFees_pp0p0_c20200703__20200705__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAdvisoryBoardServiceAgreementMember_zwFc7lS1wa1" title="Payments for fees">1,500 per day for any special project requiring more than six hours of advisory service in a single day performed upon a written request from the Company. Either party may terminate the Pathology Advisory Agreement at any time upon ten days’ written notice to the other party unless either party neglects or fails to perform its obligations under the Pathology Advisory Agreement; then the termination notice shall be effective upon receipt of the same. Effective January 1, 2021, the Company entered into a consulting agreement with Mr. Kucharchuk, a member of the Board of Directors, to serve as a strategic advisor. The agreement was effective for a period of twelve months, commencing on January 1, 2021 and shall renew on a month-to month basis, subject to the right of the Company and Mr. Kucharchuk to terminate the agreement pursuant to the agreement. Pursuant to the agreement, Mr. Kucharchuk shall be paid $<span id="xdx_903_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_c20210101__20210101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeS4qpUTLoU2" title="Compensation fees">2,000 per month. As of December 31, 2022 and September 30, 2022, the Company had an accounts payable – related payable balance of $6,000 and $12,000 related to this consulting agreement, respectively (See Note 8). License Agreements GMU License Agreement In September 2006, the Company entered into an exclusive license agreement with George Mason Intellectual Properties (“GMU License Agreement”), a non-profit corporation formed for the benefit of George Mason University (“GMU”) which: (1) grants an exclusive worldwide license, with the right to grant sublicenses, under the licensed inventions to make, have made, import, use, market, offer for sale and sell products designed, manufactured, used and/or marketed for all fields and for all uses, subject to the exclusions as defined in the GMU License Agreement; (2) grants an exclusive option to license past, existing, or future inventions in the Company’s field, from inventors that are obligated to assign to GMU and who have signed a memorandum of understanding acknowledging that developed intellectual property will be offered, subject to the exclusions as defined in the GMU License Agreement; (3) the license and option granted specifically excludes biomarkers for lung, ovarian, and breast cancers in a diagnostic field of use and GMU inventions developed using materials obtained from third parties under agreements granting rights to inventions made using said materials and; (4) grants right to assign or otherwise transfer the license so long as such assignment or transfer is accompanied by a change of control transaction and GMU is given 14 days’ prior notice. In addition, the Company is required to make an annual payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_pp0p0_c20060901__20060930__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__dei--LegalEntityAxis__custom--GeorgeMasonUniversityMember_zOReAVVNVxda" title="Royalty expense">50,000 to GMU as well as pay GMU a quarterly royalty equal to the net revenue multiplied by one and one-half percent (<span id="xdx_90C_ecustom--RevenuePercentage_dp_c20060901__20060930__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__dei--LegalEntityAxis__custom--GeorgeMasonUniversityMember_zWPD94Q0peZc" title="Revenue percentage">1.5%), due on a quarterly basis or a quarterly sublicense royalty equal to the net revenue multiplied by fifteen percent (<span id="xdx_90B_ecustom--RevenuePercentage_dp_c20060901__20060930__us-gaap--AwardTypeAxis__custom--SublicenseRoyaltyMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__dei--LegalEntityAxis__custom--GeorgeMasonUniversityMember_zq3HpNx0KkH7" title="Revenue percentage">15%). Further, the Company has the right of first refusal for all technology associated with RPPA technology from GMU. As of December 31, 2022 and September 30, 2022, the Company has accrued royalty fees of $<span id="xdx_90D_eus-gaap--AdvanceRoyalties_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__dei--LegalEntityAxis__custom--GeorgeMasonUniversityMember_zHJTw4gRz9Ic" title="Advance royalties">2,526 and $<span id="xdx_906_eus-gaap--AdvanceRoyalties_c20220930__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__dei--LegalEntityAxis__custom--GeorgeMasonUniversityMember_pp0p0" title="Advance royalties">2,443, respectively, reflected in the accompanying unaudited balance sheet in accrued liabilities. NIH License Agreement In March 2018, the Company entered into two license agreements (“NIH License Agreements”) with the National Institutes of Health (“NIH”) which grants the Company an exclusive and a nonexclusive United States license for certain patents. Pursuant to the NIH License Agreements, the Company is required to make an annual payment of $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20180301__20180331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_pp0p0" title="Royalty expense">1,000 to the NIH as well as pay the NIH a royalty equal to the net sales multiplied by three percent (<span id="xdx_903_ecustom--RevenuePercentage_c20180301__20180331__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_pdd" title="Revenue percentage">3.0%) every June 30th and December 31st. Commencing on January 1st of the year following the year of the first commercial sale, the Company is subject to a non-refundable minimum annual royalty of $5,000. In addition, a sublicense royalty equal to the net revenue multiplied by ten percent (<span id="xdx_90A_ecustom--RevenuePercentage_pid_dp_c20180301__20180331__us-gaap--AwardTypeAxis__custom--SublicenseRoyaltyMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_zOrh2nbB6kF3" title="Revenue percentage">10%) will be payable upon sublicensing. As of December 31, 2022 and September 30, 2022, the Company has accrued royalty fees of $<span id="xdx_905_eus-gaap--AdvanceRoyalties_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--NationalInstitutesOfHealthMember_z61ml6Yt5dj1" title="Advance royalties">0. Lease In December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025 (see Note 7). On June 10, 2021, the Company entered into an amendment to its existing Warehouse Lease (“Lease Amendment”), effective October 3, 2021, for its laboratory facility in Golden, CO (see Note 7). The Lease Amendment provided for: (i) an extension to the term of the original lease to five years following the completion of the Company’s improvements to the Expansion Premises (defined below); (ii) an expansion of the premises to include the premises located at Unit 404, Building F, 15000 West 6th Avenue, Golden, Colorado 80401, consisting of approximately 4,734 rentable square feet (the “Expansion Premises”); (iii) an annual base rent modification; (iv) an increase to the security deposit; (v) tenant improvement allowance; (vi) additional parking and; (vii) two renewal options, each for five year terms, for a total of ten years. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) Pursuant to the Lease Amendment, the Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893 for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394 for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve; (13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen. Other Contingencies Pursuant to ASC 450-20 – Loss Contingencies, liabilities for contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. As of December 31, 2022 and September 30, 2022, the Company has recorded a contingent liability of $80,240 and $78,440, respectively, resulting from certain liabilities of Avant prior to the asset sale and recapitalization transaction (see Note 1). The contingent liabilities consisted of two notes payables with a total outstanding principal balance of $40,000 as of December 31, 2022 and September 30, 2022 and accrued interest payable of $40,240 and $38,440 as of December 31, 2022 and September 30, 2022, respectively. Legal Action On December 10, 2021, YPH LLC filed a complaint against the Company in the District Court for the Southern District of New York alleging that Theralink breached its Certificate of Designation for Series C-1 Convertible Preferred Stock by failing to honor a conversion notice submitted to it by YPH. Based on these and other allegations, Plaintiff asserted a breach of contract claim claiming that it has damages in excess of $100 million. The case continues to be in the pleadings stage with Theralink filing its last response on March 30, 2022. The Company believes these claims are without merit and intends to defend plaintiffs’ lawsuits vigorously. The Company currently believes the likelihood of a loss contingency related to these matters is remote and, therefore, no provision for a loss contingency is required. On August 16, 2022, Erika Singleton filed a complaint against the Company in the Eighth Judicial District Court, Clark County, Nevada, Case No. A-22-857038-C. Plaintiff alleges that the Company did not provide her with physical stock certificates for 200,000 shares of common stock Plaintiff purchased for $2,000 in 2017. Based on these and other allegations, Plaintiff asserts claims against the Company for breach of contract, violation of Florida securities law, fraud, and unjust enrichment. The court has set the hearing on our motion to dismiss for March 23, 2022. The Plaintiff has until March 2, 2023 to file her opposition to our motion to dismiss and we will then have until March 16, 2023 to file our reply.

300000

1.50

49047059

420691653

49047059

420691653

469738712

0.0036

125000

112500

60000

49047059

420691653

49047059

420691653

469738712

0.0036

207500

192500

225000

Mr. Chilcott is entitled to participate in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock which were granted on August 16, 2022 with an exercise price of $0.0036 and an expiration date of August 15, 2032 and subject to vesting terms

0.0036

225000

300000

The Board also approved two new bonuses for which Mr. Chilcott was eligible: (i) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $1,000,000; and (ii) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $2,000,000 in the aggregate. On December 6, 2022, the Board approved a bonus compensation plan pursuant to which Thomas E. Chilcott, III, the Company’s Chief Financial Officer, was eligible for: (i) a $150,000 bonus payable upon the successful filing of the Company’s report on Form 10-K for the annual period ended September 30, 2022 (the “ Annual Report ”) on or before December 29, 2022; or (ii) a $100,000 bonus payable upon the successful filing of the Company’s Annual Report on or before January 13, 2023 (collectively, the “Bonus”)

150000

400000

0.35

150000000

0.20

2000

88786943

0.0036

1500

272

77972192

0.0036

1500

2000

6000

12000

50000

0.015 0.15

2526

2443

1000

3.0 0.10

In December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025

P61M

4734

80240

78440

40000

40240

38440

100000000

200000

2000

NOTE 11 – SUBSEQUENT EVENTS On January 27, 2023, the Company consummated the second closing (the “Second Closing”) of the Offering pursuant to the terms and conditions of that certain Purchase Agreement, dated as of November 29, 2022, by and among the Company, certain accredited investors (the “Second Closing Purchasers”) and Cavalry Fund I Management LLC, a Delaware limited liability company, in its capacity as Collateral Agent. At the Second Closing, the Company sold the Purchasers (i) New Debentures in an aggregate principal amount of $1,045,000 and (ii) Warrants to purchase up to 298,571,429 shares of Common Stock, subject to adjustments provided by the Warrants, which represents 100% warrant coverage. The Company received a total of $950,000 in gross proceeds at the Second Offering, taking into account the 10% original issue discount, before deducting offering expenses and commissions. The Purchase Agreement contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, covenants that restrict the ability of the Company without the prior written consent of the Debenture holders, to incur additional indebtedness, and repay outstanding indebtedness, create or permit liens on assets, redeem its Common Stock, settle outstanding litigation, or enter into transactions with affiliates. Pursuant to the terms of the Placement Agency Agreement, the Company agreed to (i) pay Gunnar a cash placement fee of 10% of the gross cash proceeds raised in the Second Offering, and (ii) issue to Gunnar additional PA Warrants on the terms identical to the Warrants sold in the Second Offering in an amount equal to 10% of the New Debentures sold to Second Closing Purchasers. As a result of the foregoing, the Company paid Gunnar an aggregate commission of $<span id="xdx_90A_eus-gaap--PaymentsForCommissions_c20230127__20230127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GunnarMember_za6MWatSotXi" title="Commission payable">95,000 in connection with the Second Closing. The Company also paid $<span id="xdx_906_eus-gaap--PaymentsForLegalSettlements_c20230127__20230127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GunnarMember_zRZyafc79Ot" title="Legal fees payable">7,500 in fees to Gunnar’s legal counsel. THERALINK TECHNOLOGIES, INC. CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS DECEMBER 31, 2022 (UNAUDITED) The New Debentures mature on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20230127__20230127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--NewDebenturesMember_ziIBPPPGu3Hg">November 29, 2023, subject to a three-month extension at the sole discretion of the Company. The New Debentures bear interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--NewDebenturesMember_z0WKdswFNUo3">10% per annum payable upon conversion or maturity. The Debentures are convertible into shares of Common Stock at any time after the maturity date and prior to Mandatory Conversion (as defined below) at the conversion price equal to the lesser of: (i) $0.003 per share and (ii) <span id="xdx_907_eus-gaap--DebtDefaultShorttermDebtDescriptionOfViolationOrEventOfDefault_c20230127__20230127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--NewDebenturesMember_zqqtlD2n03Ad">70% of the average of the VWAP (as defined in the Debentures) (or 50% of the average of such VWAP if an event of default has occurred and has not been cured) of the Common Stock during the ten Trading Day (as defined in the New Debentures) period immediately prior to the applicable conversion date. The New Debentures are subject to Mandatory Conversion in the event the Company closes a Qualified Offering. The conversion price per share of Common Stock in the case of a Mandatory Conversion shall be the Qualified Offering Price. Alternatively, upon a Mandatory Conversion, the holders of the New Debentures may elect to exchange their Debentures for newly issued convertible preferred securities at a price per share equal to the Qualified Offering Price or the five-day VWAP of the Common Stock prior to the date that is 181 days after the closing of the Qualified Offering. <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20230127__20230127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYVOFMuyJuEk" title="Debt instrument security description">Notwithstanding the preceding, holders of New Debentures shall have the right to require satisfaction of up to 40% of all amounts outstanding under the New Debentures, in cash, at the time of a Qualified Financing. Investors that are exchanging shareholders shall have the right to require satisfaction of up to 10% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing. The New Debentures also contain certain price protection provisions providing for adjustment of the number of shares of Common Stock issuable upon conversion of the Debentures in case of certain future dilutive events or stock-splits and dividends. The Company’s obligations under the Purchase Agreement and the New Debentures are secured by a first priority lien on all of the assets of the Company pursuant to that certain Security Agreement, dated November 29, 2022 (the “Security Agreement”) by and among the Company, the Purchasers and the Collateral Agent. In connection with the issuance of the Underlying Securities discussed above, the Company determined that the terms of the Debentures and Warrants contain an embedded conversion option to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. In accordance with ASC 815-40 -Derivatives and Hedging - Contracts in an Entity’s Own Stock, the embedded conversion option contained in the Debentures and the Warrants shall be accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion options will be determined using the Binomial Lattice valuation model. At the end of each period and on Debenture conversion date or repayment, the Company revalues the derivative liabilities resulting from the embedded option.

1045000

298571429

950000

Pursuant to the terms of the Placement Agency Agreement, the Company agreed to (i) pay Gunnar a cash placement fee of 10% of the gross cash proceeds raised in the Second Offering, and (ii) issue to Gunnar additional PA Warrants on the terms identical to the Warrants sold in the Second Offering in an amount equal to 10% of the New Debentures sold to Second Closing Purchasers

95000

7500

2023-11-29

0.10

0.003

70% of the average of the VWAP (as defined in the Debentures) (or 50% of the average of such VWAP if an event of default has occurred and has not been cured) of the Common Stock during the ten Trading Day (as defined in the New Debentures) period immediately prior to the applicable conversion date

Notwithstanding the preceding, holders of New Debentures shall have the right to require satisfaction of up to 40% of all amounts outstanding under the New Debentures, in cash, at the time of a Qualified Financing. Investors that are exchanging shareholders shall have the right to require satisfaction of up to 10% of all amounts outstanding under the Debentures, in cash, at the time of a Qualified Financing.

These vested options are only exercisable upon the company filing an S-8 to register the underlying shares.